
<html lang="en"     class="pb-page"  data-request-id="f5826760-21d3-4d8f-8061-7fdb494e902e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-22;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.5b00857;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-[(2S)-2-Aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol a Selective 5-HT2 Receptor Agonist" /></meta><meta name="dc.Creator" content="Jesse A.  May" /></meta><meta name="dc.Creator" content="Najam A.  Sharif" /></meta><meta name="dc.Creator" content="Marsha A.  McLaughlin" /></meta><meta name="dc.Creator" content="Hwang-Hsing  Chen" /></meta><meta name="dc.Creator" content="Bryon S.  Severns" /></meta><meta name="dc.Creator" content="Curtis R.  Kelly" /></meta><meta name="dc.Creator" content="William F.  Holt" /></meta><meta name="dc.Creator" content="Richard  Young" /></meta><meta name="dc.Creator" content="Richard A.  Glennon" /></meta><meta name="dc.Creator" content="Mark R.  Hellberg" /></meta><meta name="dc.Creator" content="Thomas R.  Dean" /></meta><meta name="dc.Description" content="Recently, it has been reported that 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2S)-2-aminopropyl]indazol-6-ol (AL-34..." /></meta><meta name="Description" content="Recently, it has been reported that 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2S)-2-aminopropyl]indazol-6-ol (AL-34..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 9, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00857" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00857" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00857" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00857" /></link>
        
    
    

<title>Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-[(2S)-2-Aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol a Selective 5-HT2 Receptor Agonist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00857" /></meta><meta property="og:title" content="Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-[(2S)-2-Aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol a Selective 5-HT2 Receptor Agonist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0003.jpeg" /></meta><meta property="og:description" content="Recently, it has been reported that 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2S)-2-aminopropyl]indazol-6-ol (AL-34662) was shown to have good efficacy in this nonhuman primate model of ocular hypertension as well as a desirable physicochemical and permeability profile, subsequently identified cardiovascular side effects in multiple species precluded further clinical evaluation of this compound. Herein, we report selected structural modifications that resulted in the identification of (8R)-1-[(2S)-2-aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol (13), which displayed an acceptable profile to support advancement for further preclinical evaluation as a candidate for proof-of-concept studies in humans." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00857"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00857">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00857&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00857&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00857&amp;href=/doi/10.1021/acs.jmedchem.5b00857" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 8818-8833</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00774" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00925" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Ocular Hypotensive Response in Nonhuman Primates of (8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol a Selective 5-HT<sub>2</sub> Receptor Agonist</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jesse+A.++May">Jesse A. May</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Najam+A.++Sharif">Najam A. Sharif</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marsha+A.++McLaughlin">Marsha A. McLaughlin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hwang-Hsing++Chen">Hwang-Hsing Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryon+S.++Severns">Bryon S. Severns</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Curtis+R.++Kelly">Curtis R. Kelly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+F.++Holt">William F. Holt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Young">Richard Young</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Glennon">Richard A. Glennon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+R.++Hellberg">Mark R. Hellberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+R.++Dean">Thomas R. Dean</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Ophthalmology Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box 980540, Richmond, Virginia 23298, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 817-975-9199. E-mail: <a href="/cdn-cgi/l/email-protection#7a101b171b03104b4f4f3a19121b080e1f0854141f0e"><span class="__cf_email__" data-cfemail="adc7ccc0ccd4c79c9898edcec5ccdfd9c8df83c3c8d9">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00857&amp;href=/doi/10.1021%2Facs.jmedchem.5b00857" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 8818â8833</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 9, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 June 2015</li><li><span class="item_label"><b>Published</b> online</span>9 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00857" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00857</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8818%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJesse%2BA.%2BMay%252C%2BNajam%2BA.%2BSharif%252C%2BMarsha%2BA.%2BMcLaughlin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D22%26contentID%3Dacs.jmedchem.5b00857%26title%3DOcular%2BHypotensive%2BResponse%2Bin%2BNonhuman%2BPrimates%2Bof%2B%25288R%2529-1-%255B%25282S%2529-2-Aminopropyl%255D-8%252C9-dihydro-7H-pyrano%255B2%252C3-g%255Dindazol-8-ol%2Ba%2BSelective%2B5-HT2%2BReceptor%2BAgonist%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8833%26publicationDate%3DNovember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00857"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1160</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00857" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-[(2S)-2-Aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol a Selective 5-HT2 Receptor Agonist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jesse&quot;,&quot;last_name&quot;:&quot;A. May&quot;},{&quot;first_name&quot;:&quot;Najam&quot;,&quot;last_name&quot;:&quot;A. Sharif&quot;},{&quot;first_name&quot;:&quot;Marsha&quot;,&quot;last_name&quot;:&quot;A. McLaughlin&quot;},{&quot;first_name&quot;:&quot;Hwang-Hsing&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Bryon&quot;,&quot;last_name&quot;:&quot;S. Severns&quot;},{&quot;first_name&quot;:&quot;Curtis&quot;,&quot;last_name&quot;:&quot;R. Kelly&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;F. Holt&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Young&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Glennon&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;R. Hellberg&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;R. Dean&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;8818-8833&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00857&quot;},&quot;abstract&quot;:&quot;Recently, it has been reported that 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2S)-2-aminopropyl]indazol-6-ol (AL-34662) was shown to have good efficacy in this nonhuman primate model of ocular hypertension as well as a desirable physicochemical and permeability profile, subsequently identified cardiovascular side effects in multiple species precluded further clinical evaluation of this compound. Herein, we report selected structural modifications that resulted in the identification of (8R)-1-[(2S)-2-aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol (13), which displayed an acceptable profile to support advancement for further preclinical evaluation as a candidate for proof-of-concept studies in humans.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00857" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00857&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00857" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00857&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00857" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00857&amp;href=/doi/10.1021/acs.jmedchem.5b00857" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00857" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00857" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (718 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00857%26sid%3Dliteratum%253Aachs%26pmid%3D26551970%26genre%3Darticle%26aulast%3DMay%26date%3D2015%26atitle%3DOcular%2BHypotensive%2BResponse%2Bin%2BNonhuman%2BPrimates%2Bof%2B%25288R%2529-1-%255B%25282S%2529-2-Aminopropyl%255D-8%252C9-dihydro-7H-pyrano%255B2%252C3-g%255Dindazol-8-ol%2Ba%2BSelective%2B5-HT2%2BReceptor%2BAgonist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D22%26spage%3D8818%26epage%3D8833%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291137" title="Lipids">Lipids</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/jmcmar.2015.58.issue-22/20151125/jmcmar.2015.58.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recently, it has been reported that 5-HT<sub>2</sub> receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2<i>S</i>)-2-aminopropyl]indazol-6-ol (AL-34662) was shown to have good efficacy in this nonhuman primate model of ocular hypertension as well as a desirable physicochemical and permeability profile, subsequently identified cardiovascular side effects in multiple species precluded further clinical evaluation of this compound. Herein, we report selected structural modifications that resulted in the identification of (8<i>R</i>)-1-[(2<i>S</i>)-2-aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>13</b>), which displayed an acceptable profile to support advancement for further preclinical evaluation as a candidate for proof-of-concept studies in humans.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glaucoma is a leading cause of blindness, though presently there is no known cure for this disease. An elevation of intraocular pressure remains the primary indicator for projecting an increased probability of the onset of primary open angle glaucoma, an ocular neuropathy which can lead to the loss of vision.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The reduction of this elevated intraocular pressure (IOP) has been demonstrated to be an effective treatment for preventing the progression of glaucoma.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> While a number of therapeutic agents are now available for the treatment of glaucoma through several different physiological mechanisms that lead to a decrease of IOP in an attempt to mitigate vision loss, there remains a significant portion of patients for whom these drugs are either contraindicated or not effective. There is, therefore, a critical medical need to identify alternate therapeutic approaches for efficiently decreasing the elevated IOP in patients with ocular hypertension in an attempt to maintain vision. This need is presently most urgent in view of an ever increasing percentage of the population entering the age-group cohort with the highest risk for the development of glaucoma.</div><div class="NLM_p">The presence of serotonin (5-hydroxytryptamine, 5-HT) in the eye is well established, and specific classes of the numerous receptors for this ubiquitous neurotransmitter have been identified in the ocular tissues of the anterior segment of the eye; several of these receptors have been suggested to have a significant role in maintaining normal IOP. The specific roles reported for the different 5-HT receptors based on animal studies has been somewhat contradictive and further has shown an apparent species variation; hence, the influence of these 5-HT receptors remains unclear.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The expression of 5-HT<sub>2</sub> receptor mRNA in human ciliary body, ciliary muscle, and trabecular meshwork cells has been noted, and furthermore, functional 5-HT<sub>2</sub> receptors have been identified in the ocular tissues critical to modulating IOP such as the ciliary epithelium, ciliary muscle, and trabecular meshwork cells.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> The presence of functionally active 5-HT<sub>2</sub> receptors in these tissues known to be involved in the control of IOP suggests that serotonin may have an important role in the regulation of IOP through these receptors. Activation of 5-HT<sub>2</sub> receptors following the topical ocular administration of 5-HT<sub>2</sub> receptor agonists has been shown to result in a significant reduction of IOP in a nonhuman primate (NHP) model of ocular hypertension.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">We have previously reported that a peripherally acting selective 5-HT<sub>2</sub> receptor agonist 1-[(2<i>S</i>)-2-aminopropyl]indazol-6-ol (<b>1</b>, AL-34662, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) exhibited good efficacy in a NHP model of ocular hypertension.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, this compound was subsequently shown to be unacceptable for further consideration as a clinical proof-of-concept candidate based on undesirable cardiovascular issues observed during late stage preclinical in vivo pharmacology evaluations. This response was hypothesized to be due to the previously unidentified potent Î±<sub>1D</sub> receptor agonist activity of the molecule (vide infra). Therefore, identification of a compound lacking this activity was of interest. In view of the favorable ocular antihypertensive efficacy and lack of CNS effects observed for the pyrano[3,2-<i>e</i>]indole compound <b>2</b> (AL-37350A, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> but which lacked acceptable solution stability due to the indole moiety, it was of interest to explore the efficacy of the corresponding pyrano[2,3-<i>g</i>]indazole compound <b>3</b> (AL-38022A, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which would be expected to have an increased solution stability comparable to that of the indazole analogue <b>1</b>. A comparison between these two fused pyrano-heterocyclic analogues showed that <b>3</b> did indeed display a greatly increased solution stability: estimated half-life (<i>t</i><sub>1/2</sub>) as an aqueous solution (pH 7.4) of 15.1 years (25 Â°C).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The comparable calculated polar surface areas for these two compounds (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) suggested that <b>3</b> might also lack unfavorable CNS effects. However, there was concern that permeability into the CNS might be problematic since the distribution coefficient for <b>3</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) was about 15-fold higher than that for <b>2</b>, and the MDCK/MDR cell permeability <i>P</i><sub>app-PD</sub> for <b>3</b> was 9-fold higher than that for <b>2</b>; and furthermore, <b>2</b> was a substrate for the P-gp efflux system, while <b>3</b> was not a substrate (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). It was subsequently established during an acute rabbit safety study that extremely severe CNS effects were caused by <b>3</b>; this significant CNS liability precluded any further evaluation of compound <b>3</b> in monkeys.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> It is of interest to note that though the comparable tPSA values for <b>2</b> and <b>3</b> were suggestive of low CNS permeability for these compounds, the experimentally determined DC<sub>7.4</sub> and P<sub>appÂ PD</sub> values more favorably predicted the outcome observed from the in vivo studies.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Herein, we report selected structural modifications of <b>3</b> that were evaluated and resulted in the identification of a lead compound within this series, which displayed an acceptable profile to support advancement for further preclinical evaluation as a candidate for proof-of-concept studies in humans.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Physiochemical and Permeability Data for Compounds and Topically Dosed Ocular Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">cmpds (<b>4</b>,Â RÂ =Â )</th><th class="colsep0 rowsep0" align="center">tPSA<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (Ã<sup>2</sup>)</th><th class="colsep0 rowsep0" align="center">DC<sub>7.4</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>appÂ PD</sub>, nm/s<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a>[P-gp substrate, efflux ratio]</th><th class="colsep0 rowsep0" align="center">rabbit cornea<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a><i>P</i><sub>app</sub> nm/s (Â±sd)</th><th class="colsep0 rowsep0" align="center">rabbit conjunctiva<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a><i>P</i><sub>app</sub> nm/s (Â±sd)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">51.0</td><td class="colsep0 rowsep0" align="left">0.281</td><td class="colsep0 rowsep0" align="left">18.5 [yes, 9.3]</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">53.1</td><td class="colsep0 rowsep0" align="left">4.39<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">164 [no]<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">451Â Â±Â 65</td><td class="colsep0 rowsep0" align="left">298Â Â±Â 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">-OH</td><td class="colsep0 rowsep0" align="left">73.3</td><td class="colsep0 rowsep0" align="left">0.349</td><td class="colsep0 rowsep0" align="left">5.4 [yes, 5.8]</td><td class="colsep0 rowsep0" align="left">53Â Â±Â 6</td><td class="colsep0 rowsep0" align="left">87Â Â±Â 59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">79.1</td><td class="colsep0 rowsep0" align="left">0.0</td><td class="colsep0 rowsep0" align="left">2.5 [no, 2.8]</td><td class="colsep0 rowsep0" align="left">11Â Â±Â 2</td><td class="colsep0 rowsep0" align="left">38Â Â±Â 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">88.3</td><td class="colsep0 rowsep0" align="left">0.0</td><td class="colsep0 rowsep0" align="left">1.6 [no, 1.3]</td><td class="colsep0 rowsep0" align="left">13Â Â±Â 2</td><td class="colsep0 rowsep0" align="left">69Â Â±Â 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">82.5</td><td class="colsep0 rowsep0" align="left">0.223</td><td class="colsep0 rowsep0" align="left">1.6 [yes, 22]</td><td class="colsep0 rowsep0" align="left">44Â Â±Â 6</td><td class="colsep0 rowsep0" align="left">242Â Â±Â 62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">91.4</td><td class="colsep0 rowsep0" align="left">0.294</td><td class="colsep0 rowsep0" align="left">5.0 [yes, 5.0]</td><td class="colsep0 rowsep0" align="left">20Â Â±Â 6</td><td class="colsep0 rowsep0" align="left">141Â Â±Â 55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CONH-(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">101</td><td class="colsep0 rowsep0" align="left">0.312</td><td class="colsep0 rowsep0" align="left">4.3 [yes, 7.0]</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32c</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CONH-(CH<sub>2</sub>)<sub>3</sub>NH<sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left"> < 0.10</td><td class="colsep0 rowsep0" align="left"> < 6.0 [no]</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32d</b></td><td class="colsep0 rowsep0" align="left">-OCH<sub>2</sub>CO-[N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>N]- (pyridin-2-yl)</td><td class="colsep0 rowsep0" align="left">96.0</td><td class="colsep0 rowsep0" align="left"> < 0.10</td><td class="colsep0 rowsep0" align="left">2.8 [yes, 22]</td><td class="colsep0 rowsep0" align="left">45Â Â±Â 7</td><td class="colsep0 rowsep0" align="left">72Â Â±Â 34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">timolol</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">1.16</td><td class="colsep0 rowsep0" align="left">33.9 [yes, 26.2]</td><td class="colsep0 rowsep0" align="left">242Â Â±Â 3</td><td class="colsep0 rowsep0" align="left">94.2Â Â±Â 22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">betaxolol</td><td class="colsep0 rowsep0" align="left">50.7</td><td class="colsep0 rowsep0" align="left">6.34</td><td class="colsep0 rowsep0" align="left">202 [yes, 6.0]</td><td class="colsep0 rowsep0" align="left">232Â Â±Â 10</td><td class="colsep0 rowsep0" align="left">61.1Â Â±Â 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">dorzolamide</td><td class="colsep0 rowsep0" align="left">151</td><td class="colsep0 rowsep0" align="left">1.72</td><td class="colsep0 rowsep0" align="left">4.0 [yes, 7.8]</td><td class="colsep0 rowsep0" align="left">9.0Â Â±Â 9</td><td class="colsep0 rowsep0" align="left">15.5Â Â±Â 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">brinzolamide</td><td class="colsep0 rowsep0" align="left">164</td><td class="colsep0 rowsep0" align="left">6.56</td><td class="colsep0 rowsep0" align="left">11.7 [yes, 68]</td><td class="colsep0 rowsep0" align="left">4.4Â Â±Â 1.0</td><td class="colsep0 rowsep0" align="left">37.1Â Â±Â 27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">apraclonidine</td><td class="colsep0 rowsep0" align="left">62.4</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">3.8 [no]</td><td class="colsep0 rowsep0" align="left">21Â Â±Â 7</td><td class="colsep0 rowsep0" align="left">29Â Â±Â 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">brimonidine</td><td class="colsep0 rowsep0" align="left">62.2</td><td class="colsep0 rowsep0" align="left">1.53</td><td class="colsep0 rowsep0" align="left">30.9 [no]</td><td class="colsep0 rowsep0" align="left">238Â Â±Â 4</td><td class="colsep0 rowsep0" align="left">79.2Â Â±Â 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">pilocarpine</td><td class="colsep0 rowsep0" align="left">44.1</td><td class="colsep0 rowsep0" align="left">1.39</td><td class="colsep0 rowsep0" align="left">36.8 [no]</td><td class="colsep0 rowsep0" align="left">189Â Â±Â 9</td><td class="colsep0 rowsep0" align="left">248Â Â±Â 76</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Calculated with ACD/logP, v.12.01.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Experimental values.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">MDCK(MDR) cell permeability, by Absorption Systems, L.P.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Ex vivo experiments by Absorption Systems, L.P.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a>.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines the synthesis of epimers <b>13</b> and <b>14</b>, initiated by the protection of <b>5</b><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> with <i>t</i>-butyldimethylchlorosilane to give <b>6</b> followed by debenzylation with Pd/C under hydrogen to give phenol <b>7</b>, which upon subsequent bromination with <i>N</i>-bromosuccinimide in tetrahydrofuran gave the 7-bromo-6-hydroxy indazole <b>8</b> in good yield; no additional bromination products were identified. Alkylation of <b>8</b> with epibromohydrin in the presence of potassium carbonate in acetone afforded epoxide <b>9</b>, which was treated with magnesium and 1,2-dibromoethane to give the 6-(1-bromo-2-hydroxy-propoxy) intermediate that was immediately treated with ethyl vinyl ether to give the <i>O</i>-protected compound <b>10</b>. Metalation of <b>10</b> with <i>n</i>-butyllithium at â78 Â°C with subsequent cyclization, along with concomitant cleavage of the silyl ether protecting group, led to the formation of pyranoindazole <b>11</b>. Treatment of <b>11</b> with methanesulfonic anhydride and then sodium azide in DMF gave the intermediate azide, which was deprotected to afford <b>12</b>. The stereoisomers of compound <b>12</b> were separated by chiral HPLC to give <b>12a</b> and <b>12b</b>, hydrogenation of which gave the desired amines <b>13</b> and <b>14</b>, respectively. An alternative asymmetric synthetic method for obtaining compound <b>12a</b> is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Alkylation of compound <b>7</b> with propargyl bromide in the presence of potassium carbonate in acetone gave the 6-propargyloxyindazole <b>15</b>, which readily underwent a Claisen rearrangementâcyclization when heated in mesitylene (200 Â°C) to give the C7 cyclization product pyrano[2,3-<i>g</i>]indazole <b>16</b>, in good yield; the C5 cyclization product (pyrano[2,3-<i>f</i>]indazole) was not detected. Hydroboration of compound <b>16</b> with 9-BBN followed by treatment with hydrogen peroxide gave a mixture of the 8-hydroxy epimers <b>17a (</b><i>R</i>-C8-OH) and <b>17b (</b><i>S</i>-C8-OH) in a 9:1 ratio. The pure major isomer <b>17a</b> was obtained by column chromatography. Protection of <b>17a</b> with ethyl vinyl ether followed by treatment with <i>tetra-n-</i>butylammonium fluoride gave alcohol <b>18</b>, which was converted to compound <b>12a</b> using the same procedure as that earlier described for the preparation of compound <b>12</b> from <b>11</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Synthesis of the 8-(<i>R</i>)-amino analogue of compound <b>13</b> was accomplished by the conversion of <b>12b</b> to the diazide <b>19</b>, and subsequent reduction provided the diamine <b>20</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Preparation of the 8-(<i>R</i>)-2-aminoethoxy analogue <b>25</b> from <b>17a</b> is outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>: sequential O-alkylation (<b>21</b>), removal of the silyl protecting group (<b>22</b>), and reduction of the ester gave the diol <b>23</b>, which was converted to the desired diazide (<b>24</b>) and then was reduced to the targeted 2-aminoethoxy compound <b>25</b>. Conversion of the <i>R</i>-hydroxyl group of ester <b>22</b> to the <i>S</i>-azide (<b>26</b>) in the manner described above followed by treatment with LAH, which reduced both the ester and the azide, gave the desired crude amino alcohol; however, to expedite purification of this compound the amine was protected with a carbobenzyloxy group (<b>27</b>). Following purification, reductive cleavage of the protecting group provided the desired compound <b>28</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The amide analogues <b>32a</b>â<b>d</b> were synthesized in four steps from the chiral alcohol <b>12a</b> as illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. This sequence began with O-alkylation using sodium hydride and isopropyl 2-bromoacetate to afford <b>29</b> followed by transesterification with methanolic hydrochloric acid to provide the methyl ester <b>30</b>. Substitution with selected amines was accomplished by treatment at ambient temperature in an appropriate solvent (i.e., methylamine in THF; 2-methoxyethylamine in methanol; 1,3-propanediamine in methanol) to afford the desired azido-amides (<b>31a-c</b>). However, for 1-(pyridine-2-yl)-piperazine, no additional solvent was used; this reaction required prolonged heating to give <b>31d</b>. Catalytic hydrogenation readily provided the corresponding amines, <b>32a</b>â<b>d</b>.</div><div class="NLM_p">Single crystal X-ray diffraction studies established that for compound <b>13</b> the C8 carbon atom has an R configuration and that the C2â² atom of the <i>N</i>1-(2-aminopropyl) moiety has the S configuration; this stereochemistry is depicted for compound <b>13</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: *Ref <a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">10</a>. (a) <i>t</i>-Butyldimethylchlorosilane, imidazole, THF; (b) H<sub>2</sub>, Pd/C, MeOH; (c) NBS, THF; (d) epibromohydrin, K<sub>2</sub>CO<sub>3</sub>, acetone; (e) (1) Mg, 1,2-dibromoethane, THF; (2) ethyl vinyl ether, TsOH, DCM; (f) (1) <i>n</i>-butyllithium, THF, â78 Â°C; (2) TBAF, THF; (g) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (3) HCl; (h) chiral HPLC separation; (i) H<sub>2</sub>, Pd/C, MeOH.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) propargyl bromide, K<sub>2</sub>CO<sub>3</sub>, acetone; (b) mesitylene, 200 Â°C; (c) (1) 9-BBN, THF; (2) H<sub>2</sub>O<sub>2</sub>, MeOH; (3) column chromatography; (d) (1) pyridine-TsOH, ethyl vinyl ether; (2) TBAF, THF; (e) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (3) TsOH, MeOH; (4) TEA.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (b) H<sub>2</sub>, Pd/C, MeOH; (c) NaH, <i>t</i>-butylbromoacetate, DMF; (d) TBAF, THF; (e) LAH, THF; (f) (1) LAH, THF; (2) CbzCl, NaHCO<sub>3</sub>.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, DMF, isopropyl 2-bromoacetate; (b) Methanolic 3 N HCl; (c) amine, solvent or neat; (d) 10% PdâC, hydrogen, methanol.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The effort to decrease the CNS activity of <b>3</b> explored the incorporation of polar functionality within the pyrano-ring through C8 and/or C9 substitution. A limited preliminary investigation of several 8,9-disubstituted analogues did not appear to warrant further exploration of this disubstituted series. Hence, the focus was directed to the synthetically more readily accessible C8 substituted series of compounds (<b>4</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), wherein compounds with a polar surface area greater than that of <b>3</b> were selected (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The experimental distribution coefficients for these compounds were greater than 10-fold lower than that of compound <b>3</b>. Incorporation of a substituent at C8 is well tolerated, and there does not appear to be a preferred stereochemistry for the substituent, at least for the hydroxyl group, since <b>13</b> and <b>14</b> have essentially the same functional response at the receptors; however, this substitution does result in a modest overall decrease in affinity at the 5-HT<sub>2</sub> receptors as well as a decrease in both functional potency and efficacy at the 5-HT<sub>2</sub> receptors relative to the unsubstituted compound <b>3</b> in the in vitro assays as listed in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The affinity of compounds at the three 5-HT<sub>2</sub> receptor subtypes was generally of the order 5-HT<sub>2C</sub> â¥ 5-HT<sub>2A</sub> > 5-HT<sub>2B</sub>, and the functional response at the receptor subtypes displayed a similar preference; however, none of these compounds demonstrated a high level of selectivity for a single receptor subtype. The binding affinity data showed <b>32a</b> to have only a marginal preference for 5-HT<sub>2C</sub> vs 5-HT<sub>2B</sub> (15-fold), which was not observed in the functional assay. Compound <b>13</b> and <b>28</b> showed a slight preference for 5-HT<sub>2C</sub> vs 5-HT<sub>2B</sub> (16-fold and 15-fold, respectively), in the functional assay; but only an equally modest preference for 5-HT<sub>2A</sub> or 5-HT<sub>2C</sub> vs 5-HT<sub>2B</sub> (10-fold and 15-fold, respectively) was observed in the functional assay for <b>32b</b>. Compound <b>32d</b> showed only a nominal preference for 5-HT<sub>2A/C</sub> vs 5-HT<sub>2B</sub> (â¤10-fold) in this assay. The potent agonist response observed for <b>32d</b> suggests that a region within the receptor has been identified that is capable of accommodating considerable steric bulk, indicating that perhaps the pyridyl-piperazinyl moiety reaches beyond the transmembrane domain of the receptor. Identification of such a location within the 5-HT<sub>2</sub> receptor might find utility for subsequent inclusion of a suitable marker functionality within this framework to assist in exploring the role of ligandâreceptor interactions at the molecular level.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Human Cloned Receptor Data</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> hÂ 5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> hÂ 5-HT<sub>2B</sub></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> hÂ 5-HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub>, (nM) (RI)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> hÂ 5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub>, (nM) (RI)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> hÂ 5-HT<sub>2B</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub>, (nM) (RI)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> hÂ 5-HT<sub>2C</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.8Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">2.4Â Â±Â 0.6</td><td class="colsep0 rowsep0" align="left">0.59Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="left">1.68Â Â±Â 0.38 (113)</td><td class="colsep0 rowsep0" align="left">3.98Â Â±Â 0.81 (81)</td><td class="colsep0 rowsep0" align="left">0.30Â Â±Â 0.15 (107)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">7.3Â Â±Â 2.8</td><td class="colsep0 rowsep0" align="left">8.6Â Â±Â 3.6</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="left">7.03Â Â±Â 0.84 (111)</td><td class="colsep0 rowsep0" align="left">13.5Â Â±Â 3.8 (80)</td><td class="colsep0 rowsep0" align="left">0.82Â Â±Â 0.26 (112)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">9.13Â Â±Â 2.99 (109)</td><td class="colsep0 rowsep0" align="left">26.6Â Â±Â 11.2 (79)</td><td class="colsep0 rowsep0" align="left">0.77Â Â±Â 0.16 (106)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">15.3Â Â±Â 1.5</td><td class="colsep0 rowsep0" align="left">30Â Â±Â 7</td><td class="colsep0 rowsep0" align="left">3.9Â Â±Â 0.8</td><td class="colsep0 rowsep0" align="left">27.6Â Â±Â 20.3 (109)</td><td class="colsep0 rowsep0" align="left">39.9Â Â±Â 17.9 (88)</td><td class="colsep0 rowsep0" align="left">5.12Â Â±Â 0.98 (109)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">153Â Â±Â 8.8</td><td class="colsep0 rowsep0" align="left">125Â Â±Â 30</td><td class="colsep0 rowsep0" align="left">25.3Â Â±Â 2.4</td><td class="colsep0 rowsep0" align="left">67.3Â Â±Â 2.35 (109)</td><td class="colsep0 rowsep0" align="left">34.1Â Â±Â 0.1 (102)</td><td class="colsep0 rowsep0" align="left">20.8Â Â±Â 3.5 (109)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">20Â Â±Â 8.6</td><td class="colsep0 rowsep0" align="left">39Â Â±Â 3</td><td class="colsep0 rowsep0" align="left">6.3Â Â±Â 3.9</td><td class="colsep0 rowsep0" align="left">9.15Â Â±Â 4.55 (110)</td><td class="colsep0 rowsep0" align="left">38.0Â Â±Â 1.55 (83)</td><td class="colsep0 rowsep0" align="left">2.5Â Â±Â 1.0 (110)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">13.3Â Â±Â 1.2</td><td class="colsep0 rowsep0" align="left">29.7Â Â±Â 6.9</td><td class="colsep0 rowsep0" align="left">1.83Â Â±Â 0.42</td><td class="colsep0 rowsep0" align="left">9.85Â Â±Â 2.85 (110)</td><td class="colsep0 rowsep0" align="left">31.6Â Â±Â 4.7 (90)</td><td class="colsep0 rowsep0" align="left">3.68Â Â±Â 0.90 (106)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">7.2Â Â±Â 1.9</td><td class="colsep0 rowsep0" align="left">21.3Â Â±Â 2.4</td><td class="colsep0 rowsep0" align="left">3.4Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="left">13.3Â Â±Â 8.27 (110)</td><td class="colsep0 rowsep0" align="left">136Â Â±Â 94 (90)</td><td class="colsep0 rowsep0" align="left">8.95Â Â±Â 1.36 (110)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32c</b></td><td class="colsep0 rowsep0" align="left">13Â Â±Â 2.1</td><td class="colsep0 rowsep0" align="left">16Â Â±Â 4.0</td><td class="colsep0 rowsep0" align="left">1.32Â Â±Â 0.25</td><td class="colsep0 rowsep0" align="left">15.7Â Â±Â 2.91 (112)</td><td class="colsep0 rowsep0" align="left">43.8Â Â±Â 12.0 (90)</td><td class="colsep0 rowsep0" align="left">7.40Â Â±Â 0.20 (108)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32d</b></td><td class="colsep0 rowsep0" align="left">12.0Â Â±Â 0.58</td><td class="colsep0 rowsep0" align="left">5.9Â Â±Â 0.71</td><td class="colsep0 rowsep0" align="left">5.3Â Â±Â 0.72</td><td class="colsep0 rowsep0" align="left">13.9Â Â±Â 8.66 (116)</td><td class="colsep0 rowsep0" align="left">148Â Â±Â 74 (90)</td><td class="colsep0 rowsep0" align="left">23.8Â Â±Â 9.1 (108)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Cloned human receptors, [<sup>125</sup>I]-DOI as radioligand; values are the mean of three determinations Â± SEM.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Aequorin based [Ca<sup>2+</sup>]<sub>i</sub> mobilization assay; values are the means of replicate experiments Â± SEM or range, agonist response relative to Î±-Me-5-HT for the 2A and 2B receptors and relative to 5-HT for the 2C receptor.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a>.</p></div></div></div><div class="NLM_p">The possibility of compounds entering the CNS was further estimated by assessing their permeability of MDCK/MDR cells, a well-documented model of CNS penetration.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Compounds of interest were those that had passive diffusion (<i>P</i><sub>appÂ PD</sub>) of <50 nm/s in this model (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). For comparison, the permeability of the structurally related compound <b>3</b>, which has been shown to readily enter the CNS, is also included. The compounds included in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> showed a 30- to 100-fold lower passive permeability in the MDCK/MDR cells than that observed for <b>3</b>, suggesting that these compounds would have a low propensity to traverse the bloodâbrain barrier. Furthermore, it is of interest to note that while <b>3</b> is not a substrate for the P-glycoprotein efflux protein, which would favor entry into the CNS, all of the present compounds bearing a nonamine C8 substituent are substrates for this efflux system, an association which most probably contributes to the low permeability for these particular compounds. For comparison, the passive diffusion of several well-known topically administered ophthalmologic agents was also determined in this same model (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p">As an estimate of the ability of a compound to gain access to the ocular target tissues, ciliary body, and trabecular meshwork, which modulate aqueous humor dynamics and thus IOP, the permeability through the excised rabbit cornea and conjunctiva was determined. The compounds evaluated showed modest corneal permeability, comparable to that of apraclonidine, or the carbonic anhydrase inhibitors dorzolamide and brinzolamide, but considerably lower than the Î²-adrenergic receptor blockers, betaxolol and timolol, or the Î±<sub>2</sub>-adrenergic receptor agonist brimonidine (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). All of the compounds of the present study displayed a higher permeability through the conjunctiva than the cornea, unlike for timolol, betaxolol, and brimonidine where conjunctival permeability was considerably reduced. Interestingly, brinzolamide showed nearly a 10-fold increase in permeability through the conjunctiva compared to the cornea. Hence, by comparison the compounds of this study would be anticipated to readily gain access to the target tissues following topical ocular administration.</div><div class="NLM_p">As noted above, compound <b>1</b> was found to cause an undesirable elevation of the mean arterial blood pressure in porcine (39%) and canine (52%, racemic) models and also decreased heart rate in pigs (32%). These detrimental effects were hypothesized to likely arise from agonist activity at the Î±<sub>1D</sub> adrenoceptor.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> Expanded evaluation of the receptor activity profile of compound <b>1</b> showed that it did indeed have rather potent Î±<sub>1D</sub> receptor agonist activity: prazosin (a potent and selective Î±<sub>1</sub>-antagonist) potently blocked the effects of <b>1</b> (IC<sub>50</sub> = 2.1 Â± 0.5 nM; <i>n</i> = 3) in the isolated rat aorta contraction assay. Hence, identification of compounds lacking this problematic activity was of interest. In contrast to compound <b>1</b>, compounds <b>13</b> and <b>28</b> showed no significant Î±<sub>1D</sub> agonist activity, based on the lack of any significant contractile response for these compounds in the rat aorta contraction assay (EC<sub>50</sub> > 30 Î¼M).</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vivo Studies with the Lasered Cynomolgus Monkey Model of Chronic Ocular Hypertension</h3><div class="NLM_p">In this model, a test compound that decreases IOP in the lasered eye by more than 20% relative to the baseline pressure is considered to have a biologically significant response; however, a compound that decreases IOP by more than 25% is of particular interest as a potential candidate for further preclinical evaluation. As noted above, compounds of interest for evaluation in the monkey model initially undergo evaluation in an acute topical ocular rabbit safety study to assess suitability for in vivo testing. This preliminary safety study showed that compounds <b>13</b>, <b>14</b>, <b>20</b>, and <b>28</b> had no significant adverse effects which would preclude their evaluation in ocular hypertensive monkeys; a summary of these studies (300 Î¼g dose) is provided in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Compound <b>13</b>, which provided an IOP reduction of greater than 25% at both the 3 and 6 h reading was the most effective of these compounds. Compound <b>14</b>, the C8 epimer of <b>13</b>, was less effective than <b>13</b> reducing IOP by 25% only at the 6 h time point and showing a modest reduction of 17% at the 3 h reading. Neither compound <b>20</b> nor <b>28</b> achieved the desired IOP reduction of 25% at any time point. As noted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the IOP reduction of <b>13</b> showed a good doseâresponse relationship when further evaluated at 100 Î¼g and 30 Î¼g doses. The 300 Î¼g (1%) dose appears to be at the top of the doseâresponse curve since increasing the dose above this level (i.e., 2%, 4%) did not result in additional peak IOP reduction. On the basis of its overall favorable profile, compound <b>13</b> was selected as the preferred compound for further evaluation as described below.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of Selected Compounds on IOP in Hypertensive Eyes of Conscious Cynomolgus Monkeys</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">postdose IOP reduction, %<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (Î¼g)</th><th class="colsep0 rowsep0" align="center">baseline IOP (mmHg)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1Â h</th><th class="colsep0 rowsep0" align="center">3Â h</th><th class="colsep0 rowsep0" align="center">6Â h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">33.9Â (3.63)</td><td class="colsep0 rowsep0" align="left">0.9Â (2.16)</td><td class="colsep0 rowsep0" align="left">14.4<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a> (3.65)</td><td class="colsep0 rowsep0" align="left">19.9<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a> (6.45)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">36.9Â (2.14)</td><td class="colsep0 rowsep0" align="left">9.2Â (3.4)</td><td class="colsep0 rowsep0" align="left">17.2<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (2.3)</td><td class="colsep0 rowsep0" align="left">25.7<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (4.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">35.1Â (2.64)</td><td class="colsep0 rowsep0" align="left">7.6Â (2.91)</td><td class="colsep0 rowsep0" align="left">25.8<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (3.53)</td><td class="colsep0 rowsep0" align="left">30.2<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (4.48)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">34.3Â (2.45)</td><td class="colsep0 rowsep0" align="left">7.9Â (4.06)</td><td class="colsep0 rowsep0" align="left">17.3<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (3.87)</td><td class="colsep0 rowsep0" align="left">25.1<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (4.76)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">36.0Â (2.37)</td><td class="colsep0 rowsep0" align="left">7.4Â (4.06)</td><td class="colsep0 rowsep0" align="left">15.3<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (3.23)</td><td class="colsep0 rowsep0" align="left">20.8<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (5.43)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">38.5Â (2.73)</td><td class="colsep0 rowsep0" align="left">7.6Â (4.44)</td><td class="colsep0 rowsep0" align="left">19.1<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (4.40)</td><td class="colsep0 rowsep0" align="left">19.8<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a> (7.72)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Phosphate buffered saline, pH 7.4.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Value (SEM).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">The vehicle control group conducted with each study did not exceed the inherent model IOP variability of Â±15%.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last"><i>p</i> < 0.001.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last"><i>p</i> < 0.01.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last"><i>p</i> < 0.5.</p></div></div></div><div class="NLM_p">When compound <b>13</b> was dosed by topical ocular administration in the normotensive (nonlasered) eye of the monkeys, this treatment did not show significantly altered IOP in either the dosed normal eye or the contralateral lasered eye (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Also, compound <b>13</b> had no effect on the pupil since there was no mydriasis or miosis observed in the treated left eye, which had not undergone laser trabeculoplasty. Thus, the IOP lowering action of <b>13</b> appears to be locally mediated, rather than through a centrally or systemically mediated effect.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IOP Response Following Topical Ocular Administration of <b>13</b> to the Normal Eye of Conscious Cynomolgus Monkeys</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">postdose IOP reduction, %<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (Î¼g)</th><th class="colsep0 rowsep0" align="center">baseline IOP (mmHg)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1Â h</th><th class="colsep0 rowsep0" align="center">3Â h</th><th class="colsep0 rowsep0" align="center">6Â h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">300, OS<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">19.3Â (1.31)</td><td class="colsep0 rowsep0" align="left">2.7Â (2.77)</td><td class="colsep0 rowsep0" align="left">9.3Â (4.09)</td><td class="colsep0 rowsep0" align="left">10.5Â (3.79)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0, OD<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">30.9Â (1.78)</td><td class="colsep0 rowsep0" align="left">2.4Â (2.84)</td><td class="colsep0 rowsep0" align="left">5.7Â (2.50)</td><td class="colsep0 rowsep0" align="left">10.6Â (4.07)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Phosphate buffered saline, pH 7.4.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Value (SEM).</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">The vehicle control group conducted with each study did not exceed inherent model IOP variability of Â±15%.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Normal, normotensive treated left eye OS.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Lasered (hypertensive, OD) right eye contralateral to treatment.</p></div></div></div><div class="NLM_p">It is of interest to note that compound <b>13</b> did not demonstrate any significant efficacy for IOP reduction in Dutch-belted rabbits that naturally have elevated IOPs compared to that of other strains of rabbit nor in normotensive cats (300 Î¼g, mixed breed) following topical ocular administration of doses that were effective when applied to the hypertensive eye of monkeys. However, such species differences following topical ocular administration are not unprecedented; for example, neither rabbit nor cat IOP is modulated by prostaglandin FP-receptor agonists, while FP-receptor agonists are effective at reducing IOP in nonhuman primates as well as humans. Further, a reduction in IOP is observed in rabbits treated with prostaglandin DP-receptor agonists.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Similarly, cabergoline lowers IOP in monkeys but not in Dutch-belted rabbits.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">The duration of the IOP effect of <b>13</b> in cynomolgus monkeys after a single a.m. dose (300 Î¼g) followed by a subsequent single p.m. dose (300 Î¼g) administered topically to the hypertensive right eye of the animals was evaluated; IOP reductions of 27.9% and 26.7% were observed 12 h after the morning and evening doses, respectively (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The IOP readings for compound <b>1</b>, which was administered using the same protocol, showed a maximum reduction of 21.5% 10 h after the first dose, and the IOP was not maintained for 12 h after the second dose, suggesting a significant improvement in duration of action for <b>13</b> compared to <b>1</b>. Further assessment of the duration of the IOP lowering effect of <b>13</b> in nonhuman primates was conducted by the topical administration of formulations of <b>13</b> that would be anticipated to significantly increase residence time of the compound on the ocular surface. As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, a low dose (75 Î¼g) formulation gave good reduction of IOP at the 12 h reading (29.1%) but could not maintain the desired reduction to the 24 h time period. However, the two higher dose formulations (300 Î¼g) demonstrated that a significant level of IOP reduction (36.6% and 27.7%) could be maintained in the treated hypertensive eye 24 h after administration of a single topical ocular dose.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Duration of IOP Reduction in Hypertensive Eyes of Conscious Cynomolgus Monkeys: Comparison between <b>13</b> and <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="6" align="center">postdose IOP reduction, %<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (Î¼g)</th><th class="colsep0 rowsep0" align="center">baseline IOP (mmHg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1Â h</th><th class="colsep0 rowsep0" align="center">3Â h</th><th class="colsep0 rowsep0" align="center">6Â h</th><th class="colsep0 rowsep0" align="center">10Â h</th><th class="colsep0 rowsep0" align="center">12Â h</th><th class="colsep0 rowsep0" align="center">2/12Â h<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">34.6Â (2.86)</td><td class="colsep0 rowsep0" align="left">5.5Â (4.63)</td><td class="colsep0 rowsep0" align="left">18.4<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (4.29)</td><td class="colsep0 rowsep0" align="left">22.5<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (4.72)</td><td class="colsep0 rowsep0" align="left">25.9<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (4.85)</td><td class="colsep0 rowsep0" align="left">27.9<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (5.48)</td><td class="colsep0 rowsep0" align="left">26.7<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (5.66)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">35.4Â (2.4)</td><td class="colsep0 rowsep0" align="left">7.4Â (3.3)</td><td class="colsep0 rowsep0" align="left">18.8<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a> (6.1)</td><td class="colsep0 rowsep0" align="left">20.7<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (3.9)</td><td class="colsep0 rowsep0" align="left">21.5<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (3.0)</td><td class="colsep0 rowsep0" align="left">17.8<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a> (6.8)</td><td class="colsep0 rowsep0" align="left">15.3Â (7.0)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Phosphate buffered saline, pH 7.4.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Value (SEM).</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">The vehicle control group conducted with each study did not exceed inherent model IOP variability of Â±15%.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">2/12 indicates 12 h after second dose, 24 h after first dose.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last"><i>p</i> < 0.001.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last"><i>p</i> < 0.01.</p></div><div class="footnote" id="t5fn7"><sup>g</sup><p class="last"><i>p</i> < 0.05.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Duration of IOP Reduction in Hypertensive Eyes of Conscious Cynomolgus Monkeys: Exploratory Sustained Release Formulations of <b>13</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="6" align="center">postdose IOP reduction, %<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (Î¼g)</th><th class="colsep0 rowsep0" align="center">baseline IOP (mmHg)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1Â h</th><th class="colsep0 rowsep0" align="center">3Â h</th><th class="colsep0 rowsep0" align="center">6Â h</th><th class="colsep0 rowsep0" align="center">10Â h</th><th class="colsep0 rowsep0" align="center">12Â h</th><th class="colsep0 rowsep0" align="center">24Â h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">300<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">39.9Â (3.90)</td><td class="colsep0 rowsep0" align="left">13.4Â (4.83)</td><td class="colsep0 rowsep0" align="left">28.1<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a> (5.82)</td><td class="colsep0 rowsep0" align="left">34.4<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (3.76)</td><td class="colsep0 rowsep0" align="left">39.6<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (3.80)</td><td class="colsep0 rowsep0" align="left">32.5<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (5.28)</td><td class="colsep0 rowsep0" align="left">36.6<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (4.11)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">300<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">36.8Â (2.87)</td><td class="colsep0 rowsep0" align="left">11.8Â (3.81)</td><td class="colsep0 rowsep0" align="left">29.8<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (2.80)</td><td class="colsep0 rowsep0" align="left">28.0<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (3.94)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">27.7<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (3.91)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">75<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">39.6Â (3.34)</td><td class="colsep0 rowsep0" align="left">10.4Â (3.59)</td><td class="colsep0 rowsep0" align="left">23.2<a class="ref internalNav" href="#t6fn9" aria-label="i">i</a> (4.42)</td><td class="colsep0 rowsep0" align="left">23.9<a class="ref internalNav" href="#t6fn9" aria-label="i">i</a> (4.84)</td><td class="colsep0 rowsep0" align="left">33.7<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a> (5.28)</td><td class="colsep0 rowsep0" align="left">29.1<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a> (5.70)</td><td class="colsep0 rowsep0" align="left">24.4<a class="ref internalNav" href="#t6fn9" aria-label="i">i</a> (4.19)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Phosphate buffered saline, pH 7.4.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Value (SEM).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">The vehicle control group conducted with each study did not exceed the inherent model IOP variability of Â±15%.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">0.5% Amberlite, QD.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">0.1% Amberlite/0.001% DDP, QD.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">0.6% xanthan gum, QD.</p></div><div class="footnote" id="t6fn7"><sup>g</sup><p class="last"><i>p</i> < 0.001.</p></div><div class="footnote" id="t6fn8"><sup>h</sup><p class="last"><i>p</i> < 0.01.</p></div><div class="footnote" id="t6fn9"><sup>i</sup><p class="last"><i>p</i> < 0.05.</p></div></div></div><div class="NLM_p">Agonist activation of the 5-HT<sub>2A</sub> receptor has been shown to differentially activate two signal transduction pathways: phospholipase C mediated inositol accumulation and phospholipase A2 mediated arachidonic acid release, where the stimulation of arachidonic acid release is independent of inositol accumulation.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> Since prostaglandins, i.e., FP and DP prostaglandin receptor agonists, have been shown to be efficacious<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> in the treatment of glaucoma, it was of interest to determine if the release of endogenous prostaglandins might be involved, at least in part, in the lowering of IOP observed with <b>13</b> by evaluating what effect a cyclooxygenase inhibitor might have on the IOP reduction observed for <b>13</b> in monkeys.</div><div class="NLM_p">Treatment of the hypertensive (lasered) eye of monkeys with <b>13</b>, following pretreatment with bromfenac, a cyclooxygenase inhibitor well-known<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> to readily traverse the cornea following topical ocular administration, provided a statistically significant reduction of IOP compared to the baseline value at each reading time point: 1 h (13.1%), 3 h (25.0%), and 6 h (28.9%) (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). For comparison, the response for animals similarly dosed only with compound <b>13</b>, but pretreated with the vehicle, also provided a statistically significant reduction of IOP at each reading time point: 1 h (11.3%), 3 h (24.7%), and 6 h (26.0%) (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). The mean IOP in vehicle pretreated eyes was not significantly different from the mean IOP of bromfenac pretreated eyes at any time after dosing. Thus, pretreatment with bromfenac does not alter the IOP lowering effect of a 150 Î¼g dose of <b>13</b> in hypertensive eyes in the monkey. These results suggest that the effect of <b>13</b> on IOP is not mediated by the synthesis and release of endogenous prostaglandins.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effect of Bromfenac on Lowering of IOP Induced by <b>13</b> in Ocular Hypertensive Cynomolgus Monkeys</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">postdose IOP reduction, hypertensive eye (OD lasered), %<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (Î¼g)</th><th class="colsep0 rowsep0" align="center">baseline IOP (mmHg)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">1Â h</th><th class="colsep0 rowsep0" align="center">3Â h</th><th class="colsep0 rowsep0" align="center">6Â h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bromfenac<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a>Â <b>/13</b></td><td class="colsep0 rowsep0" align="left">120/150</td><td class="colsep0 rowsep0" align="left">44.6Â (2.05)</td><td class="colsep0 rowsep0" align="left">13.1Â (2.74)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">25.0Â (3.45)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">28.9Â (3.25)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">41.8Â (1.38)</td><td class="colsep0 rowsep0" align="left">11.3Â (2.16)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">24.7Â (2.79)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">26.0Â (3.45)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Phosphate buffered saline, pH 7.4.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Value (SEM).</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">The vehicle control group conducted with each study did not exceed the inherent model IOP variability of Â±15%.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Bromfenac administered as one 30 Î¼L drop, topical, and ocular every 15 min for 4 doses, then baseline IOP measured, waited for 10 min, and then dosed with <b>13</b>; crossover with 1 week wash-out, <i>n</i> = 17.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last"><i>p</i> < 0.001.</p></div></div></div><div class="NLM_p">Activation of the 5-HT<sub>2B</sub> receptors expressed on heart valve leaflets that leads to a valvular hyperplasia has now been established as a serious drug-induced heart disease observed for some therapeutic agents subsequent to chronic oral therapy.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25">(22-25)</a> Most notable in this regard are the anorectic agent <i>d</i>-fenfluramine (active metabolite, <i>d</i>-norfenfluramine) and the anti-Parkinsonism ergolines pergolide and cabergoline, also potent 5-HT<sub>2B</sub> receptor agonists.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Hence, a compound with weak or no agonist activity at the 5-HT<sub>2B</sub> receptor would be most desirable. While the systemic concentration achieved in humans following topical ocular administration of <b>13</b> is not known at this point, this will need to be established, and there will be a need to carefully assess the posology for any eventual clinical candidate that might have even modest activity at this receptor to limit systemic exposure. However, the lack of selectivity among the 5-HT<sub>2</sub> receptor subtypes for compound <b>13</b> is not considered detrimental at this stage; in fact, it remains to be determined whether or not a multireceptor subtype profile is a requirement for the robust IOP reduction observed.</div><div class="NLM_p">Evaluation of <b>13</b> in a large panel of relevant receptors, ion-channels, second messengers, enzymes, and transporters further demonstrates its selectivity for 5-HT<sub>2</sub> receptors. Only low to weak affinity or functional response was noted for <b>13</b> at other 5-HT, adrenergic (alpha and beta subtypes), dopaminergic receptors and subtypes (<a class="ref internalNav" href="#tbl8" aria-label="Tables 8">Tables 8</a> and <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>), or muscarinic, nicotinic, glutamatergic, GABAergic, opioid, sigma, and various ion-channels transporters and various peptidergic and growth factor/hormone receptors (Table S2, <a href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Binding of <b>13</b> to Serotonergic Receptors and Î±-Adrenergic Receptor Subtypes and Transmitter Uptake Systems<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">receptor</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">687</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1D/1B</sub></td><td class="colsep0 rowsep0" align="left">2,100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>49,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>4</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>5A</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT uptake site</td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1B</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²<sub>1</sub></td><td class="colsep0 rowsep0" align="left">>78,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²<sub>2</sub></td><td class="colsep0 rowsep0" align="left">42,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>1</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2S</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2L</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>4.2</sub></td><td class="colsep0 rowsep0" align="left">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">norepinephrine uptake</td><td class="colsep0 rowsep0" align="left">>100,000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Data are an average of duplicate determinations performed at Alcon. The majority of these assays used an antagonist radioligand.</p></div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Functional Response of <b>13</b> in Selected Serotonergic and Adrenergic Receptor Assays</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">> 10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub></td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1D</sub> (rat aorta assay: agonism)<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>30,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2A</sub> (adenylyl cyclase assay: agonism)</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2B</sub> (adenylyl cyclase assay: agonism)</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2C</sub> (adenylyl cyclase assay: agonism)</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Mean Â± SEM and relative efficacy, <i>E</i><sub>max</sub> (%); all data were generated at Alcon except as noted.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Inhibition of cAMP production.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">Assay performed at MDS Pharma Services (Panlabs).</p></div></div></div><div class="NLM_p">Though the specific functional mechanism leading to the reduction of IOP by 5-HT<sub>2</sub> receptor agonists remains to be determined, one possible operational mechanism of action for the lowering of IOP by these compounds has been suggested to be an increase in the flow of aqueous humor through the uveoscleral outflow pathway, as observed in monkeys treated with <i>R</i>-DOI, which is known to be a selective 5-HT<sub>2</sub> receptor agonist.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Since, as we have shown, compound <b>13</b> is a selective 5-HT<sub>2</sub> receptor agonist with a comparable pharmacological profile to that of <i>R</i>-DOI, we suggest that <b>13</b> could also be mediating its IOP-lowering effects, at least in part, by the uveoscleral outflow pathway. However, since functional 5-HT<sub>2</sub> receptors are also located on both human ciliary muscle and trabecular meshwork (TM) cells,<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> it is possible that <b>13</b> might also promote aqueous humor outflow via the conventional TM pathway to lower IOP.</div><div class="NLM_p">In view of the well-known association of 5-HT<sub>2</sub> receptor activation in the brain with hallucinations, it was necessary to assess the potential for these effects with <b>13</b>; consequently, its discriminative stimulus effects were evaluated in a rat drug discrimination paradigm using DOM (1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane) as the training drug.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Unlike compound <b>3</b>, which fully generalized to the DOM stimulus (ED<sub>50</sub> = 0.05 mg/kg; <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>), compound <b>13</b> did not generalize to the DOM stimulus, with the animals making only 12% of their responses on the DOM-appropriate lever at a dose of 0.5 mg/kg. Higher doses resulted in a disruption of behavior. Thus, the results of the rat drug discrimination study suggest that although to some extent <b>13</b> does appear to gain access to the CNS, it does not appear to elicit a DOM-like behavior in rats, suggesting a minimal likelihood for a hallucinogenic response in humans.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Results of Drug Discrimination Studies for <b>13</b> and Selected Standard Compounds in DOM-Trained Rats and Doses for Human Response Where Known</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">ED<sub>50</sub> (mg/kg)</th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">lit. value</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">95% CL</th><th class="colsep0 rowsep0" align="center">hallucinogenic dose, (mg,Â p.o.)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DOM</td><td class="colsep0 rowsep0" align="left">0.44<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.3<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.2â0.6</td><td class="colsep0 rowsep0" align="left">1â5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R-DOI</td><td class="colsep0 rowsep0" align="left">0.26<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.2<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.1â0.3</td><td class="colsep0 rowsep0" align="left">1.5â3.0 (<i>rac</i>)<a class="ref internalNav" href="#t10fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-MeOâDMT</td><td class="colsep0 rowsep0" align="left">1.22<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.86<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.50â1.45</td><td class="colsep0 rowsep0" align="left">5â10 (parenteral)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.05<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.03â0.10</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">32%Â @Â 1<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">12%Â @Â 0.5<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a>.</p></div><div class="footnote" id="t10fn2"><sup>b</sup><p class="last">Ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</p></div><div class="footnote" id="t10fn3"><sup>c</sup><p class="last">Ref <a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a>.</p></div><div class="footnote" id="t10fn4"><sup>d</sup><p class="last">Ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>.</p></div><div class="footnote" id="t10fn5"><sup>e</sup><p class="last">Ref <a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">39</a>.</p></div><div class="footnote" id="t10fn6"><sup>f</sup><p class="last">Maximum percentage DOM-appropriate responding at the highest responding-dose shown.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>13</b> has been shown to have an overall profile favorable for consideration as a candidate for further preclinical evaluation in support of a proof-of-concept study to evaluate the utility of 5-HT<sub>2</sub> receptor agonists for the treatment of ocular hypertension and glaucoma in humans. Furthermore, it showed a long duration of IOP reduction in nonhuman primates; though it is difficult to predict duration of action across species, this observation is nonetheless quite encouraging for this new class of agents. Results from drug discrimination studies suggest that there are no apparent CNS issues associated with the potent 5-HT<sub>2A</sub> receptor agonist activity of this compound, which did not generalize to the DOM discriminative stimulus in rats. Additional studies will be required to determine the likelihood of any potential liability associated with 5-HT<sub>2B</sub> receptor agonist activity for such compounds when chronically dosed via a topical ocular route, compared to that observed following systemic delivery of therapeutics with this undesirable activity. In view of the extremely robust reduction of IOP observed for <b>13</b>, further investigation of what involvement each of the numerous signaling events initiated by 5-HT<sub>2</sub> receptor subtype activation might have in this favorable response is warranted to gain a better understanding of the specific biochemical events that lead to the reduction of IOP in primates for this class of compounds; perhaps leading to the identification of more specific targets to pursue for the treatment of ocular hypertension.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General</h3><div class="NLM_p">All starting materials and reagents were purchased from commercial suppliers; these were used without further purification following the confirmation of identity. Melting points were determined in open capillaries using a Thomas-Hoover Uni-Melt Apparatus and are uncorrected. Organic extracts were dried with magnesium sulfate. Chromatography refers to column chromatography conducted on 230â400 mesh silica gel from E. Merck. Silica gel TLC plates were obtained from EM Separation Technology. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were determined on either a Bruker AMX 200 MHz spectrometer, Bruker AVANCE III 400 MHz spectrometer, or a Bruker DRX 600 MHz spectrometer. Chemical shift values are reported in parts per million (Î´) relative to tetramethylsilane as internal standard. Mass spectra were obtained on a Finnigan TSQ45 triple quadrupole mass spectrometer, and HPLC-MS analyses were recorded on a Finnigan LCQ Classic mass spectrometer. Optical rotations were determined using a Jasco DIP-370 Polarimeter. All compounds subjected to biological testing showed >95% purity as determined by combustion analysis. Elemental analyses were performed by Atlantic Microlabs, Norcross, Georgia and are within Â±0.4% of the theoretical values. Evaporations were performed under reduced pressure on a rotary evaporator at 40 Â°C unless otherwise indicated.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> </h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> 7-Bromo-1-[(2<i>R</i>)-2-[<i>tert</i>-butyl(dimethyl)silyl]oxypropyl]indazol-6-ol (<b>8</b>)</h5><div class="NLM_p">A solution of (2<i>R</i>)-1-(6-benzyloxyindazol-1-yl)propan-2-ol (<b>5</b>)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (9.41 g, 0.0334 mol) in THF (50 mL, dry) was prepared under nitrogen at room temperature. Imidazole (4.54 g, 0.0667 mol) and <i>tert</i>-butyldimethylchlorosilane (8.05 g, 0.0534 mol) were added to this solution, and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was treated with saturated aqueous sodium bicarbonate (300 mL) and extracted with ethyl acetate (2 Ã 200 mL), and the combined organic layers were dried, filtered, and evaporated to a yellow oil; column chromatography (silica, gradient, ethyl acetate/hexane; 1:9 to 2:8) gave <b>6</b> ([(1<i>R</i>)-2-(6-benzyloxyindazol-1-yl)-1-methyl-ethoxy]-<i>tert</i>-butyl-dimethyl-silane) as a yellow oil (12.4 g, 93%). Single compound by LC-MS (APCI) <i>m</i>/<i>z</i> 397 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.79 (s, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.39â7.25 (m, 4H), 7.16 (s, 1H), 6.80â6.75 (m, 2H), 5.02 (s, 2H), 4.23 (m, 1H), 4.12 (m, 2H), 1.12 (d, <i>J</i> = 4.0 Hz, 3H), 0.65 (s, 9H), â0.23 (s, 3H), â0.54 (s, 3H).</div><div class="NLM_p">To a solution of <b>6 (</b>28.5 g, 0.072 mol) in methanol (280 mL) was added 10% Pd/C (2.8 g), and this mixture was maintained under hydrogen (1 atm, balloon) with stirring for 2 days. A white solid was observed in the reaction mixture; this solid was dissolved by the addition of acetone (250 mL), and the catalyst was removed by filtration through diatomaceous earth. Evaporation of the filtrate gave <b>7</b> (1-[(2<i>R</i>)-2-[<i>tert</i>-butyl(dimethyl)silyl]oxypropyl]indazol-6-ol) as a gray solid (20.3 g, 92%): mp 171â172 Â°C, which was a single compound by LC-MS (APCI) <i>m</i>/<i>z</i> 307 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) Î´ 9.50 (s, 1H), 7.83 (d, <i>J</i> = 4.0 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 6.76 (s, 1H), 6.62 (m, 1H), 4.14 (m, 3H), 1.14 (s, 3H), 0.67 (s, 9H), â0.19 (s, 3H), â0.48 (s, 3H).</div><div class="NLM_p last">To a stirred solution of <b>7</b> (3.79 g, 12.4 mmol) in anhydrous THF (100 mL) at 0 Â°C was added <i>N</i>-bromosuccinimide (2.20 g, 12.4 mmol). The reaction mixture was stirred for 30 min, quenched by the addition of a saturated aqueous solution of sodium thiosulfate (50 mL), and extracted with ethyl acetate (3 Ã 100 mL). The combined extracts were washed with a saturated aqueous solution of sodium bicarbonate (100 mL) and dried. Column chromatography (silica, gradient, ethyl acetate/hexane) gave <b>8</b> as a solid (3.66 g, 77%): mp 103â105 Â°C; LC-MS (APCI) <i>m</i>/<i>z</i> 385, 387 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz) Î´ 7.90 (s, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 6.89 (d, <i>J</i> = 8.0 Hz, 1H), 5.87 (s, 1H), 4.93 (dd, <i>J</i> = 8.0, 14 Hz, 1H), 4.49 (m, 1H), 4.41 (m, 1H), 1.21 (d, <i>J</i> = 6.0 Hz, 3H), 0.73 (s, 9H), â0.15 (s, 3H), â0.46 (s, 3H).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> [(1<i>R</i>)-2-[7-Bromo-6-[3-bromo-2-(1-ethoxyethoxy)propoxy]indazol-1-yl]-1-methyl-ethoxy]-<i>tert</i>-butyl-dimethyl-silane (<b>10</b>)</h5><div class="NLM_p">To a suspension of <b>8</b> (3.66 g, 9.51 mmol) and potassium carbonate powder (1.92 g, 1.46 mmol) in acetone (200 mL) was added epibromohydrin (1.32 mL, 15.1 mmol). The suspension was heated at reflux overnight, and the reaction was monitored by TLC. The suspension was cooled, filtered through diatomaceous earth, and evaporated to dryness. Column chromatography (silica, gradient, of ethyl acetate/hexane (2% to 10%) gave <b>9</b> ([(1<i>R</i>)-2-[7-bromo-6-(oxiran-2-ylmethoxy)indazol-1-yl]-1-methyl-ethoxy]-<i>tert</i>-butyl-dimethyl-silane) as an oil (3.32 g, 79%): <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): Î´ 7.92 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.95 (m, 1H), 4.61 (m, 1H), 4.40 (m, 1H), 4.17â4.11 (m, 2H), 3.43 (br s, 1H), 2.94â2.86 (m, 2H), 1.19 (d, <i>J</i> = 6.0 Hz, 3H), 0.73 (s, 9H), â0.14 (s, 3H), â0.41 (s, 3H).</div><div class="NLM_p last">A mixture of magnesium (0.39 g, 16.1 mmol) and 1,2-dibromoethane (1.13 g, 6.02 mmol) in anhydrous THF (50 mL) was heated at 60 Â°C with stirring under nitrogen for 30 min. The reaction mixture was cooled on ice, and a solution of <b>9</b> (1.77 g, 4.01 mmol) in THF (5 mL) was added. The mixture was stirred for 1 h, heated at 50 Â°C for 10 min, cooled, and poured into an aqueous solution of ammonium chloride. Extraction of this mixture with ethyl acetate (3 Ã 100 mL) and evaporation of the extracts gave the crude bromohydrin (1-bromo-3-[7-bromo-1-[(2<i>R</i>)-2-[<i>tert</i>-butyl(dimethyl)silyl]oxypropyl]indazol-6-yl]oxy-propan-2-ol) as an oil (1.88 g, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): Î´ 7.93 (s, 1H), 7.6 (d, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 1H), 5.01 (dd, <i>J</i> = 8, 14 Hz, 1H), 4.54 (dd, <i>J</i> = 6, 14 Hz, 1H), 4.37â4.18 (m, 4H), 3.72 (m, 2H), 2.75 (d, <i>J</i> = 4.0 Hz, 1H), 1.18 (d, <i>J</i> = 6.0 Hz, 3H), 0.71 (s, 9H), â0.14 (s, 3H), â0.44 (s, 3H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 50 mHz) Î´ 154.1, 137.9, 133.4, 121.6, 121.0, 109.9, 71.8, 68.4, 68.2, 56.3, 36.7, 25.4, 21.0, 17.3, â5.1, â5.7. This oil was dissolved in dichloromethane (50 mL) and cooled on ice. To the cold solution was added <i>p-</i>toluenesulfonic acid (0.05 g) and ethyl vinyl ether (1 mL, 10.5 mmol) with stirring; after 30 min, TLC showed no starting material. The reaction mixture was poured into a saturated aqueous solution of sodium bicarbonate (100 mL) and extracted with dichloromethane (3 Ã 50 mL). The combined extracts were dried, filtered, and evaporated to dryness to give a crude oil; column chromatography (silica, gradient, ethyl acetate/hexane 6% to 8%) provided <b>10</b> as an oil (1.79 g, 81%): LC-MS (APCI) <i>m</i>/<i>z</i> 593, 595, 597 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): Î´ 7.92 (s, 1H), 7.6 (d, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 1H), 5.04â4.94 (m, 2H), 4.61â4.58 (m, 1H), 4.35â4.24 (m, 4H), 3.77â3.58 (m, 4H), 1.43 (m, 2H), 1.28â1.17 (m, 7H), 0.70 (s, 9H), â0.14 (s, 3H), â0.41 (m, 3H).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> 1-[(2<i>S</i>)-2-Azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>12</b>)</h5><div class="NLM_p">To a stirred solution of <b>10</b> (1.78 g, 2.99 mmol) in anhydrous THF (100 mL) under nitrogen at â78 Â°C was added via syringe a 2.5 M solution of <i>n</i><b>-</b>butyllithium in hexanes (1.56 mL, 3.90 mmol). The reaction mixture was stirred for 1 h and quenched by the addition of a saturated aqueous solution of sodium bicarbonate (100 mL); this mixture was allowed to warm to room temperature and extracted with ethyl acetate (3 Ã 100 mL). The combined extracts were dried, filtered, and evaporated to dryness to give a crude oil (1.3 g): LC-MS (APCI) <i>m</i>/<i>z</i> 435 [M + H]<sup>+</sup>. The oil (0.90 g, 2.07 mmol) was mixed with anhydrous THF (50 mL) and to the solution was added a 1 M solution of tetra-<i>n</i>-butylammonium fluoride in THF (3.11 mL, 3.11 mmol). The mixture was stirred overnight, evaporated to dryness, mixed with a saturated aqueous solution of sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 Ã 50 mL). The combined extracts were dried, filtered, and evaporated to give a crude oil; column chromatography (silica, gradient, ethyl acetate/hexane 10% to 40%) gave <b>11</b> ((2<i>R</i>)-1-[8-(1-ethoxyethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]propan-2-ol) as an oil (0.35 g, 53%): LC-MS (APCI) <i>m</i>/<i>z</i> 321 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): Î´ 7 0.89 (s, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 6.73 (d, <i>J</i> = 8.0 Hz, 1H), 4.97 (m, 1H), 4.52â3.98 (m, 6H), 3.69â3.03 (m, 5H), 1.41â1.18 (m, 9H).</div><div class="NLM_p last">To a stirred solution of <b>11</b> (0.82 g, 2.56 mmol) in anhydrous THF (80 mL) at 0 Â°C was added triethylamine (1.29 g, 12.8 mmol) and methanesulfonic anhydride (1.11 g, 6.40 mmol); this mixture was stirred for 1 h and evaporated to dryness. The residue was mixed with anhydrous DMF (100 mL) and sodium azide (3.32 g, 51.2 mmol) followed by heating at 95 Â°C for 7 h. The reaction mixture was cooled and mixed with a saturated aqueous solution of sodium bicarbonate (200 mL), extracted with ethyl acetate (3 Ã 100 mL), and the combined extracts were evaporated to give the azide as an oil (0.72 g, 81%). A solution of this oil in THF (50 mL) containing 2 N HCl (10 mL) was stirred at room temperature for 30 min and then poured into a saturated aqueous solution of sodium bicarbonate (100 mL); this mixture was extracted with ethyl acetate (3 Ã 50 mL). The combined extracts were dried, filtered, and evaporated to give a crude oil; column chromatography (silica, gradient, ethyl acetate/hexane 20% to 40%) gave <b>12</b> as an oil (0.85 g, 79%): LC-MS (APCI) <i>m</i>/<i>z</i> 274 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): Î´7.95 (s, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 6.64 (d, <i>J</i> = 8.4 Hz, 1H), 5.22 (t, <i>J</i> = 0.72 Hz, 1H), 4.54â4.45 (m, 2H), 4.11 (m, 3H), 3.86 (m, 1H), 3.36 (m, 1H), 2.97 (m, 1H), 1.24 (d, <i>J</i> = 6.6 Hz, 3H).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (8<i>R</i>)-1-[(2<i>S</i>)-2-Azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>12a</b>) and (8<i>S</i>)-1-[(2<i>S</i>)-2-Azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>12b</b>)</h4><div class="NLM_p last">The diastereomeric mixture <b>12</b> (1.35 g) was separated (Chiral Technologies, Inc.) using a CHIRACEL OJ column: eluent 2-propanol/hexane 1:9 at 25 Â°C. UV detector, 235 nm: <b>12b</b> (0.679 g) and <b>12a</b> (0.653 g), the first (6.09 min) and second (6.97 min) peaks, respectively. For the final analysis of diastereomeric purity, a CHIRACEL OD, 10 Î¼m column was used with ethanol/hexane (5/95) as mobile phase: <b>12b</b> and <b>12a</b> showed de of 99.5% and 97.8%, respectively. (Note: Under the final analytical conditions, the order of elution of the two diastereomers was reversed relative to that observed for the prep column.)</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>13</b>)</h4><div class="NLM_p">Diastereomer <b>12a</b> (0.23 g) was dissolved in MeOH and Pd/C (10%, 0.04 g) added; this mixture was placed under hydrogen at atmospheric pressure for 16 h. The catalyst was removed by filtration, washed with MeOH, and the filtrate evaporated to give <b>13</b> (0.21 g). Crystallization from methanol/ethyl acetate gave a pale yellow solid: mp 126â128 Â°C; [Î±]<sub>D</sub> = +47.7 (0.352%, MeOH); [Î±]<sub>405</sub> = +112 (0.352%, MeOH); LC-MS (APCI) <i>m</i>/<i>z</i> 248 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): Î´ 7.85 (s, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 1H), 6.71 (d, <i>J</i> = 8.4 Hz, 1H), 4.39 (d, <i>J</i> = 4.2 Hz, 1H), 4.29 (m, 2H), 4.11 (m, 2H), 3.45 (m, 1H), 3.28 (dd, <i>J</i> = 4.8, 11.4 Hz, 2H), 1.12 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 mHz): Î´ 153.32, 139.97, 133.93, 119.94, 119.93 (C4), 113.63, 100.56, 69.22, 62.53, 58.75, 48.45, 30.89, 20.90. Anal. (C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>) C, H, N.</div><div class="NLM_p last">Crystals suitable for X-ray analysis were obtained from 2-propanol; this analysis established the absolute stereochemistry of R for the hydroxyl group at position C8 (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf" class="ext-link">Supporting Information</a>.)</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (8<i>S</i>)-1-[(2<i>S</i>)-2-aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>14</b>)</h4><div class="NLM_p last">Treatment of diasteroisomer <b>12b</b> using the same procedure as that described above for the preparation of <b>13</b> provided amine <b>14</b> as an oil: LC-MS (APCI) <i>m</i>/<i>z</i> 248 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 200 MHz): Î´ 7.89 (s, 1H), 7.42 (d, <i>J</i> = 8.6 Hz, 1H,), 6.62 (d, <i>J</i> = 8.6 Hz, 1H), 4.26 (m, 2H), 4.09 (m, 2H), 3.84 (m, 1H), 3.45â2.85 (m, 6H), 0.94 (d, <i>J</i> = 6.4 Hz, 3H); [Î±]<sub>D</sub> = â6.21 (0.467%, MeOH); [Î±]<sub>405</sub> = â13.5 (0.467%, MeOH). Anal. (C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>Â· 0.2 H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Alternate Synthesis of (8<i>R</i>)-1-[(2<i>S</i>)-2-Azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>12a</b>)</h4><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> <i>tert</i>-Butyl-dimethyl-[(1<i>R</i>)-1-methyl-2-(7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl)ethoxy]silane (<b>16</b>)</h5><div class="NLM_p">A solution of <b>7</b> (10.9 g, 0.0357 mol) in acetone (250 mL) was degassed with reduced pressure and nitrogen; pulverized potassium carbonate (6.90 g, 0.0357 mol) and propargyl bromide (5.19 mL, 0.0464 mol) were added to the solution, and the mixture was refluxed for 18 h. Additional potassium carbonate (1.97 g, 0.014 mol) and propargyl bromide (1.2 mL, 0.0107 mol) were added, and the mixture was refluxed an additional 2 h. The reaction mixture was filtered, and the filtrate evaporated to a dark yellow oil (12.2 g); column chromatography (silica gel, gradient, ethyl acetate/hexane, 8:2 to 7:3) gave <b>15</b> (<i>tert</i>-butyl-dimethyl-[(1<i>R</i>)-1-methyl-2-(6-prop-2-ynoxyindazol-1-yl)ethoxy]silane) as a yellow oil (10.9 g, 89%): LC-MS (APCI) <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): Î´ 7.89 (s, 1H), 7.56 (d, <i>J</i> = 6.0 Hz, 1H), 6.89 (s, 1H), 6.83 (dd, <i>J</i> = 6, 12 Hz, 1H), 4.75 (s, 2H), 4.33 (m, 1H), 4.22 (m, 2H), 2.54 (m, 1H), 1.22 (d, <i>J</i> = 6 Hz, 3H), 0.74 (s, 9H), â0.12 (s, 3H), â0.41 (s, 3H).</div><div class="NLM_p last">A suspension of <b>15</b> (10.94 g, 0.0318 mol) in mesitylene (60 mL) was degassed with reduced pressure and nitrogen, followed by heating the mixture at 200 Â°C in a sealed glass pressure vessel for 2 h and 190 Â°C for 18 h. Column chromatography of the brown solution (silica gel, hexane/ethyl acetate 9:1) gave <b>16</b> as a yellow solid (9.53 g, 87%): mp 58â59 Â°C; LC-MS (APCI) <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): Î´ 7.86 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.23 (d, <i>J</i> = 11 Hz, 1H), 6.70 (d, <i>J</i> = 9.0 Hz, 1H), 5.83 (dt, <i>J</i> = 4.2, 9.6 Hz, 1H), 4.73 (m, <i>J</i> = 4.2, 13.8, 24.0 Hz, 2H), 4.45â4.30 (m, 2H), 4.36 (m, 1H), 1.26 (d, <i>J</i> = 6.0 Hz, 3H), 0.71 (s, 9H), â0.16 (s, 3H), â0.46 (s, 3H).</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (8<i>R</i>)-1-[(2<i>R</i>)-2-[<i>tert</i>-Butyl(dimethyl)silyl]oxypropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>17a</b>)</h5><div class="NLM_p last">To a solution of <b>16</b> (1.0 g, 2.91 mmol) in anhydrous THF (80 mL) was added a 0.5 M solution of 9-BBN in THF (1.3 mL, 6.4 mmol) and heated at reflux temperature for 2 h. The mixture was cooled on ice, and the reaction quenched by the addition of MeOH (5 mL) and then 30% H<sub>2</sub>O<sub>2</sub> (5 mL) over about 1 min. The mixture was stirred for 1 h at ambient temperature until one major polar product was detected on TLC. The volatiles were evaporated, and the residue was mixed with a saturated solution of sodium bicarbonate (50 mL) and extracted with ethyl acetate (3 Ã 50 mL). The combined extracts were dried, filtered, and concentrated to give a crude oil (NMR showed a 9:1 mixture of diastereomers). Column chromatography (silica, gradient 10% to 30% ethyl acetate/hexane) gave <b>17a</b> [<i>R</i>-C8-OH] as an oil (0.56g, 53%): LC-MS (APCI) <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): Î´ 7.90 (s, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 6.60 (d, <i>J</i> = 8.0 Hz, 1H), 5.25 (s, 1H), 4.45â4.29 (m, 2H), 4.21 (m, 1H), 4.05 (m, 2H), 3.77 (m, 1H), 3.58 (m, 1H), 2.82 (m, 1H), 1.21 (d, <i>J</i> = 6.0 Hz, 3H), 0.61 (s, 9H), â0.22 (s, 3H), â0.64 (s, 3H). Also obtained was an oil (0.22 g) that consisted of a mixture of the two unresolved isomers: <b>17a</b>, <i>R</i>-C8-OH and <b>17b</b>: <i>S</i>-C8-OH.</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (8<i>R</i>)-1-[(2<i>S</i>)-2-Azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-ol (<b>12a</b>)</h5><div class="NLM_p">To a mixture of <b>17a</b> (0.56 g, 1.55 mmol) and pyridinium <i>p</i>-toluenesulfonate (0.05 g) in methylene chloride (50 mL) at 0 Â°C was added ethyl vinyl ether (1 mL). After 1 h, the ice bath was removed, and the mixture was stirred for additional 1 h. TLC showed a less polar compound. TEA (1 mL) was added to the mixture and evaporated to dryness, and anhydrous THF (10 mL) was added, followed by tetra-<i>n</i>-butylammonium fluoride (1 M, 3.1 mL). The mixture was stirred for 1 h and evaporated to give a crude product. Column chromatography (silica, gradient, 10% to 30% ethyl acetate/hexane) gave <b>18</b> ((2<i>R</i>)-1-[(8<i>R</i>)-8-(1-ethoxyethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]propan-2-ol) as an oil (0.47 g, 96%): LC-MS (APCI) <i>m</i>/<i>z</i> 321 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): Î´ 7.88 (s, 1H), 7.43 (d, <i>J</i> = 6.0 Hz, 1H), 6.73 (d, <i>J</i> = 6.0 Hz, 1H), 4.94 (d, <i>J</i> = 6.0 Hz, 1H), 4.52â4.39 (m, 2H), 4.32â4.25 (m, 3H), 3.99 (m, 1H), 3.68 (m, 1H), 3.59 (m, 3H), 3.05 (m, 1H), 1.39 (d, <i>J</i> = 5.4 Hz, 3H), 1.29 (m, 3H), 1.24 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p last">To a solution of <b>18</b> (0.46 g, 1.44 mmol) in anhydrous THF (50 mL) at 0 Â°C was added triethylamine (0.73 g, 1.0 mL, 7.19 mmol) and methanesulfonic anhydride (0.50 g, 2.88 mol) with stirring. The ice bath was removed, and the reaction was stirred for about 20 min. The mixture was concentrated to dryness, and the residue was mixed with sodium azide (1.05 g, 16.1 mmol) and anhydrous DMF (50 mL). The mixture was heated at 100 Â°C for about 5 h, cooled, and mixed with a saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (2 Ã 100 mL). The combined organic layers were dried, filtered, and evaporated to a yellow residue. Column chromatography (gradient, 1% to 10% ethyl acetate/hexane) gave an oil (0.38 g, 77%), which was dissolved in MeOH (10 mL), and treated with TsOH (cat.) for 1 h at ambient temperature followed by the addition of TEA (0.1 mL); this mixture was stirred for 5 min and evaporated to a residue. Column chromatography (gradient, 10% to 35% ethyl acetate/hexane) gave <b>12a</b> as a solid (0.27 g, 99%): LC-MS (APCI) <i>m</i>/<i>z</i> 274 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): Î´ 7.96 (s, 1H), 7.45 (d, <i>J</i> = 9.0 Hz, 1H), 6.64 (d, <i>J</i> = 9.0 Hz, 1H), 5.22 (s, 1H), 4.54â4.43 (ddd, <i>J</i> = 4.2, 8.4, 14.4 Hz, 2H), 4.12 (m, 3H), 3.86 (dd, <i>J</i> = 6.6, 10.2 Hz, 1H), 3.41 (dd, <i>J</i> = 5.4, 15.6 Hz, 1H), 2.92 (dd, <i>J</i> = 6.0, 15.6 Hz, 1H), 1.25 (d, <i>J</i> = 6.6 Hz, 3H).</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> </h4><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (8<i>R</i>)-8-Azido-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazole (<b>19</b>)</h5><div class="NLM_p last">To a stirred solution of <b>12b</b> (0.44 g, 1.61 mmol) in anhydrous THF (50 mL) at 0 Â°C was added triethylamine (0.65 g, 6.44 mmol) and methanesulfonic anhydride (0.56 g, 3.22 mmol). The mixture was stirred for 1 h and evaporated to dryness. The residue was mixed with anhydrous DMSO (50 mL), sodium azide (1.05 g, 16.1 mmol), and heated at 90 Â°C for 5 h. The reaction mixture was cooled and mixed with a saturated aqueous solution of sodium bicarbonate (100 mL), extracted with ethyl acetate (3 Ã 80 mL), and evaporated to give an oil. Column chromatography (silica, gradient of ethyl acetate/hexane (5% to 25%)) gave the azide <b>19</b> as an oil (0.19 g, 40%): LC-MS (ESI) <i>m</i>/<i>z</i> 299 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz): Î´7.92 (s, 1H), 7.46 (d, <i>J</i> = 12 Hz, 1H), 6.75 (d, <i>J</i> = 12 Hz, 1H), 4.44 (m, 2H), 4.27 (d, <i>J</i> = 12 Hz, 1H), 4.16â4.09 (m, 3H), 3.38 (m, 2H), 1.35 (d, <i>J</i> = 6.0 Hz, 3H).</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-amine (<b>20</b>)</h5><div class="NLM_p last">The oil <b>19</b> (0.19 g, 0.64 mmol) was dissolved in MeOH, and Pd/C (10%, 0.019 g) was added; this mixture was placed under hydrogen (1 atm) for 16 h. The reaction mixture was filtered and the filtrate evaporated to give an oil, which was dissolved in MeOH and treated with 2 N HCl/EtOH. Evaporation gave a crude solid that was triturated with a mixture of methanol in dichloromethane to give <b>20</b> as a pale yellow solid (0.16 g, 98%): mp >300 Â°C; LC-MS (ESI) <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): Î´ 8.66 (br s, 3H), 8.45 (br s, 3H), 8.04 (s, 1H), 7.56 (d, <i>J</i> = 6.0 Hz, 1H), 6.75 (d, <i>J</i> = 6.0 Hz, 1H), 4.75 (m, 1H), 4.61 (m, 1H), 4.31 (m, 2H), 3.86 (br s, 1H), 3.79 (br t, 1H), 3.64 (m, 1H), 3.46 (m, 1H), 1.15 (d, <i>J</i> = 6.0 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): Î´ 152.7, 139.2, 134.3, 120.0, 119.6, 113.6, 99.9, 65.1, 52.5, 47.2, 42.6, 24.9, 15.9. Anal. (C<sub>13</sub>H<sub>18</sub>N<sub>4</sub>OÂ·3HClÂ·0.33 C<sub>2</sub>H<sub>5</sub>OHÂ·0.5 H<sub>2</sub>O) C, H, N.</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> </h4><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> (2<i>R</i>)-1-[(8<i>R</i>)-8-(2-Hydroxyethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]propan-2-ol (<b>23</b>)</h5><div class="NLM_p">To a stirred solution of <b>17a</b> (2.05 g, 5.66 mmol) in anhydrous DMF (60 mL) at 0 Â°C was added sodium hydride (60% dispersion in mineral oil, 0.34 g, 8.49 mmol). The mixture was stirred for 20 min, and to this solution was added <i>t</i>-butyl bromoacetate (1.32 g, 6.79 mmol) and sodium iodide (0.1 g). The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was poured into a saturated aqueous solution of sodium bicarbonate (100 mL) and extracted with ethyl acetate (3 Ã 100 mL). The combined extracts were dried, filtered, and evaporated to dryness. Column chromatography (silica, gradient of ethyl acetate/hexane (5% to 25%) gave <b>21</b> (<i>tert</i>-butyl 2-[[(8<i>R</i>)-1-[(2<i>R</i>)-2-[<i>tert</i>-butyl(dimethyl)silyl]oxypropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetate) as an oil (2.11 g, 78%): LC-MS (APSI) <i>m</i>/<i>z</i> 477 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.85 (s, 1H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 6.67 (d, <i>J</i> = 8.0 Hz, 1H), 4.53â4.25 (m, 4H), 4.15 (s, 2H), 4.03 (m, 2H), 3.80 (m, 1H), 3.02 (m, 1H), 1.50 (s, 9H), 1.25 (d, <i>J</i> = 8.0 Hz, 3H), 0.66 (s, 9H), â0.20 (s, 3H), â0.62 (s, 3H).</div><div class="NLM_p">To a stirred solution of <b>21</b> (2.60 g, 4.41 mmol) in anhydrous THF (50 mL) was added a solution of tetra-<i>n</i>-butylammonium fluoride (1 M in THF, 5.29 mL, 5.29 mmol). The mixture was stirred overnight at room temperature, evaporated to dryness, mixed with a saturated aqueous solution of sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 Ã 60 mL). The combined extracts were dried, filtered, and evaporated to give <b>22</b> (<i>tert</i>-butyl 2-[[(8<i>R</i>)-1-[(2<i>R</i>)-2-hydroxypropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetate) as an oil (1.32 g, 82%): LC-MS (APCI) <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.88 (s, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 1H), 6.72 (d, <i>J</i> = 8.4 Hz, 1H), 4.52 (m, 1H), 4.41â4.25 (m, 3H), 4.16 (d, <i>J</i> = 2.4 Hz, 2H), 4.15â4.04 (m, 2H), 3.56 (m, 1H), 3.50 (d, <i>J</i> = 3.2 Hz, 1H), 3.18 (m, 1H), 1.49 (s, 9H), 1.28 (d, <i>J</i> = 6.0 Hz, 3H).</div><div class="NLM_p last">To a stirred solution of <b>22</b> (0.65 g, 1.80 mmol) in anhydrous THF at 0 Â°C was added lithium aluminum hydride (1 M in THF, 1.80 mL, 1.80 mmol). The mixture was stirred at room temperature for 1 h, cooled on ice, and quenched by the addition of 2 N HCl. The mixture was extracted with ethyl acetate (3 Ã 60 mL), dried, filtered, and evaporated to dryness. Column chromatography (silica, gradient, 5% to 10% ethyl acetate in hexane) gave <b>23</b> ((2<i>R</i>)-1-[(8<i>R</i>)-8-(2-hydroxyethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]propan-2-ol) as an oil (0.37 g, 71%): LC-MS (APCI) <i>m</i>/<i>z</i> 293 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.88 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 6.73 (d, <i>J</i> = 8.0 Hz, 1H), 4.53 (dd, <i>J</i> = 4.0, 12 Hz, 2H), 4.36 (m, 1H), 4.12 (m, 2H), 4.01 (m, 1H), 3.49 (m, 1H), 3.37 (d, <i>J</i> = 3.6 Hz, 1H), 3.13 (dd, <i>J</i> = 5.6, 16 Hz, 1H), 1.99 (br s, 1H), 1.28 (d, <i>J</i> = 6.0 Hz, 3H).</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> (2<i>S</i>)-1-[(8<i>R</i>)-8-(2-Aminoethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]propan-2-amine (<b>25</b>)</h5><div class="NLM_p">To a stirred solution of <b>23</b> (0.37 g, 1.27 mmol) in anhydrous THF (20 mL) at 0 Â°C was added triethylamine (0.64 g, 6.34 mmol) and methanesulfonic anhydride (0.66 g, 3.81 mmol). The mixture was stirred for 30 min, evaporated to dryness, and mixed with anhydrous dimethyl sulfoxide (30 mL) and sodium azide (0.83 g, 12.7 mmol). The mixture was heated at 90 Â°C for 4 h, cooled, mixed with a saturated aqueous solution of sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 Ã 50 mL). The combined extracts were filtered and evaporated to give <b>24</b> ((8<i>R</i>)-8-(2-azidoethoxy)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazole) as an oil (0.36 g, 84%): LC-MS (ESI) <i>m</i>/<i>z</i> 343 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.91 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 6.73 (d, <i>J</i> = 8.4 Hz, 1H), 4.46 (m, 2H), 4.22 (m, 1H), 4.12 (m, 3H), 3.82 (m, 2H), 3.42 (m, 4H), 1.32 (d, <i>J</i> = 6.4 Hz, 3H).</div><div class="NLM_p last">To a solution of <b>24</b> (0.36 g, 1.05 mmol) in methanol (10 mL) was added Pd/C (10%, 0.03 g) and the mixture stirred under hydrogen (1 atm) for 2 days followed by filtration and evaporation of the filtrate to an oil. The oil was dissolved in methanol (5 mL), and 2 N HCl/EtOH (3 mL) was added followed by evaporation to a solid that was triturated with methanol/dichloromethane (1:10), filtered, and dried to give <b>25</b> as an off-white solid (0.25 g, 60%): mp 282â285 Â°C; LC-MS (APCI) <i>m</i>/<i>z</i> 291 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) Î´ 8.46 (br s, 3H), 8.14 (br s, 2H), 8.01 (s, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 6.68 (d, <i>J</i> = 8.0 Hz, 1H), 4.80 (dd, <i>J</i> = 4.0, 12 Hz, 1H), 4.64 (dd, <i>J</i> = 8.0, 12 Hz, 1H), 4.17 (s, 2H), 4.05 (t, <i>J</i> = 4.0 Hz, 1H), 3.89â3.82 (m, 3H), 3.50 (dd, <i>J</i> = 4.0, 16 Hz, 1H), 3.27 (dd, <i>J</i> = 4.4, 17 Hz, 1H), 3.00 (br s, 2H), 1.15 (s, 3H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 mHz) Î´ 153.1, 139.7, 134.3, 119.4, 119.2, 113.3, 101.2, 69.24, 65.7, 64.4, 52.4, 47.3, 38.7, 27.1, 15.9. Anal. (C<sub>15</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>Â·2 HClÂ·0.25 H<sub>2</sub>O) C, H, N.</div></div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> </h4><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>tert</i>-Butyl 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetate (<b>26</b>)</h5><div class="NLM_p last">A solution of <b>22</b> (0.4 g, 1.33 mmol) in THF (14 mL) was cooled in an ice bath, triethylamine (0.74 mL, 5.3 mmol) and methanesulfonic anhydride (0.42 g, 2.39 mmol) were added, and the mixture was stirred for 40 min followed by the addition of sodium azide (0.86 g, 13.3 mmol) and evaporation to a residue, which was taken up in DMSO (14 mL) and stirred at 90 Â°C for 2.5 h. The reaction mixture was cooled to room temperature and quenched with brine (50 mL); this mixture was extracted with ethyl acetate (3 Ã 100 mL). The combined extracts were dried, filtered, and evaporated to give a colorless oil (0.49 g); column chromatography (silica gel, hexane/ethyl acetate) gave <b>26</b> as a colorless solid: (0.42 g, 82%); mp 72â74 Â°C; LC-MS (APCI) <i>m</i>/<i>z</i> 388 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´7.90 (s, 1H), 7.45 (d, <i>J</i> = 6 Hz, 1H), 6.70 (d, <i>J</i> = 6 Hz, 1H), 4.5 (m, 2H), 4.3 (m, 1H), 4.1 (m, 5H), 3.35 (m, 2H), 1.50 (s, 9H), 1.32 (d, <i>J</i> = 4 Hz, 3H).</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]ethanol (<b>28</b>)</h5><div class="NLM_p">A solution of <b>26</b> (1.2 g, 3.1 mmol) in THF (30 mL) was cooled in an ice bath, and a 1 N solution of lithium aluminum hydride in THF (6.2 mL, 6.2 mmol) was added, and the reaction mixture was allowed to warm to room temperature with stirring. After stirring for 1 h, the reaction mixture was cooled in an ice bath and quenched by the dropwise addition of 2 N aqueous potassium hydroxide (0.317 mL). The solids were filtered off, and the filtrate was evaporated to give <b>28</b> as a pale yellow oil (0.76 g, 84%), which was about 90% pure by LC-MS (APCI) <i>m</i>/<i>z</i> 292 [M + H]<sup>+</sup>. To facilitate purification, a solution of this crude material (0.76 g, 2.61 mmol) in ethyl acetate (50 mL) and benzyl chloroformate (0.39 mL, 2.61 mmol) was treated with aqueous saturated sodium bicarbonate (50 mL) with stirring at room temperature for 1 h. The organic layer was collected, and the aqueous layer was extracted with ethyl acetate (2 Ã 100 mL). The combined organic layers were dried, filtered, and evaporated to give the carbamate <b>27</b> (benzyl <i>N</i>-[(1<i>S</i>)-2-[(8<i>R</i>)-8-(2-hydroxyethoxy)-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl]-1-methylâethyl]carbamate) as a colorless oil (0.41 g, 37%): LC-MS (APCI) <i>m</i>/<i>z</i> 426 [M + H]<sup>+</sup>; (CDCl3, 400 MHz) Î´ 7.83 (s, 1H), 7.41 (d, <i>J</i> = 8.8 Hz, 1H), 7.33 (m, 5H), 6.73 (d, <i>J</i> = 8.8 Hz, 1H), 5.25 (br s, 1H), 5.05 (s, 2H), 4.70 (d, <i>J</i> = 10 Hz, 1H), 4.41 (dd, <i>J</i> = 6.8, 14.6 Hz), 4.22â4.02 (m, 4H), 3.81â3.76 (m, 4H), 3.4 (br s, 2H), 1.13 (d, <i>J</i> = 6.4 Hz, 3H).</div><div class="NLM_p last">A solution of <b>27</b> (0.36 g, 0.85 mmol) in methanol (20 mL) was stirred with 10% Pd/C (36 mg) under hydrogen (1 atm) for 2 days. The reaction mixture was filtered and evaporated to give <b>28</b> as a pale yellow syrup: (0.23 g, 93%); LC-MS (APCI) <i>m</i>/<i>z</i> 292 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ 7.84 (s, 1H), 7.39 (d, <i>J</i> = 8.8 Hz, 1H), 6.70 (d, <i>J</i> = 8.8 Hz, 1H), 4.39 (m, 2H), 4.17 (m, 2H), 4.01 (m, 1H), 3.78â3.71 (m, 4H), 3.50 (m, 1H), 3.35 (dd, <i>J</i> = 5.6, 13 Hz, 2H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ 155.4, 141.4, 135.1, 121.1, 120.8, 114.9, 102.3, 71.5, 67.6, 62.5, 58.4, 29.3, 19.9. Anal. (C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>Â·0.25 H<sub>2</sub>OÂ·0.125 CDCl<sub>3</sub>) C, H, N.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Methyl 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetate (<b>30</b>)</h4><div class="NLM_p last">A solution of <b>12a</b> (1.92 g, 7 mmol) in DMF (20 mL) was cooled by an ice bath (0 Â°C) and was treated with sodium hydride (60% in oil, 0.56 g, 14 mmol). After bubbling ceased, the reaction was treated with isopropyl bromoacetate (1.82 mL, 14 mmol) and allowed to warm to room temperature over 2 h. The reaction mixture was poured into aqueous saturated sodium bicarbonate (150 mL), extracted with ethyl acetate (3 Ã 100 mL), and the combined organic phases were washed with brine (100 mL) and dried. The filtrate was evaporated to a yellow residue; column chromatography (silica, 20% ethyl acetate/hexane) gave <b>29</b> (isopropyl 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetate) as a colorless oil (1.69 g, 64%): LC-MS (APCI) <i>m</i>/<i>z</i> 374 [M + H]<sup>+</sup>. A solution of <b>29</b> (1.69 g, 4.5 mmol) in methanol (20 mL) was combined with a 3 N solution of hydrochloric acid in methanol (5 mL, 15 mmol) and the mixture refluxed for 18 h. The reaction mixture was evaporated to a colorless residue; column chromatography (silica, 20% ethyl acetate/hexane) gave <b>30</b> as a colorless oil (1.13 g, 73%): LC-MS (APCI) <i>m</i>/<i>z</i> 346 [M + H]<sup>+</sup>. This material was used in subsequent reactions without further purification.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-<i>N</i>-methyl-acetamide (<b>32a</b>)</h4><div class="NLM_p last">A solution of <b>30</b> (0.15 g, 0.43 mmol) was treated with a 2 N solution of methylamine in THF (10 mL, 20 mmol) with stirring at room temperature for 18 h. The reaction mixture was evaporated to a yellow oil; column chromatography (silica, gradient, 20% ethyl acetate/hexane to ethyl acetate) gave <b>31a</b> (2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-<i>N</i>-methyl-acetamide) as a colorless solid (0.14 g, 94%): LC-MS (APCI) <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>. A solution of <b>31a</b> (140 mg, 0.4 mmol) in methanol (10 mL) was stirred with Pd/C (10%, 20 mg) under hydrogen (1 atm) at room temperature for 1 day. The reaction mixture was filtered and evaporated to give <b>32a</b> as a colorless solid (0.13 g, 98%): LC-MS (APCI) <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) Î´ 7.78 (m, 1H), 7.34 (d, <i>J</i> = 8.8 Hz, 1H), 6.59 (d, <i>J</i> = 8.8 Hz, 1H), 4.34 (d, <i>J</i> = 6 Hz, 2H), 4.13 (m, 1H), 4.05 (m, 3H), 4.0 (m, 1H), 3.28 (m, 3H), 2.62 (s, 3H), 0.97 (d, <i>J</i> = 6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ 172.9, 155.2, 141.2, 134.9, 128.4, 121.2, 120.9, 114.9, 102.1, 72.2, 68.9, 67.1, 59.1, 28.9, 25.9, 20.5. Anal. (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>Â·0.2 CH<sub>3</sub>OHÂ·0.8 H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-Aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-<i>N</i>-(2-methoxyethyl)acetamide (<b>32b</b>)</h4><div class="NLM_p last">A solution of <b>30</b> (0.15 g, 0.43 mmol) in methanol (10 mL) was stirred with 2-methoxyethylamine (2 mL, 23 mmol) at room temperature for 18 h. The reaction mixture was evaporated to a yellow oil; column chromatography (silica gel, gradient, hexane/ethyl acetate, 4:1 to ethyl acetate) gave <b>31b</b> (2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-<i>N</i>-(2-methoxyethyl)acetamide) as a yellow oil (0.15 g, 90%): LC-MS (APCI) <i>m</i>/<i>z</i> 389 [M + H]<sup>+</sup>. A solution of <b>31b</b> (150 mg, 0.39 mmol) in methanol (10 mL) was stirred with Pd/C (10%, 20 mg) under hydrogen (1 atm) at room temperature for 1 day. The reaction mixture was filtered and evaporated to give <b>32b</b> as a yellow syrup (0.12 g (86%): LC-MS (APCI) <i>m</i>/<i>z</i> 363 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) Î´ 7.8 (s, 1H), 7.3 (d, <i>J</i> = 8.8 Hz, 1H), 6.6 (d, <i>J</i> = 8.8 Hz, 1H), 4.3 (d, <i>J</i> = 6 Hz, 2H), 4.18 (m, 1H), 4.07 (m, 3H), 4.04 (m, 1H), 3.3 (m, 7H), 3.2 (m, 3H), 0.98 (d, <i>J</i> = 6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ 172.6, 155.2, 141.3, 135, 121.3, 121, 115, 102.1, 72.3, 71.8, 69.1, 67.1, 59.1, 58.9, 39.7, 28.9, 20.5. Anal. (C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>Â·0.5 H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(3-Aminopropyl)-2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetamide (<b>32c</b>)</h4><div class="NLM_p last">A solution of <b>30</b> (0.17 g, 0.49 mmol) in methanol (10 mL) was stirred with 1,3-propanediamine (2 mL, 24 mmol) at room temperature for 18 h. The reaction was evaporated to a yellow residue; column chromatography (silica gel, 10% methanol/dichloromethane/1% triethylamine) gave <b>31c</b> (<i>N</i>-(3-aminopropyl)-2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]acetamide) as a yellow oil (0.17 g, 89%): LC-MS (APCI) <i>m</i>/<i>z</i> 388 [M + H]<sup>+</sup>. A solution of <b>31c</b> (170 mg, 0.44 mmol) in methanol (10 mL) was stirred with Pd/C (10%, 20 mg) under hydrogen (1 atm) at room temperature for 1 day. The reaction mixture was filtered and evaporated to give <b>32c</b> as a colorless oil (0.15 g, 95%): LC-MS (APCI) <i>m</i>/<i>z</i> 362 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) Î´ 7.8 (s, 1H), 7.42 (d, <i>J</i> = 8.8 Hz, 1H), 6.6 (d, <i>J</i> = 8.8 Hz, 1H), 4.33 (d, <i>J</i> = 6 Hz, 2H), 4.2 (m, 1H), 4.05 (m, 3H), 4.02 (m, 1H), 3.25 (m, 7H), 2.45 (t, <i>J</i> = 7 Hz, 1H), 1.75 (m, 1H), 1.45 (m, 2H), 1.24 (m, 1H), 0.98 (d, <i>J</i> = 6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ 172.6, 155.2, 141.2, 134.9, 121.2, 120.9, 114.9, 102.1, 72.2, 68.9, 67.1, 66.9, 59.1, 40.8, 39.7, 37.3, 33.4, 28.8, 20.5, 7.6. Anal. (C<sub>18</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>Â·0.5 CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-aminopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-1-[4-(2-pyridyl)piperazin-1-yl]ethanone (<b>32d</b>)</h4><div class="NLM_p">To <b>30</b> (0.21 g, 0.61 mmol) was added 1-(pyridin-2-yl)piperazine (1 mL, 6.9 mmol), and this mixture was stirred at 60 Â°C for 18 h followed by heating at 90 Â°C for 2 h, and finally stirring at 60 Â°C for 3 days. The reaction mixture was cooled to room temperature, and water (100 mL) was added. The mixture was extracted into ethyl acetate (3 Ã 100 mL), and the combined organic phases were washed with water (2 Ã 100 mL), dried, filtered, and evaporated to a yellow oil; column chromatography (silica, ethyl acetate) gave <b>31d</b> (2-[[(8<i>R</i>)-1-[(2<i>S</i>)-2-azidopropyl]-8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-8-yl]oxy]-1-[4-(2-pyridyl)piperazin-1-yl]ethanone) as a colorless oil (0.19 g, 66%): LC-MS (APCI) <i>m</i>/<i>z</i> 477 [M + H]<sup>+</sup>. A solution of <b>31d</b> (190 mg, 0.40 mmol) in methanol (10 mL) was stirred with Pd/C (10%, 20 mg) under hydrogen (1 atm) at room temperature for 24 h. The reaction mixture was filtered and evaporated to give <b>32d</b> as a white solid (0.18 g, 98%): LC-MS (APCI) <i>m</i>/<i>z</i> 451 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) Î´ 7.98 (m, 1H), 7.75 (s, 1H), 7.46 (m, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 6.6 (m, 3H), 4.41 (m, 1H), 4.25 (m, 3H), 4.05 (m, 2H), 3.45 (m, 6H), 3.25 (m, 4H), 3.1 (m, 2H), 0.97 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ 170.5, 160.7, 155.2, 148.5, 141.3, 139.2, 134.9, 121.2, 120.9, 115, 114.9, 109.2, 101.9, 72, 69.2, 67.2, 59.2, 46.6, 46.1, 45.9, 42.7, 28.7, 20.4. Anal. (C<sub>24</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>Â·0.58 H<sub>2</sub>O) C, H, N.</div><div id="sec5_1_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> X-ray Crystallographic Analysis of <b>13</b></h5><div class="NLM_p">Crystals of <b>13</b> grew as clusters of colorless needles from 2-propanol. The data crystal was cut from a larger needle and had approximate dimensions of 0.39 Ã 0.29 Ã 0.22 mm<sup>3</sup>. The data were collected on a Nonius Kappa CCD diffractometer using a graphite monochromator with MoKÎ± radiation (Î» = 0.71073 Ã). A total of 330 frames of data were collected using Ï-scans with a scan range of 1Â° and a counting time of 32 s per frame. The data were collected at 153 K using an Oxford Cryostream low temperature device. Details of crystal data, data collection, and structure refinement are listed in (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf" class="ext-link">Table S3</a>). Data reduction was performed using DENZO-SMN.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The structure was solved by direct methods using SIR92<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and refined by full-matrix least-squares on F<sup>2</sup> with anisotropic displacement parameters for the non-H atoms using SHELXL-97.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The hydrogen atoms were observed in a ÎF map and refined with isotropic displacement parameters. The function, Î£<i>w</i>(|<i>F</i><sub>o</sub>|<sup>2</sup> â |<i>F</i><sub>c</sub>|<sup>2</sup>)<sup>2</sup>, was minimized, where <i>w</i> = 1/[(Ï(<i>F</i><sub>o</sub>))<sup>2</sup> + (0.0206Â·<i>P</i>)<sup>2</sup> + (0.094Â·<i>P</i>)], and <i>P</i> = (|<i>F</i><sub>o</sub>|<sup>2</sup> + 2|<i>F</i><sub>c</sub>|<sup>2</sup>)/3. <i>R</i><sub>w</sub>(<i>F</i><sup>2</sup>) refined to 0.0642, with <i>R</i>(<i>F</i>) equal to 0.0260 and a goodness of fit, <i>S</i>, = 1.065. Definitions used for calculating <i>R</i>(<i>F</i>),<i>R</i><sub>w</sub>(<i>F</i><sup>2</sup>) and the goodness of fit, <i>S</i>, are provided: <i>R</i><sub>w</sub>(<i>F</i><sup>2</sup>) = {Î£<i>w</i>(|<i>F</i><sub>o</sub>|<sup>2</sup> â |<i>F</i><sub>c</sub>|<sup>2</sup>)<sup>2</sup>/Î£<i>w</i>(|<i>F</i><sub>o</sub>|)<sup>4</sup>}<sup>1/2</sup>, where <i>w</i> is the weight given each reflection; <i>R</i>(<i>F</i>) = Î£(|<i>F</i><sub>o</sub>| â |<i>F</i><sub>c</sub>|)/Î£|<i>F</i><sub>o</sub>|} for reflections with <i>F</i><sub>o</sub> > 4(Î£(<i>F</i><sub>o</sub>)); <i>S</i> = [Î£w(|<i>F</i><sub>o</sub>|<sup>2</sup> â |<i>F</i><sub>c</sub>|<sup>2</sup>)<sup>2</sup>/(<i>n</i> â <i>p</i>)]<sup>1/2</sup>, where <i>n</i> is the number of reflections, and <i>p</i> is the number of refined parameters.</div><div class="NLM_p last">The data were checked for secondary extinction effects, but no correction was necessary. The absolute configuration was determined by internal comparison to the known configuration at C15 (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf" class="ext-link">Figure S1</a> for the atom labeling scheme). Neutral atom scattering factors and values used to calculate the linear absorption coefficient are from the International Tables for X-ray Crystallography.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> All figures were generated using SHELXTL/PC.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec5_1_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Summary of Crystal Structure Data for <b>13</b></h5><div class="NLM_p">Empirical formula, C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>; formula weight, 247.30; collection temperature, 153 K; crystal system, monoclinic; space group, <i>P</i>21; unit cell dimensions, <i>a</i> = 9.0838(2) Ã, Î± = 90Â°; <i>b</i> = 4.4965(1) Ã, Î² = 101.147(1)Â°; <i>c</i> = 14.9860(3) Ã, Î³ = 90Â°; Z, 2. Goodness-of-fit on <i>F</i><sup>2</sup>, 1.065; final <i>R</i> indices [<i>I</i> > 2Ï(<i>I</i>)], <i>R</i><sub>1</sub> = 0.0260, <i>wR</i><sub>2</sub> = 0.0632.</div><div class="NLM_p last">Crystallographic data for structure <b>13</b> is available free of charge from Cambridge Crystallographic Data Center under deposition number CCDC 1410547.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Determination of Compound Stability</h3><div class="NLM_p last">The aqueous stability of compounds was conducted in pH 7.4, 0.025 M sodium phosphate buffer. Each compound was dissolved [5 Î¼g/mL (0.0005%) and/or 1%] in buffer, and the solutions were heated at either 75 Â°C for up to 4 weeks or at 45 Â°C for up to 12 weeks. Water for injection was used for buffer preparation. For pH adjustment, 0.6 N HCl and 1.0 N NaOH stored in glass containers were used. An HPLC method was developed for the analysis of stability samples of each compound. The stability results (percent degradation) were used for calculation of the predicted half-life of a compound at 25 Â°C. This prediction was based on the time required for a 10% loss of compound (T<sub>90</sub>) and the fact that the rate of degradation for a first order reaction decreases 50% for every 10 Â°C drop in temperature.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Determination of Distribution Coefficients</h3><div class="NLM_p last">Partitioning of compounds between <i>n</i>-octanol and aqueous buffer was determined at pH 7.4 using 0.1 M phosphate buffer (shake-flask method). The initial concentration (<i>C</i><sub>1</sub>) of compound in buffer and the buffer concentration following extraction with <i>n</i>-octanol (<i>C</i><sub>2</sub>) were determined by RP-HPLC analysis against concentration standards for the specific compound. The distribution coefficient (<i>DC</i>) of a compound at a given pH was calculated using the equation <i>DC</i><sub>pH</sub> = (<i>C</i><sub>1</sub> â <i>C</i><sub>2</sub>)/<i>C</i><sub>2</sub>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> In Vitro Permeability and P-Glycoprotein Efflux</h3><div class="NLM_p">Permeability and transport studies were conducted and the data analyzed at Absorption Systems, Exton, Pennsylvania, using methods previously described.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Briefly, MDCK(MDR) monolayers were grown to confluence on collagen-coated, microporous, polycarbonate membranes in 12-well Costar Transwell plates. To ensure monolayer integrity, the trans-epithelial electrical resistance (TEER) was measured. Only cell monolayers with TEER values >1900 Î©Â·cm<sup>2</sup> were used. The permeability assay buffer was Hankâs Balanced Salt Solution containing 10 mM HEPES and 15 mM glucose at a pH of 7.0â7.2. Permeability through a cell-free (blank) membrane determined nonspecific binding and free diffusion of the test article through the device. Solution concentrations of the test articles were 10 Î¼M in assay buffer. At each time point, 1 and 2 h, a 200-Î¼L aliquot was taken from the receiver chamber and replaced with fresh assay buffer. Cells were dosed on the apical side [apical-to-basolateral, absorptive transport, (A-B)] or basolateral side [basolateral-to-apical, secretory transport, (B-A)] and incubated at 37 Â°C with 5% CO<sub>2</sub> and 90% relative humidity. Each determination was performed in duplicate. Lucifer Yellow permeability was measured for each monolayer after the experiment to ensure that the cell monolayer integrity and viability were not compromised by the test article. Postexperiment Lucifer Yellow permeability in monolayers was 0.24 to 0.75 nm/s.</div><div class="NLM_p last">To determine the transport of compounds in the absence of functional P-gp activity, the above experimental conditions were used but in the presence of the P-gp inhibitor cyclosporin A (CSA).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cells were preincubated for 30 min with the inhibitor (10 Î¼M), then washed. During the permeation determination period, CSA (10 Î¼M) was present on both sides of the membrane. The <i>P</i><sub>app</sub> A-B determined in the presence of CSA was taken as an estimate of the permeability attributed to passive diffusion for the compound (<i>P</i><sub>appÂ PD</sub>).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Ex Vivo Determination of Ocular Tissue Permeability</h3><div class="NLM_p">These studies were conducted and the data analyzed at Absorption Systems, LP, Exton, PA using their standard methods. In brief, the corneal and palpebral conjunctival tissues were excised from male Dutch-belted pigmented rabbits (1.5â2.5 kg body weight, 3â3.5 months old) and mounted on a Harvard vertical diffusion apparatus with a diffusion area of 0.64 cm<sup>2</sup>. Preheated (37 Â°C), pH 7.4, GBR buffer was added to the mucosal (1.5 mL) and the serosal (1.5 mL) chambers. The diffusion apparatus was maintained at 37 Â°C throughout the entire transport experiment. Oxygenation and agitation were achieved by bubbling O<sub>2</sub>/CO<sub>2</sub> (95:5) through each chamber (at a rate of 5â6 bubbles per second). After the 30 min equilibration, blank GBR buffer in the mucosal (donor) chamber was withdrawn and replaced with GBR buffer containing 10 Î¼M test compound. The transport experiments lasted 2 h and were performed in quadruplicate. Every 60 min, 0.2 mL samples were collected from the serosal (receiver) chamber and replenished with 0.2 mL blank GBR buffer, except at the last time point; at the end of the experiment, samples were also collected from the mucosal (donor) chambers for mass balance determination.</div><div class="NLM_p last">After the transport experiment, tissue integrity was assessed by measuring the permeation of low permeable marker compounds atenolol and Lucifer yellow across the tissue. Donor chambers were replaced with GBR buffer containing 100 Î¼M atenolol and 500 Î¼M Lucifer yellow, and receiver chambers were replaced with fresh blank GBR buffer. After incubation for 30 min, samples were collected from both chambers for analysis. Test compounds and atenolol were analyzed by LC-MS/MS methods, and Lucifer yellow was determined by fluorescence detection.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> In Vitro Binding Assays</h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Serotonin Human 5-HT<sub>1A</sub> Receptor Binding</h4><div class="NLM_p last">The procedure was previously described.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In brief, the binding of [<sup>3</sup>H]-8-OH-DPAT (0.25 nM final) to Chinese hamster ovary cell membranes expressing the recombinant human 5-HT<sub>1A</sub> receptor was performed in 50 mM Tris-HCl buffer (pH 7.4) in a total volume of 0.5 mL for 1 h at 27 Â°C. Unlabeled 8-OH-DPAT (10 Î¼M final) was used to define the nonspecific binding. The assays were terminated by rapid vacuum filtration and the samples counted on a scintillation counter. The data were analyzed using a nonlinear, iterative curve-fitting computer program.</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Serotonin Rat 5-HT<sub>2A</sub> Receptor Binding</h4><div class="NLM_p last">The procedure was previously described.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In brief, the relative affinities of compounds at the 5-HT<sub>2A</sub> receptor were determined by measuring their ability to compete for the binding of the agonist radioligand [<sup>125</sup>I]-DOI to rat brain 5-HT<sub>2A</sub> receptors. Aliquots of post-mortem rat cerebral cortex homogenates (400 Î¼L) dispersed in 50 mM Tris-HCl buffer (pH 7.4) were incubated with [<sup>125</sup>I]-DOI (80 pM final) in the absence or presence of methiothepin (10 Î¼M final) to define total and nonspecific binding, respectively, in a total volume of 0.5 mL. The assay mixture was incubated for 1 h at 23 Â°C in polypropylene tubes and the assays terminated by rapid vacuum filtration over Whatman GF/B glass fiber filters previously soaked in 0.3% polyethylenimine using ice-cold buffer. The samples were counted on a Î²-scintillation counter and the data analyzed using a nonlinear, iterative curve-fitting computer program.</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Cloned Human Serotonin 5-HT<sub>2</sub> Receptor Binding</h4><div class="NLM_p last">Binding affinity of compounds at the cloned human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors expressed in Chinese hamster ovary cells using the agonist [<sup>125</sup>I]-DOI (0.2 nM; 15 min at 37 Â°C) as the radioligand for each receptor was determined and reported as <i>K</i><sub>i</sub> values. These studies were conducted and the data analyzed at Cerep, Poitiers (France) using standard radioligand binding techniques as described above.</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Determination of Binding at Other Receptors and Cellular Elements</h4><div class="NLM_p last">Binding assays for 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>6</sub> serotonergic receptors and Î±<sub>1A</sub>, Î±<sub>1B</sub>, and Î±<sub>2B</sub> adrenergic receptors, and other receptor, enzyme, ion channel profiling were conducted at NovaScreen Biosciences (Hanover, MD) using their standard documented screening protocols.</div></div><div id="sec5_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Adrenergic Cloned Human Î±<sub>2A</sub> and Î±<sub>2C</sub> Receptor Binding</h4><div class="NLM_p last">Membranes from Sf9 cells expressing the cloned human Î±<sub>2A</sub> and Î±<sub>2C</sub> receptor (Biosignal, Montreal Canada) were diluted to 32 Î¼g/mL and 48 Î¼g/mL protein, respectively, in 75 mM Tris-HCl containing 12.5 mM MgCl<sub>2</sub> and 2 mM EDTA (pH 7.4). The membranes were resuspended using a Branson Sonifier 450 (Branson Ultrasonics Corp., Danbury, CT) (<20 s). Drug dilutions were made in 1:1 DMSO/ethanol (v/v) using a Biomek 2000 robot (Beckman Instruments, Fullerton, CA). The diluted compounds (25 Î¼L), followed by a volume of 200 Î¼L of receptor preparation, and finally 25 Î¼L of [<sup>3</sup>H]-clonidine (28 nM final concentration) were added by the Biomek 2000 robot to a 96 well plate. The incubations (60 min at 23 Â°C) were terminated by rapid vacuum filtration on a Tomtec Harvester 96 (Tomtec, Hamden, CT) using Whatman GF/C glass fiber filters that were previously soaked in 0.3% polyethylenimine. The filters were washed with ice cold 50 mM Tris-HCl, pH 7.4. The samples were counted on a TopCount scintillation counter (Packard Instruments, Meriden, CT).</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> In Vitro Functional Assays</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Serotonin Human 5-HT<sub>1A</sub> Receptor Activity: Inhibition of cAMP Production in Cultured Cells</h4><div class="NLM_p last">The procedure was previously described.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Briefly, Chinese hamster ovary (CHO) cells expressing the cloned human 5-HT<sub>1A</sub> receptor were preincubated with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (1 mM final), for 20 min at 23 Â°C followed by the addition of the test compounds and the incubation continued for another 20 min. The adenylyl cyclase activator, forskolin (10 Î¼M), was added and the incubation terminated after 10 min using ice cold 0.1 M acetic acid. The measurement of cAMP was performed using an enzyme immunoassay as previously described. The inhibition of forskolin-induced cAMP production by the test compounds was analyzed using a nonlinear, iterative curve-fitting computer program.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Serotonin 5-HT<sub>2A</sub> Receptor Functional Activity: [Ca<sup>2+</sup>]<sub>i</sub> Mobilization Assay</h4><div class="NLM_p last">The procedure was previously described.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Briefly, the receptor-mediated mobilization of intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) was studied with a Fluorescence Imaging Plate Reader (FLIPR) using rat vascular smooth muscle cells (A7r5, expressing native 5-HT<sub>2</sub> receptors) in 96-well culture plates. An aliquot (25 Î¼L) of the test compound was added to the Ca<sup>2+</sup>-sensitive dye-loaded cells and the fluorescence data collected in real-time at 1.0 s intervals for the first 60 s and at 6.0 s intervals for an additional 120 s. Responses were measured as peak fluorescence intensity minus basal and, where appropriate, were expressed as a percentage of a maximum 5-HT-induced response (<i>E</i><sub>max</sub>). The concentrationâresponse data were analyzed using a nonlinear, iterative curve-fitting computer program.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Serotonin 5-HT<sub>2B</sub> Receptor Functional Activity: Rat Isolated Stomach Fundus</h4><div class="NLM_p last">This assay was conducted by MDS Pharma Services, Bothell, Washington, using methods previously described.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In brief, longitudinal stomach fundus strips dissected from adult Wistar rats were mounted in 25 mL organ baths containing oxygenated Krebs buffer (pH 7.4) maintained at 37 Â°C. After a 45 min equilibration period, 10 Î¼L aliquots of test agents were added to the organ bath (10 mL volume) and isometric tension recorded via an FT03 transducer. Cumulative contractile doseâresponse curves were constructed for test agonists. Î±-Methyl-5-HT was used as a standard reference agonist. Doseâresponse data were analyzed as described above to obtain the potency values (EC<sub>50</sub>) of test agents.</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Serotonin 5-HT<sub>2C</sub> Receptor Functional Activity: [Ca<sup>2+</sup>]<sub>i</sub> Mobilization Assay</h4><div class="NLM_p last">These assays were performed as for the 5-HT<sub>2A</sub> receptor above, except that SR3T3 cells expressing the recombinant rat 5-HT<sub>2C</sub> receptor were utilized.</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Serotonin 5-HT<sub>7</sub> Receptor Functional Activity</h4><div class="NLM_p last">The procedure was previously described.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Briefly, SV-40 immortalized human corneal epithelial cells (CEPI-17-CL4 cell) were cultured in KGM (keratinocyte growth medium) with 0.15 mM CaCl<sub>2</sub>. Amphotericin B and gentamicin were replaced by penicillin (100 units/mL) and streptomycin (100 Î¼g/mL). Media and other supplements were products of Bio-Whittaker (Walkersville, MD). Agonist-dependent cyclic AMP formation was measured by a method described previously.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In brief, compounds of interest were diluted in ethanol such that the final ethanol concentration was 1%. Upon reaching confluence, the cells were rinsed twice with 0.5 mL of DMEM/F-12. The cells were incubated for 20 min in the presence or absence of 5-HT receptor antagonists with DMEM/F-12 containing 0.8 mM ascorbate and 1.0 mM of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, Sigma, St. Louis, MO) at room temperature (RT, â¼22 Â°C). Serotonin receptor agonists were added at the end of this period, and the reaction was allowed to proceed for 15 min. 5-Carboxamidotryptamine (5-CT; 100 nM) was used as a positive control. After aspiration of the reaction medium, ice cold 0.1 M acetic acid (150 Î¼L, pH 3.5) was added for the termination of cAMP synthesis and cell lysis. Finally, ice cold 0.1 M sodium acetate (225 Î¼L, pH 11.5â12.0) was added to neutralize the samples prior to analysis by the EIA. Cyclic AMP production was measured using an EIA kit purchased from Amersham Pharmacia Biotech (Piscataway, NJ). This assay was conducted according to the package insert in an automated manner using the Biomek 2000 robot (Beckman Instruments, Fullerton, CA).</div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Determination of Cloned Human 5-HT<sub>2</sub> Receptor Subtype Activity by Aequorin Based [Ca<sup>2+</sup>]<sub>i</sub> Mobilization Assay</h4><div class="NLM_p last">Functional response at the 5-HT<sub>2</sub> receptor subtypes was determined using CHO-K1 cells stably expressing mitochondrial-targeted bioluminescent aequorin, G<sub>Î±Â 16</sub>, and one of the human serotonin receptor clones 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub>. Prior to testing, cells were loaded in suspension with coelenterazine for 4â16 h and directly injected onto different concentrations of the test compound. Light emitted from the cells was measured 20â30 s following receptor activation. A luminometer (Hamamatsu, FDSS-600) was used to record luminescence in response to the test compound. The mean response signal at each of 8â11 different concentrations was integrated to provide an estimation of receptor activation, expressed as the EC<sub>50</sub> value. The efficacy of the response (<i>E</i><sub>max</sub>) at the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors is expressed relative to the response of Î±-methyl-5-HT under the same assay conditions, while the efficacy at 5-HT<sub>2C</sub> is expressed relative to the response of 5-HT. These studies were conducted at Euroscreen s.a., Brussels, Belgium.</div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Adrenergic Î±<sub>2A</sub>, Î±<sub>2B</sub>, and Î±<sub>2C</sub> Receptor Functional Assays: Cell Culture</h4><div class="NLM_p">HT29 human clonic adenocarcinoma cells expressing endogenous Î±<sub>2A</sub> receptors were grown in McCoyâs 5A Medium Modified supplemented with 10% (v/v) heat-inactivated fetal bovine serum in a humidified atmosphere of 5% CO<sub>2</sub>/95% air. Cells were subcultured with 0.05% Trypsin/0.53 mM EDTA in 48-well plates with confluence being reached in approximately 4 days. Growth medium was replaced with fresh medium 24 h before assay of confluent cells in order to avoid nutrient exhaustion.</div><div class="NLM_p">Opossum kidney (OK) proximal tubule kidney cells expressing endogenous Î±<sub>2B</sub> receptors were grown in DMEM with high glucose supplemented with 10% (v/v) heat-inactivated fetal bovine serum in a humidified atmosphere of 5% CO<sub>2</sub>/95% air. Cells were subcultured with 0.05% Trypsin/0.53 mM EDTA in 48-well plates with confluence being reached in approximately 3 days. Growth medium was replaced with fresh medium 24 h before assay of confluent cells.</div><div class="NLM_p last">The neuroblastoma Ã glioma rat-mouse hybrid NH108-15 cells expressing endogenous Î±<sub>2C</sub> receptors were grown in DMEM with high glucose supplemented with 10% (v/v) heat-inactivated fetal bovine serum in a humidified atmosphere of 5% CO<sub>2</sub>/95% air. Cells were subcultured with 0.05% Trypsin/0.53 mM EDTA in poly-<span class="smallcaps smallerCapital">d</span>-lysine coated 48 wells plates with confluence being reached in approximately 3 days. Growth medium was replaced with fresh medium 24 h before assay of confluent cells in order to avoid the nutrient exhaustion and acidic pH.</div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Cyclic AMP Functional Assays</h4><div class="NLM_p last">Confluent cultures of HT29, OK, and NG108 cells were washed twice with 0.5 mL of 15 mM HEPES-buffered DMEM (DMEM/F12), then incubated with 0.5 mL of DMEM/F12 containing 1.0 mM 3-isobutyl-1-methyl-xanthine (IBMX) and 0.8 mM ascorbate at room temperature for 20 min. At the end of this period, the appropriate serially diluted test agents in ethanol were added, such that the final ethanol concentration was 1%. Cells were incubated for a further 10 min. Then, the appropriate concentration of forskolin (for HT29 cells, 4 Î¼M; OK cells, 10 Î¼M; and NG108 cells, 1 Î¼M) was added and the cells incubated an additional 10 min. At the end of the incubation period, the media were aspirated, and 150 Î¼L of 0.1 M acetic acid at pH 3.5 was added for the termination of cAMP synthesis and activation of cell lysis. The plates were incubated at 4 Â°C for 20 min. Then, 220 Î¼L of 0.1 M sodium acetate at pH 11.5â12 was added to neutralize the samples prior to analysis of cAMP levels using an enzyme immunosorbant assay kit as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Concentrationâresponse curves were constructed and the data analyzed as described above to obtain the potency values of the compounds.</div></div><div id="sec5_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Adrenergic Î±<sub>1D</sub> Receptor Functional Assay</h4><div class="NLM_p last">Aortic rings isolated from freshly sacrificed Wistar rats were mounted in oxygenated Krebâs buffer in an organ bath and isometric contractions of the tissue recorded using standardized equipment.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These studies were performed at MDS Pharma Services (Taipei, Taiwan).</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> In Vivo Assays</h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Acute Ocular Hypotensive Response in Monkeys</h4><div class="NLM_p last">Compounds were evaluated for their ability to lower IOP in conscious cynomolgus monkeys with laser-induced ocular hypertension in the right eyes.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Briefly, IOP was determined with an applanation tonometer after light corneal anesthesia with 0.1% proparacaine; eyes were rinsed with saline after each measurement. After a baseline IOP measurement, the test compound was instilled in one 30 Î¼L aliquot to the right eyes only of 8â9 cynomolgus monkeys. Vehicle was instilled in the right eyes of 5â6 additional animals. Subsequent IOP measurements were taken at 1, 3, and 6 h. The significance of the IOP response was evaluated (Statistical Analysis System computer program) using Studentâs <i>t</i> test to compare the difference from baseline for each time point and one-way analysis of variance to compare differences in IOP between groups at each time point. A compound is considered efficacious in this model of ocular hypertension if there is a decrease from baseline IOP in the lasered eye of at least 20% following topical administration. Unless noted otherwise, compounds were routinely formulated in phosphate-buffered saline vehicle containing 0.01% benzalkonium chloride, 0.01% disodium EDTA, 0.1% polysorbate 80, and 0.8% hydroxypropyl methylcellulose and adjusted to pH 7.4. Animal studies were conducted in accordance with the resolutions for the use of laboratory animals as adopted by the National Institutes of Health and the Association for Research in Vision and Ophthalmology, and an approved Alcon Animal Care and Use Committee protocol.</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Duration of Ocular Hypotensive Response in Monkeys</h4><div class="NLM_p last">Compounds were evaluated as with the above acute response studies with additional IOP readings at 10 and 12 h; a second instillation of compound (same dose) was administered after the 12 h IOP reading, which was followed by an IOP reading 12 h after the second dose of compound. Duration studies with modified formulations were conducted as with the above acute response studies with additional IOP measurements taken at 10, 12, and 24 h following a single instillation of compound unless otherwise noted.</div></div><div id="sec5_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Effect of Bromfenac on Ocular Hypotensive Response in Monkeys</h4><div class="NLM_p last">A solution of bromfenac (0.107%) was administered in four doses of 30 Î¼g each, 15 min apart, to the hypertensive right eye of nine monkeys. Ten minutes after the administration of the last dose of bromfenac, a single 150 Î¼g dose of a 0.5% suspension of compound <b>13</b> was administered. Vehicle was instilled on the same regimen as that used for dosing bromfenac for another group of eight animals that were dosed with compound <b>13</b> only. One week later, the two groups were reversed, so that a total of 17 animals received each treatment. The percent change in IOP from baseline was determined for each animal at every IOP measurement time point: 1, 3, and 6 h postdose.</div></div><div id="sec5_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Drug Discrimination Studies in Rats</h4><div class="NLM_p last">This procedure has been described in detail previously.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Briefly, rats were trained to discriminate intraperitoneal injection of DOM (1.0 mg/kg) from a saline vehicle such that they consistently made >80% of their responses on the DOM-appropriate liver following administration of this drug dose. Administration of lower DOM doses resulted in the animals making fewer responses on the DOM-appropriate lever (ED<sub>50</sub> = 0.3 mg/kg, 95% CL = 0.2â0.6 mg/kg; 1.25 Î¼mol/kg). The response rate of the animals following the administration of different DOM doses was statistically similar (<i>p</i> > 0.05) to their response rate following the administration of the saline vehicle (13.1 Â± 2.1 responses/min). The test compounds were examined in the DOM-trained animals as outlined above. Animal studies were conducted under an approved Institutional (VCU) Animal Care and Use Committee protocol.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00857">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00857" class="ext-link">10.1021/acs.jmedchem.5b00857</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional ligand binding data for <b>13</b>; elemental analysis data; thermal ellipsoids for <b>13</b>; unit cell packing diagram; crystal data and structure refinement for <b>13</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf">jm5b00857_si_001.pdf (266.95 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00857" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jesse A. May</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5e343f333f27346f6b6b1e3d363f2c2a3b2c70303b2a"><span class="__cf_email__" data-cfemail="d4beb5b9b5adbee5e1e194b7bcb5a6a0b1a6fabab1a0">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Najam A. Sharif</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marsha A. McLaughlin</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hwang-Hsing Chen</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryon S. Severns</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Curtis R. Kelly</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William F. Holt</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Young</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box
980540, Richmond, Virginia 23298, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Glennon</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box
980540, Richmond, Virginia 23298, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark R. Hellberg</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas R. Dean</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Discovery Research, Alcon Research, Ltd., 6201 South Freeway, Fort Worth, Texas 76134, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3186e6285-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Gary Williams, Parvanaeh Katoli, Colene Drance, and Shouxi Xu of our Molecular Pharmacology Unit; Daniel Scott, Tony Wallace, and Lanaya Wood of our In Vivo Pharmacology Unit; and Wayne Schneider of our Preformulation Unit for their expert technical assistance. We also thank Dr. John Liao of our Physical Characterization Unit for conducting the DC and stability studies and Dr. Vincent M. Lynch, Department of Chemistry and Biochemistry, University of Texas, Austin, for conducting the X-ray studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i77" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i77"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i78" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i78"> Abbreviations Used</h2><tr><td class="NLM_term">DOM</td><td class="NLM_def"><p class="first last">1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane</p></td></tr><tr><td class="NLM_term">5-MeO-DMT</td><td class="NLM_def"><p class="first last">5-methoxy-<i>N</i>,<i>N</i>-dimethyltryptamine</p></td></tr><tr><td class="NLM_term">IOP</td><td class="NLM_def"><p class="first last">intraocular pressure</p></td></tr><tr><td class="NLM_term">NHP</td><td class="NLM_def"><p class="first last">nonhuman primate</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">trabecular meshwork</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Congdon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâColmain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaver, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, P.</span><span> </span><span class="NLM_article-title">Causes and prevalence of visual impairment among adults in the United States</span> <span class="citation_source-journal">Arch. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span><span class="refDoi">Â DOI: 10.1001/archopht.122.4.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1001%2Farchopht.122.4.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=15078664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2c7pvVyhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2004&pages=477-485&author=N.+Congdonauthor=B.+O%E2%80%99Colmainauthor=C.+C.+Klaverauthor=R.+Kleinauthor=B.+Munozauthor=D.+S.+Friedmanauthor=J.+Kempenauthor=H.+R.+Taylorauthor=P.+Mitchell&title=Causes+and+prevalence+of+visual+impairment+among+adults+in+the+United+States&doi=10.1001%2Farchopht.122.4.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and prevalence of visual impairment among adults in the United States</span></div><div class="casAuthors">Congdon Nathan; O'Colmain Benita; Klaver Caroline C W; Klein Ronald; Munoz Beatriz; Friedman David S; Kempen John; Taylor Hugh R; Mitchell Paul</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-85</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVES:  To estimate the cause-specific prevalence and distribution of blindness and low vision in the United States by age, race/ethnicity, and gender, and to estimate the change in these prevalence figures over the next 20 years.  METHODS:  Summary prevalence estimates of blindness (both according to the US definition of < or =6/60 [< or =20/200] best-corrected visual acuity in the better-seeing eye and the World Health Organization standard of < 6/120 [< 20/400]) and low vision (< 6/12 [< 20/40] best-corrected vision in the better-seeing eye) were prepared separately for black, Hispanic, and white persons in 5-year age intervals starting at 40 years.  The estimated prevalences were based on recent population-based studies in the United States, Australia, and Europe.  These estimates were applied to 2000 US Census data, and to projected US population figures for 2020, to estimate the number of Americans with visual impairment.  Cause-specific prevalences of blindness and low vision were also estimated for the different racial/ethnic groups.  RESULTS:  Based on demographics from the 2000 US Census, an estimated 937 000 (0.78%) Americans older than 40 years were blind (US definition).  An additional 2.4 million Americans (1.98%) had low vision.  The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness.  Cataract was the leading cause of low vision, responsible for approximately 50% of bilateral vision worse than 6/12 (20/40) among white, black, and Hispanic persons.  The number of blind persons in the US is projected to increase by 70% to 1.6 million by 2020, with a similar rise projected for low vision.  CONCLUSIONS:  Blindness or low vision affects approximately 1 in 28 Americans older than 40 years.  The specific causes of visual impairment, and especially blindness, vary greatly by race/ethnicity.  The prevalence of visual disabilities will increase markedly during the next 20 years, owing largely to the aging of the US population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhXjB6io5E4SCEBeYuoi7AfW6udTcc2eZgHLie0-fcM7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7pvVyhuw%253D%253D&md5=b6cf1e965ebb1d210f07439d0e4da2da</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1001%2Farchopht.122.4.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.122.4.477%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Colmain%26aufirst%3DB.%26aulast%3DKlaver%26aufirst%3DC.%2BC.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DD.%2BS.%26aulast%3DKempen%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DH.%2BR.%26aulast%3DMitchell%26aufirst%3DP.%26atitle%3DCauses%2520and%2520prevalence%2520of%2520visual%2520impairment%2520among%2520adults%2520in%2520the%2520United%2520States%26jtitle%3DArch.%2520Ophthalmol.%26date%3D2004%26volume%3D122%26spage%3D477%26epage%3D485%26doi%3D10.1001%2Farchopht.122.4.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Weinreb, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F. A.</span><span> </span><span class="NLM_article-title">The pathophysiology and treatment of glaucoma: a review</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">1901</span><span class="NLM_x">â</span> <span class="NLM_lpage">11</span><span class="refDoi">Â DOI: 10.1001/jama.2014.3192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1001%2Fjama.2014.3192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGkt7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1901-11&author=R.+N.+Weinrebauthor=T.+Aungauthor=F.+A.+Medeiros&title=The+pathophysiology+and+treatment+of+glaucoma%3A+a+review&doi=10.1001%2Fjama.2014.3192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The pathophysiology and treatment of glaucoma: a review</span></div><div class="casAuthors">Weinreb, Robert N.; Aung, Tin; Medeiros, Felipe A.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1901-1911, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Glaucoma is a worldwide leading cause of irreversible vision loss.  Because it may be asymptomatic until a relatively late stage, diagnosis is frequently delayed.  A general understanding of the disease pathophysiol., diagnosis, and treatment may assist primary care physicians in referring high-risk patients for comprehensive ophthalmol. examn. and in more actively participating in the care of patients affected by this condition.  Objective: To describe current evidence regarding the pathophysiol. and treatment of open-angle glaucoma and angle-closure glaucoma.  Evidence Review: A literature search was conducted using MEDLINE, the Cochrane Library, and manuscript refs. for studies published in English between Jan. 2000 and Sept. 2013 on the topics open-angle glaucoma and angle-closure glaucoma.  From the 4334 abstrs. screened, 210 articles were selected that contained information on pathophysiol. and treatment with relevance to primary care physicians.  Findings: The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head.  Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role.  Redn. of intraocular pressure is the only proven method to treat the disease.  Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression.  Conclusions and Relevance: Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with pos. family history or with suspicious optic nerve head findings for complete ophthalmol. examn.  They can improve treatment outcomes by reinforcing the importance of medication adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgeries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6gdyXxGMVDrVg90H21EOLACvtfcHk0lgVa-4KZfiBEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGkt7zE&md5=114e7c3bacec0c76aa835f7a3a94f287</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3192%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DAung%26aufirst%3DT.%26aulast%3DMedeiros%26aufirst%3DF.%2BA.%26atitle%3DThe%2520pathophysiology%2520and%2520treatment%2520of%2520glaucoma%253A%2520a%2520review%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D311%26spage%3D1901%26epage%3D11%26doi%3D10.1001%2Fjama.2014.3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Boland, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jampel, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollenweider, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chelladurai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez-Cuervo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, K. A.</span><span> </span><span class="NLM_article-title">Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">279</span><span class="refDoi">Â DOI: 10.7326/0003-4819-158-4-201302190-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.7326%2F0003-4819-158-4-201302190-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=23420235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BC3szpt12ntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2013&pages=271-279&author=M.+V.+Bolandauthor=A.+M.+Ervinauthor=D.+S.+Friedmanauthor=H.+D.+Jampelauthor=B.+S.+Hawkinsauthor=D.+Vollenweiderauthor=Y.+Chelladuraiauthor=D.+Wardauthor=C.+Suarez-Cuervoauthor=K.+A.+Robinson&title=Comparative+effectiveness+of+treatments+for+open-angle+glaucoma%3A+a+systematic+review+for+the+US+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-158-4-201302190-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Boland Michael V; Ervin Ann-Margret; Friedman David S; Jampel Henry D; Hawkins Barbara S; Vollenweider Daniela; Chelladurai Yohalakshmi; Ward Darcy; Suarez-Cuervo Catalina; Robinson Karen A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glaucoma is an acquired degeneration of the optic nerve and a leading cause of blindness worldwide.  Medical and surgical treatments that decrease intraocular pressure may prevent visual impairment and blindness.  PURPOSE:  To compare the effectiveness of medical, laser, and surgical treatments in adults with open-angle glaucoma with regard to decreasing intraocular pressure and preventing optic nerve damage, vision loss, and visual impairment.  DATA SOURCES:  MEDLINE, CENTRAL, and an existing database for systematic reviews (through 2 March 2011); MEDLINE, EMBASE, LILACS, and CENTRAL for primary studies (through 30 July 2012).  STUDY SELECTION:  English-language systematic reviews; randomized, controlled trials; and quasi-randomized, controlled trials for most outcomes and observational studies for quality of life and harms.  DATA EXTRACTION:  Two investigators abstracted or checked information about study design, participants, and outcomes and assessed risk of bias and strength of evidence.  DATA SYNTHESIS:  High-level evidence suggests that medical, laser, and surgical treatments decrease intraocular pressure and that medical treatment and trabeculectomy reduce the risk for optic nerve damage and visual field loss compared with no treatment.  The direct effect of treatments on visual impairment and the comparative efficacy of different treatments are not clear.  Harms of medical treatment are primarily local (ocular redness, irritation); surgical treatment carries a small risk for more serious complications.  LIMITATION:  Heterogeneous outcome definitions and measurements among the included studies; exclusion of many treatment studies that did not stratify results by glaucoma type.  CONCLUSION:  Medical and surgical treatments for open-angle glaucoma lower intraocular pressure and reduce the risk for optic nerve damage over the short to medium term.  Which treatments best prevent visual disability and improve patient-reported outcomes is unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9U_u_lrxQNdj_Vg2vObihfW6udTcc2eapC8tr7aVaJLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpt12ntw%253D%253D&md5=a6b2c197aa7a879e14fb40bdc74839d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-158-4-201302190-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-158-4-201302190-00008%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DM.%2BV.%26aulast%3DErvin%26aufirst%3DA.%2BM.%26aulast%3DFriedman%26aufirst%3DD.%2BS.%26aulast%3DJampel%26aufirst%3DH.%2BD.%26aulast%3DHawkins%26aufirst%3DB.%2BS.%26aulast%3DVollenweider%26aufirst%3DD.%26aulast%3DChelladurai%26aufirst%3DY.%26aulast%3DWard%26aufirst%3DD.%26aulast%3DSuarez-Cuervo%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DK.%2BA.%26atitle%3DComparative%2520effectiveness%2520of%2520treatments%2520for%2520open-angle%2520glaucoma%253A%2520a%2520systematic%2520review%2520for%2520the%2520US%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2013%26volume%3D158%26spage%3D271%26epage%3D279%26doi%3D10.7326%2F0003-4819-158-4-201302190-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Sharif, N.</span><span> </span><span class="NLM_article-title">Ocular Hypotension: Involvement of Serotonergic 5-HT<sub>2</sub> Receptors</span>. In  <span class="citation_source-journal">5-HT<sub>2C</sub> Receptors in the Pathophysiology of CNS Disease (The Receptors)</span>; <span class="NLM_contrib-group">Di Giovanni, G.; Esposito, E.; Di Matteo, V.</span> Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">; </span>Chapter 26, Vol.  <span class="NLM_volume">22</span>, pp  <span class="NLM_fpage">523</span><span class="NLM_x">â</span> <span class="NLM_lpage">43</span>.<span class="refDoi">Â DOI: 10.1007/978-1-60761-941-3_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1007%2F978-1-60761-941-3_26" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=523-43&author=N.+Sharifauthor=G.+Di+Giovanni&author=E.+Esposito&author=V.+Di+Matteo&title=Ocular+Hypotension%3A+Involvement+of+Serotonergic+5-HT2+Receptors&doi=10.1007%2F978-1-60761-941-3_26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-941-3_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-941-3_26%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%26atitle%3DOcular%2520Hypotension%253A%2520Involvement%2520of%2520Serotonergic%25205-HT2%2520Receptors%26jtitle%3D5-HT2C%2520Receptors%2520in%2520the%2520Pathophysiology%2520of%2520CNS%2520Disease%2520%2528The%2520Receptors%2529%26aulast%3DDi%2BGiovanni%26aufirst%3DG.%26pub%3DHumana%2520Press%26date%3D2011%26volume%3D22%26spage%3D523%26epage%3D43%26doi%3D10.1007%2F978-1-60761-941-3_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drace, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senchyna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of a serotonin receptor (5HT<sub>7</sub>) stimulating cAMP production in human corneal epithelial cells</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4837</span><span class="NLM_x">â</span> <span class="NLM_lpage">4844</span><span class="refDoi">Â DOI: 10.1167/iovs.02-1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.02-1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=14578406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD3srgtFaktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=4837-4844&author=J.+Y.+Criderauthor=G.+W.+Williamsauthor=C.+D.+Draceauthor=P.+Katoliauthor=M.+Senchynaauthor=N.+A.+Sharif&title=Pharmacological+characterization+of+a+serotonin+receptor+%285HT7%29+stimulating+cAMP+production+in+human+corneal+epithelial+cells&doi=10.1167%2Fiovs.02-1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells</span></div><div class="casAuthors">Crider Julie Y; Williams Gary W; Drace Colene D; Katoli Parvaneh; Senchyna Michelle; Sharif Najam A</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4837-44</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  To study the mRNA and pharmacology of a serotonin (5-HT) receptor positively coupled to adenylyl cyclase in normal, primary (P-CEPI), and immortalized human corneal epithelial cells (CEPI-17-CL4), by using numerous 5-HT agonists and antagonists.  To determine and compare cloned human 5-HT7 receptor binding affinities of compounds with their functional potency data.  METHODS:  RT-PCR was used to detect the presence of an mRNA for the human 5-HT7 receptor in CEPI-17-CL4 cells.  Receptor-mediated production of cAMP in cultured cells was measured using an enzyme immunoassay.  Compound binding affinities were determined using [3H]-lysergic acid diethylamide ([3H]-LSD) binding to cell membranes of human embryonic kidney (HEK-293) cells expressing the cloned human 5-HT7 receptor.  RESULTS:  RT-PCR revealed the presence of a 5-HT7 receptor mRNA in CEPI-17-CL4 cells.  Normal P-CEPI cells generated cAMP in response to 5-HT (-log EC50; pEC50=7.6), 5-carboxamidotryptamine (5-CT; pEC50=7.8), 5-methoxy-tryptamine (pEC50=7.0) and 5-methoxy-dimethyl-tryptamine (pEC50=5.7).  In CEPI-17-CL4 cells, serotonergic agonists also stimulated cAMP production with different potencies (pEC50): 5-CT (7.4)>5-HT (6.5)> or =5-methoxy-tryptamine (6.1)>5-methoxy-dimethyl-tryptamine (5.4)> or =8-OH-DPAT (<5.0)=alpha-methyl-5-HT (<5.0).  Various 5-HT receptor antagonists inhibited cAMP production induced by 5-CT in CEPI-17-CL4 cells with different potencies (pKi): methiothepin (8.5)>mesulergine (8.1)=metergoline (8.0)>spiperone (7.4)> or =clozapine (7.2)=SB-258719 (7.2)>mianserin (6.9)>ketanserin (6.3).  Antagonist pKi values in P-CEPI cells were methiothepin (8.7), spiperone (7.4) and SB-258719 (6.6).  The rank order of affinity for displacement of [3H]-LSD from the cloned human 5-HT7 receptor was: methiothepin>ritanserin>mesulergine=clozapine> or =metergoline=5-HT>SB-258719> or =spiperone>mianserin> or =ketanserin.  The functional agonist and antagonist potency data obtained from CEPI-17-CL4 cells correlated well with cloned human 5-HT7 receptor binding affinity data (r=0.69), with P-CEPI cell functional data (r=0.85), and with functional potency data in the literature for the cloned human 5-HT7 receptor (r=0.88).  CONCLUSIONS:  These collective data support the presence of a pharmacologically defined, adenylyl cyclase-coupled 5-HT7 receptor in the CEPI-17-CL4 cells that may have relevance to physiological and/or pathologic functions of 5-HT7 receptors in the human cornea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEd-24j4VqV3RxY89Cm6SyfW6udTcc2eYpTIE2e6zTEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srgtFaktg%253D%253D&md5=554eda853f3f78f89f522c9e33db5389</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1167%2Fiovs.02-1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.02-1292%26sid%3Dliteratum%253Aachs%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DWilliams%26aufirst%3DG.%2BW.%26aulast%3DDrace%26aufirst%3DC.%2BD.%26aulast%3DKatoli%26aufirst%3DP.%26aulast%3DSenchyna%26aufirst%3DM.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520serotonin%2520receptor%2520%25285HT7%2529%2520stimulating%2520cAMP%2520production%2520in%2520human%2520corneal%2520epithelial%2520cells%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2003%26volume%3D44%26spage%3D4837%26epage%3D4844%26doi%3D10.1167%2Fiovs.02-1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span> </span><span class="NLM_article-title">Human trabecular meshwork cells express functional serotonin-2 (5HT<sub>2</sub>) receptors: role in IOP reduction</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4001</span><span class="NLM_x">â</span> <span class="NLM_lpage">4010</span><span class="refDoi">Â DOI: 10.1167/iovs.06-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.06-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=16936116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtFejuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=4001-4010&author=N.+A.+Sharifauthor=C.+R.+Kellyauthor=M.+A.+McLaughlin&title=Human+trabecular+meshwork+cells+express+functional+serotonin-2+%285HT2%29+receptors%3A+role+in+IOP+reduction&doi=10.1167%2Fiovs.06-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction</span></div><div class="casAuthors">Sharif Najam A; Kelly Curtis R; McLaughlin Marsha</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4001-10</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  To apply a multidisciplinary approach to the identification and pharmacological characterization of the serotonin (5HT) receptors that mediate functional responses in human trabecular meshwork (h-TM) cells.  To correlate in vitro findings with intraocular pressure (IOP) changes in conscious ocular hypertensive cynomolgus monkeys.  METHODS:  Documented methods were used, including reverse transcription-polymerase chain reaction (RT-PCR), phosphoinositide (PI) turnover, and intracellular Ca2+ ([Ca2+]i) mobilization.  IOP was measured using standard applanation pneumatonometry.  RESULTS:  h-TM cells expressed robust mRNA signals for 5HT2A and 5HT2B receptors. 5HT and its analogues stimulated PI turnover and [Ca2+]i mobilization in h-TM cells from multiple donors (20/24 donors' TM cells responded).  The agonist potencies (EC50) of compounds in mobilizing [Ca2+]i were (nM): 5-methoxy tryptamine, 8 +/- 4; (R)-DOI, 18 +/- 6; alpha-methyl-5HT, 22 +/- 3; 5HT, 40 +/- 7; 5-methoxy-dimethyl tryptamine, 64 +/- 27; and BW-723C86, 1213 +/- 210.  These effects were potently blocked by the 5HT2A-receptor-selective antagonist, M-100907 (Ki = 1 +/- 0.3 nM), but weakly by antagonists of 5HT2B and 5HT2C receptors.  Only 5HT2 receptor agonists such as (R)-DOI (300 microg lowered IOP 34.4% from baseline of 38.2 mm Hg; P < 0.001) and alpha-methyl-5HT (250 microg lowered IOP 30.8% from baseline of 41.8 mm Hg; P < 0.001) lowered IOP in ocular hypertensive cynomolgus monkeys.  CONCLUSIONS:  Strong signals for 5HT2A and 5HT2B receptor mRNAs were detected in h-TM cells.  The receptors that coupled to PI hydrolysis and [Ca2+]i mobilization in h-TM cells were the 5HT2A receptor subtype, which also significantly lowered IOP in a primate model.  These receptors may mediate the ocular hypotensive actions of 5HT2A agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwwU9N7XqJnhJ5E29YNGvQfW6udTcc2ea8SwhiSU0s7Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtFejuw%253D%253D&md5=cff1170b25a9f7339125d4206f345b8e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1167%2Fiovs.06-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.06-0062%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26atitle%3DHuman%2520trabecular%2520meshwork%2520cells%2520express%2520functional%2520serotonin-2%2520%25285HT2%2529%2520receptors%253A%2520role%2520in%2520IOP%2520reduction%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2006%26volume%3D47%26spage%3D4001%26epage%3D4010%26doi%3D10.1167%2Fiovs.06-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, T. L.</span><span> </span><span class="NLM_article-title">Serotonin-2 (5HT<sub>2</sub>) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension</span> <span class="citation_source-journal">J. Ocul. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">â</span> <span class="NLM_lpage">401</span><span class="refDoi">Â DOI: 10.1089/jop.2006.22.389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1089%2Fjop.2006.22.389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=17238805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FjvFOnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=389-401&author=N.+A.+Sharifauthor=J.+Y.+Criderauthor=C.+R.+Kellyauthor=T.+L.+Davis&title=Serotonin-2+%285HT2%29+receptor-mediated+signal+transduction+in+human+ciliary+muscle+cells%3A+role+in+ocular+hypotension&doi=10.1089%2Fjop.2006.22.389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension</span></div><div class="casAuthors">Sharif Najam A; Kelly Curtis R; Crider Julie Y; Davis Terry L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-401</span>
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    </div><div class="casAbstract">PURPOSE AND METHODS:  The aim of this study was to characterize the serotonin (5-hydroxytryptamine; 5-HT) receptors that mediate phosphoinositide (PI) hydrolysis and intracellular Ca2+ ([Ca2+]i) mobilization in isolated cells of human ciliary muscle (h-CM) from multiple donors using a variety of agonists and antagonists.  An additional aim was to visualize the mRNAs and receptor binding sites for 5-HT2 receptors in human ciliary body (h-CB), CM, and other tissues by reverse transcriptase polymerase chain reaction and quantitative autoradiography techniques, respectively, and to correlate with ocular hypotensive activity of such compounds.  RESULTS:  CBs isolated from several donor eyes revealed the presence of 5-HT(2A2C) receptor mRNAs. [3H]-5-HT and [3H]-ketanserin autoradiography on sections of human eyes revealed a high density of 5-HT2 receptor binding sites in the iris, ciliary epithelium, and longitudinal CM.  In isolated h-CM cells, the agonists alpha-methyl-5-HT (EC50=63+/-17 nM), 5-HT (EC50=85+/-16 nM), (R)-DOI (EC50=165+/-47 nM), and 5-methoxy alpha-methyl tryptamine (EC50=1200+/-270 nM) differentially stimulated PI turnover.  These agonists also mobilized [Ca2+]i in h-CM cells with the following potencies (EC50s): 5-methoxy-tryptamine=42+/-11 nM; alpha-methyl-5-HT=36+/-11 nM; (R)-DOI=120 nM; 5-HT=130+/-36 nM; MK-212=470 nM; mCPP>1 microM; BW723C86=1766 nM.  The agonist-induced [Ca2+]i mobilization in h-CM cells was potently blocked by the 5-HT2A-selective antagonist M-100907 (IC50=1.2+/-0.4 nM) but less potently by the antagonists for 5-HT2B (RS-127445, IC50>10 microM) and 5-HT2C (RS-102221, IC50=5.8+/-2.3 microM) receptors.  CONCLUSIONS:  In conclusion, h-CB, h-CM, and CM cells express mRNAs and proteins for 5-HT2 receptor subtypes, of which the predominant functionally active subtype is the 5-HT2A receptor, as defined by agonist and antagonist activities.  These receptors may be responsible for mediating the intraocular pressure reduction observed in recent literature with a number of 5-HT2 agonists, such as (R)-DOI, alpha-methyl-5HT, and AL-34662.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDoQRj6iRMcj0SWnHPWbmmfW6udTcc2ea8SwhiSU0s7Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FjvFOnsw%253D%253D&md5=787b39232ff9cf05f399ba36829c22de</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1089%2Fjop.2006.22.389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2006.22.389%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DDavis%26aufirst%3DT.%2BL.%26atitle%3DSerotonin-2%2520%25285HT2%2529%2520receptor-mediated%2520signal%2520transduction%2520in%2520human%2520ciliary%2520muscle%2520cells%253A%2520role%2520in%2520ocular%2520hypotension%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D22%26spage%3D389%26epage%3D401%26doi%3D10.1089%2Fjop.2006.22.389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senchyna, M.</span><span> </span><span class="NLM_article-title">Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR</span> <span class="citation_source-journal">Molecular Vision</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">â</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1040-1047&author=N.+A.+Sharifauthor=M.+Senchyna&title=Serotonin+receptor+subtype+mRNA+expression+in+human+ocular+tissues+determined+by+RT-PCR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DSenchyna%26aufirst%3DM.%26atitle%3DSerotonin%2520receptor%2520subtype%2520mRNA%2520expression%2520in%2520human%2520ocular%2520tissues%2520determined%2520by%2520RT-PCR%26jtitle%3DMolecular%2520Vision%26date%3D2006%26volume%3D12%26spage%3D1040%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span> </span><span class="NLM_article-title">Evaluation of the ocular hypotensive response of serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptor ligands in conscious ocular hypertensive cynomolgus monkeys</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">â</span> <span class="NLM_lpage">309</span><span class="refDoi">Â DOI: 10.1124/jpet.103.049528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.103.049528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12676887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=301-309&author=J.+A.+Mayauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=M.+R.+Hellbergauthor=T.+R.+Dean&title=Evaluation+of+the+ocular+hypotensive+response+of+serotonin+5-HT1A+and+5-HT2+receptor+ligands+in+conscious+ocular+hypertensive+cynomolgus+monkeys&doi=10.1124%2Fjpet.103.049528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys</span></div><div class="casAuthors">May, Jesse A.; McLaughlin, Marsha A.; Sharif, Najam A.; Hellberg, Mark R.; Dean, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Published investigations of serotonin-1A (5-hydroxytryptamine1A; 5-HT1A) receptor agonists and serotonin-2A (5-hydroxytryptamine2A; 5-HT2A) receptor antagonists in nonprimate species provide conflicting results with regard to their intraocular pressure-lowering efficacy.  Thus, their therapeutic utility in the treatment of human glaucoma has been confusing.  We evaluated the effect of selected 5-HT1A agonists and 5-HT2A receptor antagonists on intraocular pressure in a nonhuman primate model, the conscious cynomolgus monkey with laser-induced ocular hypertension.  Neither selective 5-HT1A agonists [e.g., R-8-hydroxy-2-(di-n-propylamino)tetralin and flesinoxan] nor selective 5-HT2 receptor antagonists [e.g., R-(+)-Î±-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (M-100907) and 6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxamide (SB-242084)] lowered intraocular pressure in the primate model following topical ocular administration.  However, compds. that function as agonists at both the 5-HT1A and 5-HT2 receptors were found to effectively lower intraocular pressure in the model: 5-hydroxy-Î±-methyltryptamine, 5-methoxy-Î±-methyltryptamine, 5-hydroxy-N,N-dimethyltryptamine (bufotenine), and 5-methoxy-N,N-dimethyltryptamine.  Furthermore, the selective 5-HT2 receptor agonist R-(-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane lowered intraocular pressure in the primate model, demonstrating a pharmacol. response assocd. with activation of the 5-HT2 receptor.  These observations suggest that compds. that function as efficient agonists at 5-HT2 receptors should be considered as potential agents for the control of intraocular pressure in the treatment of ocular hypertension and glaucoma in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6cTSJU_WCOrVg90H21EOLACvtfcHk0liJLNCZ-g9uTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksrw%253D&md5=32d960587e00aa0746336d8b5db6881a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.049528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.049528%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DDean%26aufirst%3DT.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520ocular%2520hypotensive%2520response%2520of%2520serotonin%25205-HT1A%2520and%25205-HT2%2520receptor%2520ligands%2520in%2520conscious%2520ocular%2520hypertensive%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D301%26epage%3D309%26doi%3D10.1124%2Fjpet.103.049528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantanarayana, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinke, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">1-((<i>S</i>)-2-Aminopropyl)-1<i>H</i>-indazol-6-ol: A potent peripherally acting 5-HT<sub>2</sub> receptor agonist with ocular hypertensive activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">â</span> <span class="NLM_lpage">328</span><span class="refDoi">Â DOI: 10.1021/jm050663x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050663x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=318-328&author=J.+A.+Mayauthor=A.+P.+Dantanarayanaauthor=P.+W.+Zinkeauthor=M.+A.+McLaughlinauthor=N.+A.+Sharif&title=1-%28%28S%29-2-Aminopropyl%29-1H-indazol-6-ol%3A+A+potent+peripherally+acting+5-HT2+receptor+agonist+with+ocular+hypertensive+activity&doi=10.1021%2Fjm050663x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm050663x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050663x%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DDantanarayana%26aufirst%3DA.%2BP.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3D1-%2528%2528S%2529-2-Aminopropyl%2529-1H-indazol-6-ol%253A%2520A%2520potent%2520peripherally%2520acting%25205-HT2%2520receptor%2520agonist%2520with%2520ocular%2520hypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D318%26epage%3D328%26doi%3D10.1021%2Fjm050663x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusinko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span> </span><span class="NLM_article-title">A novel and selective 5-HT<sub>2</sub> receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-<i>e</i>]indole. 2003</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4188</span><span class="NLM_x">â</span> <span class="NLM_lpage">4195</span><span class="refDoi">Â DOI: 10.1021/jm030205t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030205t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4188-4195&author=J.+A.+Mayauthor=H.+H.+Chenauthor=A.+Rusinkoauthor=V.+M.+Lynchauthor=N.+A.+Sharifauthor=M.+A.+McLaughlin&title=A+novel+and+selective+5-HT2+receptor+agonist+with+ocular+hypotensive+activity%3A+%28S%29-%28%2B%29-1-%282-aminopropyl%29-8%2C9-dihydropyrano%5B3%2C2-e%5Dindole.+2003&doi=10.1021%2Fjm030205t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm030205t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030205t%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DRusinko%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DV.%2BM.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26atitle%3DA%2520novel%2520and%2520selective%25205-HT2%2520receptor%2520agonist%2520with%2520ocular%2520hypotensive%2520activity%253A%2520%2528S%2529-%2528%252B%2529-1-%25282-aminopropyl%2529-8%252C9-dihydropyrano%255B3%252C2-e%255Dindole.%25202003%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4188%26epage%3D4195%26doi%3D10.1021%2Fjm030205t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, C. P.</span><span> </span><span class="NLM_article-title">Pharmacological Properties and Discriminative Stimulus Effects of a Novel and Selective Serotonin-2 (5-HT<sub>2</sub>) Receptor Agonist AL-38022A [(<i>S</i>)-2-(8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl)-1-methylethylamine]</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span><span class="refDoi">Â DOI: 10.1016/j.pbb.2008.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.pbb.2008.07.015" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2009&pages=307-314&author=J.+A.+Mayauthor=N.+A.+Sharifauthor=H.-H.+Chenauthor=J.+C.+Liaoauthor=C.+R.+Kellyauthor=R.+A.+Glennonauthor=R.+Youngauthor=J.-X.+Liauthor=+Riceauthor=C.+P.+France&title=Pharmacological+Properties+and+Discriminative+Stimulus+Effects+of+a+Novel+and+Selective+Serotonin-2+%285-HT2%29+Receptor+Agonist+AL-38022A+%5B%28S%29-2-%288%2C9-dihydro-7H-pyrano%5B2%2C3-g%5Dindazol-1-yl%29-1-methylethylamine%5D&doi=10.1016%2Fj.pbb.2008.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2008.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2008.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DChen%26aufirst%3DH.-H.%26aulast%3DLiao%26aufirst%3DJ.%2BC.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.-X.%26aulast%3DRice%26aulast%3DFrance%26aufirst%3DC.%2BP.%26atitle%3DPharmacological%2520Properties%2520and%2520Discriminative%2520Stimulus%2520Effects%2520of%2520a%2520Novel%2520and%2520Selective%2520Serotonin-2%2520%25285-HT2%2529%2520Receptor%2520Agonist%2520AL-38022A%2520%255B%2528S%2529-2-%25288%252C9-dihydro-7H-pyrano%255B2%252C3-g%255Dindazol-1-yl%2529-1-methylethylamine%255D%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2009%26volume%3D91%26spage%3D307%26epage%3D314%26doi%3D10.1016%2Fj.pbb.2008.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Doan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">â</span> <span class="NLM_lpage">37</span><span class="refDoi">Â DOI: 10.1124/jpet.102.039255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-37&author=K.+M.+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs&doi=10.1124%2Fjpet.102.039255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Doan, Kelly M. Mahar; Humphreys, Joan E.; Webster, Lindsey O.; Wring, Stephen A.; Shampine, Larry J.; Serabjit-Singh, Cosette J.; Adkison, Kimberly K.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-1037</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to det. whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochem. properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compds. for drug development.  Apparent permeability (Papp) and Pgp substrate profiles for 93 CNS and non-CNS drugs were detd. by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were pos. in the calcein-AM assay when tested at 100 Î¼M.  The CNS drug set (of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (of 45, 42.2%).  Anal. of 18 physicochem. properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer pos. charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group, properties that enhance membrane permeability.  This study on a large, diverse set of marketed compds. clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochem. properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B â A/A â B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qUc-kS0MC7Vg90H21EOLACvtfcHk0liKNlQER6AtbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D&md5=bcac11a02278360d6d6ad48718f0d5be</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DK.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D37%26doi%3D10.1124%2Fjpet.102.039255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rager, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, J. I. J.</span><span> </span><span class="NLM_article-title">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1016/j.ijpharm.2004.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.ijpharm.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=15620875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2005&pages=349-59&author=Q.+Wangauthor=J.+D.+Ragerauthor=K.+Weinsteinauthor=P.+S.+Kardosauthor=G.+L.+Dobsonauthor=+Liauthor=J.+I.+J.+Hidalgo&title=Evaluation+of+the+MDR-MDCK+cell+line+as+a+permeability+screen+for+the+blood-brain+barrier&doi=10.1016%2Fj.ijpharm.2004.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span></div><div class="casAuthors">Wang, Qing; Rager, Joseph D.; Weinstein, Kathryn; Kardos, Paula S.; Dobson, Glenn L.; Li, Jibin; Hidalgo, Ismael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-359</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The objectives of this study were to (1) characterize MDR-MDCK monolayers as an in vitro model to predict brain uptake potential; (2) examine the ability of MDR-MDCK monolayers to identify the brain uptake potential of compds. that interact with P-glycoprotein (P-gp).  The study measured the bi-directional transport of 28 compds. across MDR-MDCK monolayers.  The brain uptake of a subset of the compds. was detd. in the rat brain perfusion model.  Drug concns. were analyzed by LC-MS-MS.  CNS-pos. drugs exhibited absorptive permeability coeffs. (Papp, A-B) values ranging from 3.4 Ã 10-6 to 20.2 Ã 10-6 cm/s; whereas CNS-neg. drugs showed Papp (A-B) ranging from 0.03 Ã 10-6 to 0.83 Ã 10-6 cm/s.  Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compds. known to be P-pg substrates, but only enhanced the absorptive flux of compds. with high efflux ratio (>100).  In vitro results were confirmed by brain perfusion studies on selected compds.  MDR-MDCK monolayers can be used to classify compds. into CNS-pos. or CNS-neg. based on the permeability coeffs. (Papp, A-B).  Under the authors' exptl. conditions, compds. with Papp (A-B) >3 Ã 10-6 cm/s have high brain uptake potential; compds. with Papp (A-B) < 1 Ã 10-6 cm/s are unable to penetrate the blood-brain barrier (BBB); the brain uptake of compds. with Papp (A-B) < 1 Ã 10-6 cm/s and a P-gp-mediated efflux ratio of >100 may be enhanced by inhibiting P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvF-zoLte8trVg90H21EOLACvtfcHk0lh59NmT9avYqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE&md5=7d2cb9e13b2767b337bf808e73141ae1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DRager%26aufirst%3DJ.%2BD.%26aulast%3DWeinstein%26aufirst%3DK.%26aulast%3DKardos%26aufirst%3DP.%2BS.%26aulast%3DDobson%26aufirst%3DG.%2BL.%26aulast%3DLi%26aulast%3DHidalgo%26aufirst%3DJ.%2BI.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520MDR-MDCK%2520cell%2520line%2520as%2520a%2520permeability%2520screen%2520for%2520the%2520blood-brain%2520barrier%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2005%26volume%3D288%26spage%3D349%26epage%3D59%26doi%3D10.1016%2Fj.ijpharm.2004.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gornemann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centurion, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertz, H. H.</span><span> </span><span class="NLM_article-title">Phenylephrine contracts porcine pulmonary veins via alpha (1B)-, alpha (1D)-, and alpha (2)-adrenoceptors</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">613</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">â</span> <span class="NLM_lpage">92</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2009.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.ejphar.2009.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19376108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD1MzosFGguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=613&publication_year=2009&pages=86-92&author=T.+Gornemannauthor=C.+M.+Villalonauthor=D.+Centurionauthor=H.+H.+Pertz&title=Phenylephrine+contracts+porcine+pulmonary+veins+via+alpha+%281B%29-%2C+alpha+%281D%29-%2C+and+alpha+%282%29-adrenoceptors&doi=10.1016%2Fj.ejphar.2009.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylephrine contracts porcine pulmonary veins via alpha(1B)-, alpha(1D)-, and alpha(2)-adrenoceptors</span></div><div class="casAuthors">Gornemann Tilo; Villalon Carlos M; Centurion David; Pertz Heinz H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">613</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">86-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have recently shown that the postjunctional alpha(2)-adrenoceptor mediating contraction of porcine pulmonary veins is of the alpha(2C)-subtype.  We could also demonstrate that alpha(1)-adrenoceptors might contribute to the contraction in that blood vessel.  In the present study, we aimed at characterising the alpha(1)-adrenoceptor subtype(s) involved using pharmacological and molecular biological methods.  In isolated rings of porcine pulmonary veins the typical alpha(1)-adrenoceptor agonist phenylephrine caused a concentration-dependent contraction that was inhibited by the alpha(1B)-adrenoceptor selective antagonists 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one (Rec15/2615; pA(2) 8.96+/-0.13) and 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314; pA(2) 7.22+/-0.05), as well as the alpha(1D)-adrenoceptor selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY7378; pA(2) 8.29+/-0.15, slope of the Schild plot 0.75+/-0.09, significantly different from unity, P<0.05), but not by the alpha(1A)-adrenoceptor selective antagonists (+/-)-1,3,5-trimethyl-6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-pyrimidinedione (B8805-033) and N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine (RS-17053).  These findings suggest that phenylephrine activates both alpha(1B)- and alpha(1D)-adrenoceptors.  The observation was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) in porcine pulmonary veins, where mRNA signals for alpha(1B)- and alpha(1D)-adrenoceptors could be detected.  However, the antagonist properties of rauwolscine and yohimbine (non-subtype selective alpha(2)-adrenoceptor antagonists) against phenylephrine showed that this agonist also activates alpha(2)-adrenoceptors in pulmonary veins.  This was strengthened in experiments using tissues that were stimulated with forskolin (cell permeable activator of adenylyl cyclase).  Phenylephrine mimicked the effect of the selective alpha(2)-adrenoceptor agonist UK14304 by causing an inhibition of forskolin-stimulated cAMP accumulation that was blocked by rauwolscine.  It is concluded that, in addition to alpha(1B)- and alpha(1D)-adrenoceptors, phenylephrine can stimulate alpha(2)-adrenoceptors in porcine pulmonary veins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOKKAObCJDdKe0F5ixvZgXfW6udTcc2eb6fVgKzF7Y87ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzosFGguw%253D%253D&md5=ceeee000bca4f54dceefc2f61b2b1d2e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGornemann%26aufirst%3DT.%26aulast%3DVillalon%26aufirst%3DC.%2BM.%26aulast%3DCenturion%26aufirst%3DD.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26atitle%3DPhenylephrine%2520contracts%2520porcine%2520pulmonary%2520veins%2520via%2520alpha%2520%25281B%2529-%252C%2520alpha%2520%25281D%2529-%252C%2520and%2520alpha%2520%25282%2529-adrenoceptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D613%26spage%3D86%26epage%3D92%26doi%3D10.1016%2Fj.ejphar.2009.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Jensen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigart, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laden, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMarco, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoopes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, P. C.</span><span> </span><span class="NLM_article-title">The alpha-1D is the predominant alpha-1-adrenergic receptor subtype in human apicardial coronary arteries</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">â</span> <span class="NLM_lpage">1145</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2009.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.jacc.2009.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19761933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GntbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=1137-1145&author=B.+C.+Jensenauthor=P.+M.+Swigartauthor=M.+E.+Ladenauthor=T.+DeMarcoauthor=C.+Hoopesauthor=P.+C.+Simpson&title=The+alpha-1D+is+the+predominant+alpha-1-adrenergic+receptor+subtype+in+human+apicardial+coronary+arteries&doi=10.1016%2Fj.jacc.2009.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The alpha-1D is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries</span></div><div class="casAuthors">Jensen, Brian C.; Swigart, Philip M.; Laden, Marie-Eve; DeMarco, Teresa; Hoopes, Charles; Simpson, Paul C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1137-1145</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The goal was to identify alpha-1-adrenergic receptor (AR) subtypes in human coronary arteries.  The Î±1-ARs regulate human coronary blood flow.  The Î±1-ARs exist as 3 mol. subtypes, Î±1A, Î±1B, and Î±1D, and the Î±1D subtype mediates coronary vasoconstriction in the mouse.  However, the Î±1A is thought to be the only subtype in human coronary arteries.  We obtained human epicardial coronary arteries and left ventricular (LV) myocardium from 19 transplant recipients and 6 unused donors (age 19 to 70 years; 68% male; 32% with coronary artery disease).  We cultured coronary rings and human coronary smooth muscle cells.  We assayed Î±1- and Î²-AR subtype mRNA by quant. real-time reverse transcription polymerase chain reaction and subtype proteins by radioligand binding and extracellular signal-regulated kinase (ERK) activation.  The Î±1D subtype was 85% of total coronary Î±1-AR mRNA and 75% of total Î±1-AR protein, and Î±1D stimulation activated ERK.  In contrast, the Î±1D was low in LV myocardium.  Total coronary Î±1-AR levels were one-third of Î²-ARs, which were 99% the Î²2 subtype.  The Î±1D subtype is predominant and functional in human epicardial coronary arteries, whereas the Î±1A and Î±1B are present at very low levels.  This distribution is similar to the mouse, where myocardial Î±1A- and Î±1B-ARs mediate beneficial functional responses and coronary Î±1Ds mediate vasoconstriction.  Thus, Î±1D-selective antagonists might mediate coronary vasodilation, without the neg. cardiac effects of nonselective Î±1-AR antagonists in current use.  Furthermore, it could be possible to selectively activate beneficial myocardial Î±1A- and/or Î±1B-AR signaling without causing coronary vasoconstriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyD122nJfVO7Vg90H21EOLACvtfcHk0lhs6wRna5cjmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GntbbJ&md5=89636f1cd9a7a905b968f9093dbe3b8d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DB.%2BC.%26aulast%3DSwigart%26aufirst%3DP.%2BM.%26aulast%3DLaden%26aufirst%3DM.%2BE.%26aulast%3DDeMarco%26aufirst%3DT.%26aulast%3DHoopes%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DP.%2BC.%26atitle%3DThe%2520alpha-1D%2520is%2520the%2520predominant%2520alpha-1-adrenergic%2520receptor%2520subtype%2520in%2520human%2520apicardial%2520coronary%2520arteries%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3D1137%26epage%3D1145%26doi%3D10.1016%2Fj.jacc.2009.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyba, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimko, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinke, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selliah, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeFaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrew, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamini, M. V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallee, V. L.</span><span> </span><span class="NLM_article-title">Identification and Characterization of the Ocular Hypotensive Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist</span> <span class="citation_source-journal">Surv. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S13</span><span class="NLM_x">â</span> <span class="NLM_lpage">S33</span><span class="refDoi">Â DOI: 10.1016/S0039-6257(02)00293-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2FS0039-6257%2802%2900293-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2002&pages=S13-S33&issue=Suppl.+1&author=M.+R.+Hellbergauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=L.+DeSantisauthor=T.+R.+Deanauthor=E.+P.+Kybaauthor=J.+E.+Bishopauthor=P.+G.+Klimkoauthor=P.+W.+Zinkeauthor=R.+D.+Selliahauthor=G.+Barnesauthor=J.+DeFallerauthor=A.+Kotheauthor=T.+Landryauthor=E.+K.+Sullivanauthor=R.+Andrewauthor=A.+A.+Davisauthor=L.+Silverauthor=M.+V.+W.+Bergaminiauthor=S.+Robertsonauthor=A.+L.+Weinerauthor=V.+L.+Sallee&title=Identification+and+Characterization+of+the+Ocular+Hypotensive+Efficacy+of+Travoprost%2C+a+Potent+and+Selective+FP+Prostaglandin+Receptor+Agonist%2C+and+AL-6598%2C+a+DP+Prostaglandin+Receptor+Agonist&doi=10.1016%2FS0039-6257%2802%2900293-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0039-6257%2802%2900293-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0039-6257%252802%252900293-X%26sid%3Dliteratum%253Aachs%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DDeSantis%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DKyba%26aufirst%3DE.%2BP.%26aulast%3DBishop%26aufirst%3DJ.%2BE.%26aulast%3DKlimko%26aufirst%3DP.%2BG.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26aulast%3DSelliah%26aufirst%3DR.%2BD.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DDeFaller%26aufirst%3DJ.%26aulast%3DKothe%26aufirst%3DA.%26aulast%3DLandry%26aufirst%3DT.%26aulast%3DSullivan%26aufirst%3DE.%2BK.%26aulast%3DAndrew%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DA.%2BA.%26aulast%3DSilver%26aufirst%3DL.%26aulast%3DBergamini%26aufirst%3DM.%2BV.%2BW.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DWeiner%26aufirst%3DA.%2BL.%26aulast%3DSallee%26aufirst%3DV.%2BL.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520the%2520Ocular%2520Hypotensive%2520Efficacy%2520of%2520Travoprost%252C%2520a%2520Potent%2520and%2520Selective%2520FP%2520Prostaglandin%2520Receptor%2520Agonist%252C%2520and%2520AL-6598%252C%2520a%2520DP%2520Prostaglandin%2520Receptor%2520Agonist%26jtitle%3DSurv.%2520Ophthalmol.%26date%3D2002%26volume%3D47%26issue%3DSuppl.%25201%26spage%3DS13%26epage%3DS33%26doi%3D10.1016%2FS0039-6257%2802%2900293-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drace, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, G.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camras, C.</span><span> </span><span class="NLM_article-title">Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes</span> <span class="citation_source-journal">Exp. Eye Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">â</span> <span class="NLM_lpage">397</span><span class="refDoi">Â DOI: 10.1016/j.exer.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.exer.2008.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=18992242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1SksL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2009&pages=386-397&author=N.+A.+Sharifauthor=M.+A.+McLaughlinauthor=C.+R.+Kellyauthor=P.+Katoliauthor=C.+Draceauthor=S.+Husainauthor=C.+Crossonauthor=C.+Torisauthor=G.-L.+Zhanauthor=C.+Camras&title=Cabergoline%3A+pharmacology%2C+ocular+hypotensive+studies+in+multiple+species%2C+and+aqueous+humor+dynamic+modulation+in+cynomolgus+monkey+eyes&doi=10.1016%2Fj.exer.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes</span></div><div class="casAuthors">Sharif, Najam A.; McLaughlin, Marsha A.; Kelly, Curtis R.; Katoli, Parvaneh; Drace, Colene; Husain, Shahid; Crosson, Craig; Toris, Carol; Zhan, Gui-Lin; Camras, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-397</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aims of the current studies were to det. the in vitro and in vivo ocular and non-ocular pharmacol. properties of cabergoline using well documented receptor binding, cell-based functional assays, and in vivo models.  Cabergoline bound to native and/or human cloned serotonin-2A/B/C (5HT2A/B/C), 5HT1A, 5HT7, Î±2B, and dopamine-2/3 (D2/3) receptor subtypes with nanomolar affinity.  Cabergoline was an agonist at human recombinant 5HT2, 5HT1A, and D2/3 receptors but an antagonist at 5HT7 and Î±2 receptors.  In primary human ciliary muscle (h-CM) and trabecular meshwork (h-TM) cells, cabergoline stimulated phosphoinositide (PI) hydrolysis (EC50 = 19 nM in TM; 76 nM in h-CM) and intracellular Ca2+ ([Ca2+]i) mobilization (EC50 = 570 nM in h-TM; EC50 = 900 nM in h-CM).  Cabergoline-induced [Ca2+]i mobilization in h-TM and h-CM cells was potently antagonized by a 5HT2A-selective antagonist (M-100907, Ki = 0.29-0.53 nM).  Cabergoline also stimulated [Ca2+]i mobilization more potently via human cloned 5HT2A (EC50 = 63.4 nM) than via 5HT2B and 5HT2C receptors.  In h-CM cells, cabergoline (1 Î¼M) stimulated prodn. of pro-matrix metalloproteinases-1 and -3 and synergized with forskolin to enhance cAMP prodn.  Cabergoline (1 Î¼M) perfused through anterior segments of porcine eyes caused a significant (27%) increase in outflow facility.  Topically administered cabergoline (300-500 Î¼g) in Dutch-belted rabbit eyes yielded 4.5 and 1.97 Î¼M levels in the aq. humor 30 and 90 min post-dose but failed to modulate intraocular pressure (IOP).  However, cabergoline was an efficacious IOP-lowering agent in normotensive Brown Norway rats (25% IOP decrease with 6 Î¼g at 4 h post-dose) and in conscious ocular hypertensive cynomolgus monkeys (peak redn. of 30.6% with 50 Î¼g at 3 h post-dose; 30.4% with 500 Î¼g at 7 h post-dose).  In ketamine-sedated monkeys, IOP was significantly lowered at 2.5 h after the second topical ocular dose (300 Î¼g) of cabergoline by 23 and 35% in normotensive and ocular hypertensive eyes, resp.  In normotensive eyes, cabergoline increased uveoscleral outflow (0.69 Î¼L/min-1.61 Î¼L/min, n = 13).  However, only 7 of the 11 ocular hypertensive monkeys showed significantly increased uveoscleral outflow.  These data indicate that cabergoline's most prominent agonist activity involves activation of 5HT2, 5HT1A, and D2/3 receptors.  Since 5HT1A agonists, 5HT7 antagonists, and Î±2 antagonists do not lower IOP in conscious ocular hypertensive monkeys, the 5HT2 and dopaminergic agonist activities of cabergoline probably mediated the IOP redn. obsd. with this compd. in this species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSfP_V_1ptuLVg90H21EOLACvtfcHk0ljOZdlHNCmTQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1SksL8%253D&md5=b0947f7e74baec400e406643fc4d0868</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DKatoli%26aufirst%3DP.%26aulast%3DDrace%26aufirst%3DC.%26aulast%3DHusain%26aufirst%3DS.%26aulast%3DCrosson%26aufirst%3DC.%26aulast%3DToris%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DG.-L.%26aulast%3DCamras%26aufirst%3DC.%26atitle%3DCabergoline%253A%2520pharmacology%252C%2520ocular%2520hypotensive%2520studies%2520in%2520multiple%2520species%252C%2520and%2520aqueous%2520humor%2520dynamic%2520modulation%2520in%2520cynomolgus%2520monkey%2520eyes%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2009%26volume%3D88%26spage%3D386%26epage%3D397%26doi%3D10.1016%2Fj.exer.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Berg, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maayani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaramellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span> </span><span class="NLM_article-title">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">â</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fmol.54.1.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=9658194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=94-104&author=K.+A.+Bergauthor=S.+Maayaniauthor=J.+Goldfarbauthor=C.+Scaramelliniauthor=P.+Leffauthor=W.+P.+Clarke&title=Effector+pathway-dependent+relative+efficacy+at+serotonin+type+2A+and+2C+receptors%3A+evidence+for+agonist-directed+trafficking+of+receptor+stimulus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span></div><div class="casAuthors">Berg, Kelly A.; Maayani, Saul; Goldfarb, Joseph; Scaramellini, Clare; Leff, Paul; Clarke, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">There are many examples of a single receptor coupling directly to more than one cellular signal transduction pathway.  Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same.  In the current expts., we demonstrate that agonists at the human serotonin2A (5-HT2A) and 5-HT2C receptors activate differentially two signal transduction pathways independently coupled to the receptors [phospholipase C (PLC)-mediated inositol phosphate (IP) accumulation and phospholipase A2 (PLA2)-mediated arachidonic acid (AA) release].  The relative efficacies of agonists differed depending on which signal transduction pathway was measured.  Moreover, relative to 5-HT, some 5-HT2C agonists (e.g., 3-trifluoromethylphenyl-piperazine) preferentially activated the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway.  In contrast, when two dependent responses were measured (IP accumulation and calcium mobilization), agonist relative efficacies were not different.  These data strongly support the hypothesis termed "agonist-directed trafficking of receptor stimulus" recently proposed by Kenakin [Trends Pharmacol Sci 16:232-238 (1995)].  Concn.-response curves to 5-HT2C agonists were fit well by a three-state model of receptor activation, suggesting that two active receptor states may be sufficient to explain pathway-dependent agonist efficacy.  Rational drug design that optimizes preferential effector activity within a group of receptor-selective drugs holds the promise of increased selectivity in clin. useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidEqbbZNg07Vg90H21EOLACvtfcHk0ljOZdlHNCmTQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D&md5=99239b54cc498d1254aad42298ea5684</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.54.1.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.54.1.94%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DK.%2BA.%26aulast%3DMaayani%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DJ.%26aulast%3DScaramellini%26aufirst%3DC.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26atitle%3DEffector%2520pathway-dependent%2520relative%2520efficacy%2520at%2520serotonin%2520type%25202A%2520and%25202C%2520receptors%253A%2520evidence%2520for%2520agonist-directed%2520trafficking%2520of%2520receptor%2520stimulus%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D94%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kurrasch-Orbaugh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">â</span> <span class="NLM_lpage">37</span><span class="refDoi">Â DOI: 10.1124/jpet.102.042184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.102.042184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12490596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Shtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=229-37&author=D.+M.+Kurrasch-Orbaughauthor=V.+J.+Wattsauthor=E.+L.+Barkerauthor=D.+E.+Nichols&title=Serotonin+5-hydroxytryptamine+2A+receptor-coupled+phospholipase+C+and+phospholipase+A2+signaling+pathways+have+different+receptor+reserves&doi=10.1124%2Fjpet.102.042184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves</span></div><div class="casAuthors">Kurrasch-Orbaugh, Deborah M.; Watts, Val J.; Barker, Eric L.; Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">NIH3T3 cells stably expressing the rat 5-hydroxytryptamine2A (5-HT2A) receptor (5500 fmol/mg) were used to explore further the capacity of structurally distinct ligands to elicit differential signaling through the phospholipase C (PLC) or phospholipase A2 (PLA2) signal transduction pathways.  Initial expts. were designed to verify that 5-HT2A receptor-mediated PLA2 activation in NIH3T3 cells is independent from, and not a subsequent result of, 5-HT2A receptor-mediated PLC activation.  In addn., we also explored the extent of receptor reserve for the endogenous ligand, 5-HT, for both PLC and PLA2 activation.  Finally, we employed structurally diverse ligands from the tryptamine, phenethylamine, and ergoline families of 5-HT2A receptor agonists to test the hypothesis of agonist-directed trafficking of 5-HT2A receptor-mediated PLC and PLA2 activation.  To measure agonist-induced pathway activation, we detd. the potency and intrinsic activity of each compd. to activate either the PLA2 pathway or the PLC pathway.  The results showed that a larger receptor reserve exists for 5-HT-induced PLA2 activation than for 5-HT-induced PLC activation.  Furthermore, the data support the hypothesis of agonist-directed trafficking in NIH3T3-5HT2A cells because structurally distinct ligands were able to induce preferential activation of the PLC or PLA2 signaling pathway.  From these data we conclude that structurally distinct ligands can differentially regulate 5-HT2A receptor signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYulzethbNN7Vg90H21EOLACvtfcHk0ljOZdlHNCmTQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Shtw%253D%253D&md5=634d43d309804e16dbec96c9c99ed770</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.042184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.042184%26sid%3Dliteratum%253Aachs%26aulast%3DKurrasch-Orbaugh%26aufirst%3DD.%2BM.%26aulast%3DWatts%26aufirst%3DV.%2BJ.%26aulast%3DBarker%26aufirst%3DE.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DSerotonin%25205-hydroxytryptamine%25202A%2520receptor-coupled%2520phospholipase%2520C%2520and%2520phospholipase%2520A2%2520signaling%2520pathways%2520have%2520different%2520receptor%2520reserves%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D229%26epage%3D37%26doi%3D10.1124%2Fjpet.102.042184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bucci, F. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterbury, L. D.</span><span> </span><span class="NLM_article-title">A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">â</span> <span class="NLM_lpage">2239</span><span class="refDoi">Â DOI: 10.1185/03007995.2011.626018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1185%2F03007995.2011.626018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=21992076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeisr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=2235-2239&author=F.+A.+Bucciauthor=L.+D.+Waterbury&title=A+randomized+comparison+of+to-aqueous+penetration+of+ketorolac+0.45%25%2C+bromfenac+0.09%25+and+nepafenac+0.1%25+in+cataract+patients+undergoing+phacoemulsification&doi=10.1185%2F03007995.2011.626018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized comparison of to-aqueous penetration of ketorolac 0.45%%, bromfenac 0.09%% and nepafenac 0.1%% in cataract patients undergoing phacoemulsification</span></div><div class="casAuthors">Bucci, Frank A., Jr.; Waterbury, L. David</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2235-2239</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Objective: To compare the peak to-aq. penetration of three nonsteroidal anti-inflammatory drugs: ketorolac tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%, and amfenac (the active metabolite of nepafenac) in patients undergoing phacoemulsification.  Methods: A single center, double-masked study randomized 122 patients to receive one of three treatment arms.  On-label dosing of ketorolac (BID), bromfenac (BID), and nepafenac (TID) was instructed for 1 day prior to surgery.  Patients were instructed to instill one drop the morning of surgery.  The patients received four addnl. doses 1 h prior to phacoemulsification.  After completion of the paracentesis site with a superblade, aq. humor (0.15 cc) was collected through the peripheral clear cornea with a 30-gauge needle attached to a TB syringe.  Following collection, aq. samples were stored at -40Â°C prior to anal.  Drug concns. were analyzed by liq. chromatog. tandem mass spectrometry using pos. turbo-ion spray ionization and multiple reaction monitoring mode for quantification.  An independent sample Student's t-test was used to detect between-group differences.  Results: The peak aq. concn. of ketorolac 0.45% was 10 times the concn. of bromfenac 0.09%, and five times the concn. of and 54% greater than the metabolically inactive nepafenac 0.1%.  The mean peak aq. concn. of ketorolac 0.45% was 688.87 Â± 749.6 ng/mL.  Bromfenac achieved a mean peak aq. concn. of 67.64 Â± 62.4 ng/mL. The mean peak aq. concns. of nepafenac and amfenac were 447.10 Â± 225.7 ng/mL and 140.37 Â± 56.6 ng/mL, resp.  The peak concn. of ketorolac was statistically significantly greater than bromfenac (P = 0.0005), nepafenac (P = 0.05), and amfenac (P = 0.005).  A limitation of this study is that aq. samples were collected just prior to surgery and not during the postoperative period due to ethical considerations.  Conclusions: Ketorolac 0.45% achieved significantly greater aq. concns. when compared to bromfenac 0.09% and the active metabolite of nepafenac 0.1% (amfenac) in patients undergoing phacoemulsification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjPAOQeg8Ep7Vg90H21EOLACvtfcHk0ljdf0MjysFZNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeisr3I&md5=3f2af92abdd25adabb36b3138a1fbb8b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1185%2F03007995.2011.626018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2011.626018%26sid%3Dliteratum%253Aachs%26aulast%3DBucci%26aufirst%3DF.%2BA.%26aulast%3DWaterbury%26aufirst%3DL.%2BD.%26atitle%3DA%2520randomized%2520comparison%2520of%2520to-aqueous%2520penetration%2520of%2520ketorolac%25200.45%2525%252C%2520bromfenac%25200.09%2525%2520and%2520nepafenac%25200.1%2525%2520in%2520cataract%2520patients%2520undergoing%2520phacoemulsification%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2011%26volume%3D27%26spage%3D2235%26epage%3D2239%26doi%3D10.1185%2F03007995.2011.626018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span> </span><span class="NLM_article-title">Serotonergic drugs and valvular heart disease</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">â</span> <span class="NLM_lpage">329</span><span class="refDoi">Â DOI: 10.1517/14740330902931524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1517%2F14740330902931524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19505264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslaiu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=317-329&author=R.+B.+Rothmanauthor=M.+H.+Baumann&title=Serotonergic+drugs+and+valvular+heart+disease&doi=10.1517%2F14740330902931524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonergic drugs and valvular heart disease</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-329</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT) releasers (Â±)-fenfluramine and (+)-fenfluramine were withdrawn from clin. use owing to increased risk of valvular heart disease.  One prevailing hypothesis (i.e., the 5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease.  Here, we critically evaluate the possible mechanisms responsible for fenfluramine-assocd. valve disease.  Findings from in vitro and in vivo expts. performed in our lab. are reviewed.  The data are integrated with existing literature to address the validity of the 5-HT hypothesis and suggest alternative explanations.  The overwhelming majority of evidence refutes the 5-HT hypothesis.  A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT2B receptors on heart valves by the metabolite norfenfluramine.  Future serotonergic medications should be designed to lack 5-HT2B agonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-LBvT-OQ77Vg90H21EOLACvtfcHk0ljdf0MjysFZNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslaiu74%253D&md5=1ecc83ce1f8e149d64e4d61dd9fd4418</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14740330902931524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740330902931524%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26atitle%3DSerotonergic%2520drugs%2520and%2520valvular%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2009%26volume%3D8%26spage%3D317%26epage%3D329%26doi%3D10.1517%2F14740330902931524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Elangbam, C. S.</span><span> </span><span class="NLM_article-title">Drug-induced valvulopathy: an update</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">48</span><span class="refDoi">Â DOI: 10.1177/0192623310378027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1177%2F0192623310378027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=20716786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCrtLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=837-48&author=C.+S.+Elangbam&title=Drug-induced+valvulopathy%3A+an+update&doi=10.1177%2F0192623310378027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced valvulopathy: an update</span></div><div class="casAuthors">Elangbam, Chandikumar S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">837-848</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Drug-induced valvulopathy is a serious liability for certain compd. classes in development and for some marketed drugs intended for human use.  Reports of valvulopathy led to the withdrawal of fenfluramines (anorexigens) and pergolide (antiparkinson drug) from the United States market in 1997 and 2007, resp.  The mechanism responsible for the pathogenesis of valvulopathy by these drugs is likely a result of an "off-target" effect via activation of 5-hydroxytryptamine (5-HT) 2B receptor (5-HT2BR) expressed on heart valve leaflets.  Microscopically, the affected valve leaflets showed plaques of proliferative myofibroblasts in an abundant extracellular matrix, composed primarily of glycosaminoglycans.  However, the valvular effects caused by fenfluramines and pergolide were not initially predicted from routine preclin. toxicity studies, and to date there are no specific validated animal models or preclin./toxicol. screens to accurately predict drug-induced valvulopathy.  This review covers the structure and function of heart valves and highlights major advances toward understanding the 5-HT2BR-mediated pathogenesis of the lesion and subsequently, development of appropriate animal models using novel techniques/expts., use of functional screens against 5-HT2BR, and more consistent sampling and pathol. evaluation of valves in preclin. studies that will aid in avoidance of future drug-induced valvulopathy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtdCK4EVKYXrVg90H21EOLACvtfcHk0liAFE9RrX0UmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCrtLvO&md5=b78c74a5c98673322df0d8393996df71</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1177%2F0192623310378027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310378027%26sid%3Dliteratum%253Aachs%26aulast%3DElangbam%26aufirst%3DC.%2BS.%26atitle%3DDrug-induced%2520valvulopathy%253A%2520an%2520update%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D837%26epage%3D48%26doi%3D10.1177%2F0192623310378027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hutcheson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merryman, W. D.</span><span> </span><span class="NLM_article-title">Serotonin receptors and heart valve diseaseâIt was meant 2B</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2011.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.pharmthera.2011.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=21440001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=146-157&author=J.+D.+Hutchesonauthor=V.+Setolaauthor=B.+L.+Rothauthor=W.+D.+Merryman&title=Serotonin+receptors+and+heart+valve+disease%E2%80%94It+was+meant+2B&doi=10.1016%2Fj.pharmthera.2011.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin receptors and heart valve disease-It was meant 2B</span></div><div class="casAuthors">Hutcheson, Joshua D.; Setola, Vincent; Roth, Bryan L.; Merryman, W. David</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-157</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Carcinoid heart disease was one of the first valvular pathologies studied in mol. detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue.  Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those obsd. in carcinoid patients.  The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s.  The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT2B receptor as the likely mol. target leading to heart valve tissue fibrosis.  Subsequent studies have identified numerous other activators of the 5-HT2B receptor, and consequently, the use of many of these mols. has been linked to heart valve disease.  Herein, we: review the mol. properties of the 5-HT2B receptor including factors that differentiate the 5-HT2B receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT2B receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT2B receptor activity, and speculate on potential therapeutic benefits of 5-HT2B receptor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4R8A9Ia-r3LVg90H21EOLACvtfcHk0liAFE9RrX0UmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO&md5=b97c1992208a501b1959c2f48f3ca9cd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%2BD.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMerryman%26aufirst%3DW.%2BD.%26atitle%3DSerotonin%2520receptors%2520and%2520heart%2520valve%2520disease%25E2%2580%2594It%2520was%2520meant%25202B%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D146%26epage%3D157%26doi%3D10.1016%2Fj.pharmthera.2011.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Andrejak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tribouilloy, C.</span><span> </span><span class="NLM_article-title">Drug-induced valvular heart disease: An update</span> <span class="citation_source-journal">Arch. Cardiovas. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1016/j.acvd.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.acvd.2013.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=23769407" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2013&pages=333-339&author=M.+Andrejakauthor=C.+Tribouilloy&title=Drug-induced+valvular+heart+disease%3A+An+update&doi=10.1016%2Fj.acvd.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.acvd.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acvd.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAndrejak%26aufirst%3DM.%26aulast%3DTribouilloy%26aufirst%3DC.%26atitle%3DDrug-induced%2520valvular%2520heart%2520disease%253A%2520An%2520update%26jtitle%3DArch.%2520Cardiovas.%2520Dis.%26date%3D2013%26volume%3D106%26spage%3D333%26epage%3D339%26doi%3D10.1016%2Fj.acvd.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revankar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">710</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><span class="refDoi">Â DOI: 10.1124/mol.109.058057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fmol.109.058057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19570945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1eitrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=710-22&author=X.-P.+Huangauthor=V.+Setolaauthor=P.+N.+Yadavauthor=J.+A.+Allenauthor=S.+C.+Roganauthor=B.+J.+Hansonauthor=C.+Revankarauthor=M.+Robersauthor=C.+Doucetteauthor=B.+L.+Roth&title=Parallel+functional+activity+profiling+reveals+valvulopathogens+are+potent+5-hydroxytryptamine%282B%29+receptor+agonists%3A+implications+for+drug+safety+assessment&doi=10.1124%2Fmol.109.058057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment</span></div><div class="casAuthors">Huang, Xi-Ping; Setola, Vincent; Yadav, Prem N.; Allen, John A.; Rogan, Sarah C.; Hanson, Bonnie J.; Revankar, Chetana; Robers, Matt; Doucette, Chris; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">710-722</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market.  Pharmacol. studies of VHD-assocd. medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists.  We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD.  To identify current or future drugs that might induce VHD, we screened approx. 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening.  Of these 2200 compds., 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens.  Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications.  Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity).  In these assays, the known valvulopathogens were efficacious at concns. as low as 30 nM, whereas the other compds. were less so.  Hierarchical clustering anal. of the pEC50 data revealed that ropinirole (which is not assocd. with valvulopathy) was clearly segregated from known valvulopathogens.  Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compds. likely to induce valvular heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6tCEte6PXtLVg90H21EOLACvtfcHk0liAFE9RrX0UmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1eitrvF&md5=48f3f3a220c542bc42b7378cc79d73d0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.058057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.058057%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRogan%26aufirst%3DS.%2BC.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DRevankar%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%26aulast%3DDoucette%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DParallel%2520functional%2520activity%2520profiling%2520reveals%2520valvulopathogens%2520are%2520potent%25205-hydroxytryptamine%25282B%2529%2520receptor%2520agonists%253A%2520implications%2520for%2520drug%2520safety%2520assessment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D710%26epage%3D22%26doi%3D10.1124%2Fmol.109.058057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gabelt, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, P. L.</span><span> </span><span class="NLM_article-title">Aqueous humor dynamics in monkeys after topical R-DOI</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4691</span><span class="NLM_x">â</span> <span class="NLM_lpage">6</span><span class="refDoi">Â DOI: 10.1167/iovs.05-0647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.05-0647" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4691-6&author=B.+T.+Gabeltauthor=M.+Okkaauthor=T.+R.+Deanauthor=P.+L.+Kaufman&title=Aqueous+humor+dynamics+in+monkeys+after+topical+R-DOI&doi=10.1167%2Fiovs.05-0647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0647%26sid%3Dliteratum%253Aachs%26aulast%3DGabelt%26aufirst%3DB.%2BT.%26aulast%3DOkka%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26atitle%3DAqueous%2520humor%2520dynamics%2520in%2520monkeys%2520after%2520topical%2520R-DOI%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4691%26epage%3D6%26doi%3D10.1167%2Fiovs.05-0647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosecrans, J. A.</span><span> </span><span class="NLM_article-title">Discriminative stimulus properties of the hallucinogenic agent DOM</span> <span class="citation_source-journal">Commun. Psychopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=7297054" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1980&pages=501-506&author=R.+Youngauthor=R.+A.+Glennonauthor=J.+A.+Rosecrans&title=Discriminative+stimulus+properties+of+the+hallucinogenic+agent+DOM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DRosecrans%26aufirst%3DJ.%2BA.%26atitle%3DDiscriminative%2520stimulus%2520properties%2520of%2520the%2520hallucinogenic%2520agent%2520DOM%26jtitle%3DCommun.%2520Psychopharm.%26date%3D1980%26volume%3D4%26spage%3D501%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benington, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, R. D.</span><span> </span><span class="NLM_article-title">Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1168</span><span class="refDoi">Â DOI: 10.1021/jm00352a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00352a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=1163-1168&author=R.+A.+Glennonauthor=R.+Youngauthor=F.+Beningtonauthor=R.+D.+Morin&title=Behavioral+and+serotonin+receptor+properties+of+4-substituted+derivatives+of+the+hallucinogen+1-%282%2C5-dimethoxyphenyl%29-2-aminopropane&doi=10.1021%2Fjm00352a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00352a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00352a013%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DBenington%26aufirst%3DF.%26aulast%3DMorin%26aufirst%3DR.%2BD.%26atitle%3DBehavioral%2520and%2520serotonin%2520receptor%2520properties%2520of%25204-substituted%2520derivatives%2520of%2520the%2520hallucinogen%25201-%25282%252C5-dimethoxyphenyl%2529-2-aminopropane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D1163%26epage%3D1168%26doi%3D10.1021%2Fjm00352a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Otwinowski, Z.; Minor, W.</span><span> </span><span class="NLM_article-title">DENZO-SMN</span>, in  <span class="citation_source-book">Methods in Enzymology</span>; <span class="NLM_contrib-group">Carter, C. W.,  Jr.; Sweets, R. M.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: New York,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>Macromolecular Crystallography, part A, Vol.  <span class="NLM_volume">276</span>, pp  <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&author=R.+M.+Sweets&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DDENZO-SMN%26btitle%3DMethods%2520in%2520Enzymology%26aulast%3DCarter%26aufirst%3DC.%2BW.%26pub%3DAcademic%2520Press%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Altomare, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascarano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacovazzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagliardi, A.</span><span> </span><span class="NLM_article-title">SIR92. A program for crystal structure solution</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">â</span> <span class="NLM_lpage">350</span><span class="refDoi">Â DOI: 10.1107/S0021889892010331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1107%2FS0021889892010331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK3sXlsV2rs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=343-350&author=A.+Altomareauthor=G.+Cascaranoauthor=C.+Giacovazzoauthor=A.+Guagliardi&title=SIR92.+A+program+for+crystal+structure+solution&doi=10.1107%2FS0021889892010331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Completion and refinement of crystal structures with SIR92</span></div><div class="casAuthors">Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-50</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An automatic procedure for recovering a complete crystal structure after a direct phasing process is described.  The procedure consists mainly of a Fourier recycling method that can be implemented in any direct-methods package.  The residual R value attained at the end of the process provides an est. of the degree of success of the structure detn.  The procedure can also be applied using a small mol. fragment as prior information.  The procedure was implemented into SIR92, the successor to SIR88.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2koCpbMjTTbVg90H21EOLACvtfcHk0ljcA5vtaxocxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsV2rs7Y%253D&md5=09257ca3c0f0932f25e52b0f13e40ff6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889892010331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889892010331%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DA.%26aulast%3DCascarano%26aufirst%3DG.%26aulast%3DGiacovazzo%26aufirst%3DC.%26aulast%3DGuagliardi%26aufirst%3DA.%26atitle%3DSIR92.%2520A%2520program%2520for%2520crystal%2520structure%2520solution%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D343%26epage%3D350%26doi%3D10.1107%2FS0021889892010331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span>SHELXL97. Program for the Refinement of Crystal Structures; <span class="NLM_publisher-name">University of Gottingen</span>: <span class="NLM_publisher-loc">Gottingen, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+M.+Sheldrick&title=SHELXL97.+Program+for+the+Refinement+of+Crystal+Structures"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26jtitle%3DSHELXL97.%2520Program%2520for%2520the%2520Refinement%2520of%2520Crystal%2520Structures%26pub%3DUniversity%2520of%2520Gottingen%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Wilson, A. J. C.</span>, Ed.  <span class="citation_source-book">International Tables for X-ray Crystallography</span>; <span class="NLM_publisher-name">Kluwer Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">C</span>, Tables 4.2.6.8 and 6.1.1.4.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=A.+J.+C.+Wilson&title=International+Tables+for+X-ray+Crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BJ.%2BC.%26btitle%3DInternational%2520Tables%2520for%2520X-ray%2520Crystallography%26pub%3DKluwer%2520Academic%2520Press%26date%3D1992%26volume%3DC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span>SHELXTL/PC, version 5.03; <span class="NLM_publisher-name">Siemens Analytical X-ray Instruments, Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+M.+Sheldrick&title=SHELXTL%2FPC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26jtitle%3DSHELXTL%252FPC%26pub%3DSiemens%2520Analytical%2520X-ray%2520Instruments%252C%2520Inc%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Cohen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fludzinski, L. A.</span><span> </span><span class="NLM_article-title">Contractile serotonergic receptor in rat stomach fundus</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=3668856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaL2sXmt12qsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1987&pages=264-269&author=M.+L.+Cohenauthor=L.+A.+Fludzinski&title=Contractile+serotonergic+receptor+in+rat+stomach+fundus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Contractile serotoninergic receptor in rat stomach fundus</span></div><div class="casAuthors">Cohen, Marlene L.; Fludzinski, Laura A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">264-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The possibility was examd. that 5HT-induced contractions in the rat stomach fundus were mediated by interaction with receptors identical with either 5HT1A, 5HT1B, or 5HT1C binding sites or 5HT3 receptors.  Contractile concn.-response curves for several 5HT agonists [5-carboxamidotryptamine, TR3369, MK212, quipazine, RU 24969, 8-hydroxy-2-(di-propylamino)tetralin, TVXQ7821, and BEA 1654Cl] were obtained in the rat stomach fundus.  However, neither the potency nor max. response of these agonists in contracting the rat stomach fundus correlated with the affinity of agonists at 5HT1A, 5Ht1B, or 5HT1C binding sites.  These agonists were interacting with 5HT receptors in the fundus based on the ability of 1-(1-naphthyl)piperazine (10-7M) to antagonize the contractile response of the relatively potent agonists.  TVXQ7821 and BEA1654Cl did not produce a marked contractile response in the fundus and also did not antagonize the contractile response to 5HT, suggesting that these agents have little, if any, affinity for the serotoninergic receptor-mediating contraction in the fundus.  The putative 5HT1A-selective receptor antagonists, WB410-1 and spiroxatrine, did not block 5HT-induced contractions in the rat stomach fundus in concns. consistent with their affinity at 5HT1A binding sites.  The nonselective 5HT1A and 5HT1B receptor antagonist, cyanopindolol, also did not block 5HT-induced contractions in the rat stomach fundus.  Mianserin, a selective ligand at 5HT1C binding sites, and the 5HT3 selective receptor antagonist, ICS 205-930, did not competitively or potently antagonize 5HT-induced contractions in the rat stomach fundus.  Apparently, the contractile response to 5HT in the rat stomach fundus is not mediated by interaction with receptors identical with the 5HT1A, 5HT1B, or 5HT1C binding sites in brain membranes or with 5HT3 receptors.  These data support the idea that the 5HT receptor in the rat stomach fundus is unique and distinct from known 5HT binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofOVSGK6DYk7Vg90H21EOLACvtfcHk0liKvHjedH5ArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmt12qsL0%253D&md5=5c391cfd561bb2d850db59f7fba25353</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BL.%26aulast%3DFludzinski%26aufirst%3DL.%2BA.%26atitle%3DContractile%2520serotonergic%2520receptor%2520in%2520rat%2520stomach%2520fundus%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1987%26volume%3D243%26spage%3D264%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">Adenylyl cyclase activity mediated by adrenoceptors in immortalized human trabecular meshwork and nonpigmented ciliary epithelial cells</span> <span class="citation_source-journal">J. Ocul. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span><span class="refDoi">Â DOI: 10.1089/108076802760116142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1089%2F108076802760116142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12099543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVyjtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=221-230&author=J.+Y.+Criderauthor=N.+A.+Sharif&title=Adenylyl+cyclase+activity+mediated+by+adrenoceptors+in+immortalized+human+trabecular+meshwork+and+nonpigmented+ciliary+epithelial+cells&doi=10.1089%2F108076802760116142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Adenylyl cyclase activity mediated by Î²-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells</span></div><div class="casAuthors">Crider, Julie Y.; Sharif, Najam A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Non-pigmented ciliary epithelial (NPE) and trabecular meshwork (TM) cells are important in maintaining normal aq. humor dynamics through the inflow and outflow routes, resp.  The current studies were undertaken to evaluate the ability of several Î²-adrenergic receptor agonists to stimulate various antagonists to inhibit cAMP prodn. in cultured immortalized human TM and NPE cells using an automated enzyme immunoassay.  Isoproterenol was the most potent agonist in both the NPE and TM cells.  The rank order of potency of agonists in NPE and TM cells, resp., was: isoproterenol [EC50 = 37 and 66 nM] > epinephrine [EC50 = 112 and 526 nM] > albuterol [EC50 = 426 and 785 nM] > norepinephrine [EC50 = 3 and > 10 Î¼M] > phenylephrine [EC50 > 10 Î¼M for both] = dopamine [EC50 > 10 Î¼M for both].  The isoproterenol-induced cAMP prodn. was inhibited by various antagonists with the following rank order of potency in NPE and TM cells, resp.: propranolol [Ki = 0.2 and 0.3 nM] = ICI-118551 [Ki = 0.5 and 0.4 nM] > levobunolol [Ki = 1.1 and 2.1 nM] > levobetaxolol [Ki = 13 and 14 nM] = racemic betaxolol [Ki = 43 and 19 nM] > dextrobetaxolol [Ki = 2705 and 1980 nM] > atenolol [Ki > 4000 nM for both].  These detailed pharmacol. studies using a variety of agonists and antagonists further supported the presence of Î²2-adrenergic receptors in immortalized human NPE and TM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu9hlkQhMXdbVg90H21EOLACvtfcHk0liKvHjedH5ArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVyjtrs%253D&md5=04e82e05e2a17ba0e92ea53c0e4a3818</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2F108076802760116142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076802760116142%26sid%3Dliteratum%253Aachs%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DAdenylyl%2520cyclase%2520activity%2520mediated%2520by%2520adrenoceptors%2520in%2520immortalized%2520human%2520trabecular%2520meshwork%2520and%2520nonpigmented%2520ciliary%2520epithelial%2520cells%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D18%26spage%3D221%26epage%3D230%26doi%3D10.1089%2F108076802760116142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kenny, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpot, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span> </span><span class="NLM_article-title">Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">â</span> <span class="NLM_lpage">986</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.1995.tb15907.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1111%2Fj.1476-5381.1995.tb15907.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=7582530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Glu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1995&pages=981-986&author=B.+A.+Kennyauthor=D.+H.+Chalmersauthor=P.+C.+Philpotauthor=A.+M.+Naylor&title=Characterization+of+an+alpha+1D-adrenoceptor+mediating+the+contractile+response+of+rat+aorta&doi=10.1111%2Fj.1476-5381.1995.tb15907.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an Î±1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline</span></div><div class="casAuthors">Kenny, B. A.; Chalmers, D. H.; Philpott, P. C.; Naylor, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">981-6</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">The affinities of a no. of Î±1-adrenoceptor antagonists were detd. by displacement of [3H]-prazosin binding from cloned human Î±1A-adrenoceptors (previously designated cloned Î±1c subtype), Î±1B, Î±1D and rat Î±1D-adrenoceptors, stably expressed in rat-1 fibroblasts.  Functional affinity ests. for these compds. were also detd. from noradrenaline-mediated contractions of rat aorta.  BMY 7378 displayed high affinity for cloned human Î±1D-adrenoceptors (pKi = 8.2) and was selective over Î±1A (pK1 = 6.2) and Î±1B subtypes (6.7).  WB 4101, benoxathian and phentolamine displayed high affinity for Î±1A and Î±1D adrenoceptors compared to the Î±1B subtype.  Spiperone displayed high affinity and selectivity for Î±1B adrenoceptors (pK1 8.8).  5-Methyl-urapidil was selective for cloned Î±1A adrenoceptors.  Comparative binding affinities (pKi) for compds. at cloned human and rat1D adrenoceptors were almost identical (r = 0.99, slope = 1.08).  Prazosin, doxazosin and 5-methyl-urapidil were potent, competitive antagonists of noradrenaline-mediated contractions of rat aorta (pA2 values of 9.8, 8.8 and 7.8 resp.).  The selective Î±1D antagonist BMY 7378 was also a potent antagonist on rat aorta (PKB = 8.3) but the interaction of this compd. was not consistent with competitive antagonism at a single population of receptors.  Functional affinities for compds. detd. against noradrenaline-mediated contractions of rat aorta correlated well with binding affinities at cloned Î±1D-adrenoceptors (r = 0.96), but not with Î±1A (r = 0.61) or Î±1B (r = 0.46) subtypes.  Noradrenaline-mediated contractions of rat aorta were sensitive to the alkylating effects of chloroethylclonidine (CEC).  CEC (10 Î¼M) caused a small rightward shift in the noradrenaline concn.-response curve.  CEC at 100 Î¼M caused a further shift and suppression of the max. response to noradrenaline.  The results of this study suggest that noradrenaline predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an Î±1D-adrenoceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ783cY-ZQdrVg90H21EOLACvtfcHk0liKvHjedH5ArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Glu78%253D&md5=655e4e2b98a7fd7c586b434fd4383af5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb15907.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb15907.x%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DB.%2BA.%26aulast%3DChalmers%26aufirst%3DD.%2BH.%26aulast%3DPhilpot%26aufirst%3DP.%2BC.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26atitle%3DCharacterization%2520of%2520an%2520alpha%25201D-adrenoceptor%2520mediating%2520the%2520contractile%2520response%2520of%2520rat%2520aorta%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D115%26spage%3D981%26epage%3D986%26doi%3D10.1111%2Fj.1476-5381.1995.tb15907.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Shulgin, A. T.</span><span> </span><span class="NLM_article-title">Characterization of Three New Psychotomimetics</span>. In  <span class="citation_source-book">The Psychopharmacology of Hallucinogens</span>; <span class="NLM_contrib-group">Stillman, R. C.; Willette, R. E.</span>, Eds.; <span class="NLM_publisher-name">Pergamon Press</span>: <span class="NLM_publisher-loc">Elmsford, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">1978</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&pages=74-83&author=A.+T.+Shulginauthor=R.+C.+Stillman&author=R.+E.+Willette&title=The+Psychopharmacology+of+Hallucinogens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShulgin%26aufirst%3DA.%2BT.%26atitle%3DCharacterization%2520of%2520Three%2520New%2520Psychotomimetics%26btitle%3DThe%2520Psychopharmacology%2520of%2520Hallucinogens%26aulast%3DStillman%26aufirst%3DR.%2BC.%26pub%3DPergamon%2520Press%26date%3D1978%26spage%3D74%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Shulgin, A. T.; Shulgin, A.</span> <span class="citation_source-book">PIHKAL: A Chemical Love Story</span>; <span class="NLM_publisher-name">Transform Press</span>: <span class="NLM_publisher-loc">Berkeley, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">633</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=633-637&author=A.+T.+Shulgin&author=A.+Shulgin&title=PIHKAL%3A+A+Chemical+Love+Story"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShulgin%26aufirst%3DA.%2BT.%26btitle%3DPIHKAL%253A%2520A%2520Chemical%2520Love%2520Story%26pub%3DTransform%2520Press%26date%3D1991%26spage%3D633%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kuei-Ju Cheng, Chien-Ming Hsieh, Kunal Nepali, <span class="NLM_string-name hlFld-ContribAuthor">Jing-Ping Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10533-10593. <a href="https://doi.org/10.1021/acs.jmedchem.9b01033" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01033%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOcular%252BDisease%252BTherapeutics%25253A%252BDesign%252Band%252BDelivery%252Bof%252BDrugs%252Bfor%252BDiseases%252Bof%252Bthe%252BEye%26aulast%3DCheng%26aufirst%3DKuei-Ju%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28062019%26date%3D02062020%26volume%3D63%26issue%3D19%26spage%3D10533%26epage%3D10593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Glennon</span>  . </span><span class="cited-content_cbyCitation_article-title">The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The âPhenylalkylaminomeâ with a Focus on Selected Drugs of Abuse. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2605-2628. <a href="https://doi.org/10.1021/acs.jmedchem.7b00085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00085%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252B2014%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship%25253A%252BThe%252B%2525E2%252580%25259CPhenylalkylaminome%2525E2%252580%25259D%252Bwith%252Ba%252BFocus%252Bon%252BSelected%252BDrugs%252Bof%252BAbuse%26aulast%3DGlennon%26aufirst%3DRichard%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17012017%26date%3D15032017%26date%3D13042017%26date%3D28022017%26volume%3D60%26issue%3D7%26spage%3D2605%26epage%3D2628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khalid  Boujdi</span>, <span class="hlFld-ContribAuthor ">Nabil  El Brahmi</span>, <span class="hlFld-ContribAuthor ">JÃ©rÃ´me  Graton</span>, <span class="hlFld-ContribAuthor ">Didier  Dubreuil</span>, <span class="hlFld-ContribAuthor ">Sylvain  Collet</span>, <span class="hlFld-ContribAuthor ">Monique  MathÃ©-Allainmat</span>, <span class="hlFld-ContribAuthor ">Mohamed  Akssira</span>, <span class="hlFld-ContribAuthor ">Jacques  Lebreton</span>, <span class="hlFld-ContribAuthor ">SaÃ¯d  El Kazzouli</span>. </span><span class="cited-content_cbyCitation_article-title">A regioselective C7 bromination and C7 palladium-catalyzed SuzukiâMiyaura cross-coupling arylation of 4-substituted NH-free indazoles. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (12)
                                     , 7107-7114. <a href="https://doi.org/10.1039/D0RA08598G" title="DOI URL">https://doi.org/10.1039/D0RA08598G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA08598G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA08598G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bregioselective%252BC7%252Bbromination%252Band%252BC7%252Bpalladium-catalyzed%252BSuzuki%2525E2%252580%252593Miyaura%252Bcross-coupling%252Barylation%252Bof%252B4-substituted%252BNH-free%252Bindazoles%26aulast%3DBoujdi%26aufirst%3DKhalid%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D12%26spage%3D7107%26epage%3D7114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas M.  Barnes</span>, <span class="hlFld-ContribAuthor ">Gerard P.  Ahern</span>, <span class="hlFld-ContribAuthor ">Carine  Becamel</span>, <span class="hlFld-ContribAuthor ">JoÃ«l  Bockaert</span>, <span class="hlFld-ContribAuthor ">Michael  Camilleri</span>, <span class="hlFld-ContribAuthor ">Severine  Chaumont-Dubel</span>, <span class="hlFld-ContribAuthor ">Sylvie  Claeysen</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Cunningham</span>, <span class="hlFld-ContribAuthor ">Kevin C.  Fone</span>, <span class="hlFld-ContribAuthor ">Michael  Gershon</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Di Giovanni</span>, <span class="hlFld-ContribAuthor ">Nathalie M.  Goodfellow</span>, <span class="hlFld-ContribAuthor ">Adam L.  Halberstadt</span>, <span class="hlFld-ContribAuthor ">Rachel M.  Hartley</span>, <span class="hlFld-ContribAuthor ">GhÃ©rici  Hassaine</span>, <span class="hlFld-ContribAuthor ">Katharine  Herrick-Davis</span>, <span class="hlFld-ContribAuthor ">Ruud  Hovius</span>, <span class="hlFld-ContribAuthor ">Enza  Lacivita</span>, <span class="hlFld-ContribAuthor ">Evelyn K.  Lambe</span>, <span class="hlFld-ContribAuthor ">Marcello  Leopoldo</span>, <span class="hlFld-ContribAuthor ">Finn Olav  Levy</span>, <span class="hlFld-ContribAuthor ">Sarah C. R.  Lummis</span>, <span class="hlFld-ContribAuthor ">Philippe  Marin</span>, <span class="hlFld-ContribAuthor ">Luc  Maroteaux</span>, <span class="hlFld-ContribAuthor ">Andrew C.  McCreary</span>, <span class="hlFld-ContribAuthor ">David L.  Nelson</span>, <span class="hlFld-ContribAuthor ">John F.  Neumaier</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>, <span class="hlFld-ContribAuthor ">Hugues  Nury</span>, <span class="hlFld-ContribAuthor ">Alexander  Roberts</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, <span class="hlFld-ContribAuthor ">Anne  Roumier</span>, <span class="hlFld-ContribAuthor ">Gareth J.  Sanger</span>, <span class="hlFld-ContribAuthor ">Milt  Teitler</span>, <span class="hlFld-ContribAuthor ">Trevor  Sharp</span>, <span class="hlFld-ContribAuthor ">Carlos M.  VillalÃ³n</span>, <span class="hlFld-ContribAuthor ">Horst  Vogel</span>, <span class="hlFld-ContribAuthor ">Stephanie W.  Watts</span>, <span class="hlFld-ContribAuthor ">Daniel  Hoyer</span>, . </span><span class="cited-content_cbyCitation_article-title">International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (1)
                                     , 310-520. <a href="https://doi.org/10.1124/pr.118.015552" title="DOI URL">https://doi.org/10.1124/pr.118.015552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.118.015552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.118.015552%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DInternational%252BUnion%252Bof%252BBasic%252Band%252BClinical%252BPharmacology.%252BCX.%252BClassification%252Bof%252BReceptors%252Bfor%252B5-hydroxytryptamine%25253B%252BPharmacology%252Band%252BFunction%26aulast%3DBarnes%26aufirst%3DNicholas%2BM.%26date%3D2021%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D310%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajasekhar  Chekkara</span>, <span class="hlFld-ContribAuthor ">Venkata Reddy  Gorla</span>, <span class="hlFld-ContribAuthor ">E.  Susithra</span>, <span class="hlFld-ContribAuthor ">Reddymasu  Sireesha</span>, <span class="hlFld-ContribAuthor ">Sobha Rani  Tenkayala</span>, <span class="hlFld-ContribAuthor ">Mandava Venkata Basaveswara  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anticancer evaluation of 2-Amino pyrimidine linked 7-Azaindzole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemical Data Collections</span><span> <strong>2020,</strong> <em>29 </em>, 100513. <a href="https://doi.org/10.1016/j.cdc.2020.100513" title="DOI URL">https://doi.org/10.1016/j.cdc.2020.100513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cdc.2020.100513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cdc.2020.100513%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Data%2520Collections%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banticancer%252Bevaluation%252Bof%252B2-Amino%252Bpyrimidine%252Blinked%252B7-Azaindzole%252Bderivatives%26aulast%3DChekkara%26aufirst%3DRajasekhar%26date%3D2020%26volume%3D29%26spage%3D100513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sumit  Ghosh</span>, <span class="hlFld-ContribAuthor ">Susmita  Mondal</span>, <span class="hlFld-ContribAuthor ">Alakananda  Hajra</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Catalytic Functionalization of Indazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (18)
                                     , 3768-3794. <a href="https://doi.org/10.1002/adsc.202000423" title="DOI URL">https://doi.org/10.1002/adsc.202000423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000423%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DDirect%252BCatalytic%252BFunctionalization%252Bof%252BIndazole%252BDerivatives%26aulast%3DGhosh%26aufirst%3DSumit%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D18%26spage%3D3768%26epage%3D3794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Adams</span>, <span class="hlFld-ContribAuthor ">Julien P. N.  Papillon</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments for the Treatment of Glaucoma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 189-256. <a href="https://doi.org/10.1007/7355_2019_92" title="DOI URL">https://doi.org/10.1007/7355_2019_92</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2019_92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2019_92%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BDevelopments%252Bfor%252Bthe%252BTreatment%252Bof%252BGlaucoma%26aulast%3DAdams%26aufirst%3DChristopher%2BM.%26date%3D2020%26date%3D2020%26spage%3D189%26epage%3D256%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDrug%252BDelivery%252BChallenges%252Band%252BNovel%252BTherapeutic%252BApproaches%252Bfor%252BRetinal%252BDiseases%26aulast%3DCioffi%26aufirst%3DChristopher%2BL.%26date%3D2020%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JeongâHo  Joo</span>, <span class="hlFld-ContribAuthor ">Sun Hwa  Jung</span>, <span class="hlFld-ContribAuthor ">Kook Hyun  Yu</span>, <span class="hlFld-ContribAuthor ">Hyae Gyeong  Cheon</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Decursinol Derivatives as FoxOâ1 Inhibitors in HepG2 Cells. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2019,</strong> <em>40 </em>
                                    (8)
                                     , 767-774. <a href="https://doi.org/10.1002/bkcs.11815" title="DOI URL">https://doi.org/10.1002/bkcs.11815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.11815%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BDecursinol%252BDerivatives%252Bas%252BFoxO%2525E2%252580%2525901%252BInhibitors%252Bin%252BHepG2%252BCells%26aulast%3DJoo%26aufirst%3DJeong%25E2%2580%2590Ho%26date%3D2019%26date%3D2019%26volume%3D40%26issue%3D8%26spage%3D767%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Najam A.  Sharif</span>. </span><span class="cited-content_cbyCitation_article-title">i
              Drugs and
              i
              Devices Discovery Research: Preclinical Assays, Techniques, and Animal Model Studies for Ocular Hypotensives and Neuroprotectants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ocular Pharmacology and Therapeutics</span><span> <strong>2018,</strong> <em>34 </em>
                                    (1-2)
                                     , 7-39. <a href="https://doi.org/10.1089/jop.2017.0125" title="DOI URL">https://doi.org/10.1089/jop.2017.0125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/jop.2017.0125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fjop.2017.0125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ocular%2520Pharmacology%2520and%2520Therapeutics%26atitle%3Di%252BDrugs%252Band%252Bi%252BDevices%252BDiscovery%252BResearch%25253A%252BPreclinical%252BAssays%25252C%252BTechniques%25252C%252Band%252BAnimal%252BModel%252BStudies%252Bfor%252BOcular%252BHypotensives%252Band%252BNeuroprotectants%26aulast%3DSharif%26aufirst%3DNajam%2BA.%26date%3D2018%26volume%3D34%26issue%3D1-2%26spage%3D7%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">SaÃ¯d  El Kazzouli</span>, <span class="hlFld-ContribAuthor ">GÃ©rald  Guillaumet</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalization of indazoles by means of transition metal-catalyzed cross-coupling reactions. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (43)
                                     , 6711-6727. <a href="https://doi.org/10.1016/j.tet.2016.08.031" title="DOI URL">https://doi.org/10.1016/j.tet.2016.08.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.08.031%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DFunctionalization%252Bof%252Bindazoles%252Bby%252Bmeans%252Bof%252Btransition%252Bmetal-catalyzed%252Bcross-coupling%252Breactions%26aulast%3DEl%2BKazzouli%26aufirst%3DSa%25C3%25AFd%26date%3D2016%26volume%3D72%26issue%3D43%26spage%3D6711%26epage%3D6727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: *Ref <a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">10</a>. (a) <i>t</i>-Butyldimethylchlorosilane, imidazole, THF; (b) H<sub>2</sub>, Pd/C, MeOH; (c) NBS, THF; (d) epibromohydrin, K<sub>2</sub>CO<sub>3</sub>, acetone; (e) (1) Mg, 1,2-dibromoethane, THF; (2) ethyl vinyl ether, TsOH, DCM; (f) (1) <i>n</i>-butyllithium, THF, â78 Â°C; (2) TBAF, THF; (g) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (3) HCl; (h) chiral HPLC separation; (i) H<sub>2</sub>, Pd/C, MeOH.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) propargyl bromide, K<sub>2</sub>CO<sub>3</sub>, acetone; (b) mesitylene, 200 Â°C; (c) (1) 9-BBN, THF; (2) H<sub>2</sub>O<sub>2</sub>, MeOH; (3) column chromatography; (d) (1) pyridine-TsOH, ethyl vinyl ether; (2) TBAF, THF; (e) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (3) TsOH, MeOH; (4) TEA.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) Ms<sub>2</sub>O, TEA, THF; (2) NaN<sub>3</sub>, DMF; (b) H<sub>2</sub>, Pd/C, MeOH; (c) NaH, <i>t</i>-butylbromoacetate, DMF; (d) TBAF, THF; (e) LAH, THF; (f) (1) LAH, THF; (2) CbzCl, NaHCO<sub>3</sub>.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/medium/jm-2015-00857g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00857/20151119/images/large/jm-2015-00857g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00857&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, DMF, isopropyl 2-bromoacetate; (b) Methanolic 3 N HCl; (c) amine, solvent or neat; (d) 10% PdâC, hydrogen, methanol.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Congdon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâColmain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaver, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, P.</span><span> </span><span class="NLM_article-title">Causes and prevalence of visual impairment among adults in the United States</span> <span class="citation_source-journal">Arch. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span><span class="refDoi">Â DOI: 10.1001/archopht.122.4.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1001%2Farchopht.122.4.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=15078664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2c7pvVyhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2004&pages=477-485&author=N.+Congdonauthor=B.+O%E2%80%99Colmainauthor=C.+C.+Klaverauthor=R.+Kleinauthor=B.+Munozauthor=D.+S.+Friedmanauthor=J.+Kempenauthor=H.+R.+Taylorauthor=P.+Mitchell&title=Causes+and+prevalence+of+visual+impairment+among+adults+in+the+United+States&doi=10.1001%2Farchopht.122.4.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and prevalence of visual impairment among adults in the United States</span></div><div class="casAuthors">Congdon Nathan; O'Colmain Benita; Klaver Caroline C W; Klein Ronald; Munoz Beatriz; Friedman David S; Kempen John; Taylor Hugh R; Mitchell Paul</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-85</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVES:  To estimate the cause-specific prevalence and distribution of blindness and low vision in the United States by age, race/ethnicity, and gender, and to estimate the change in these prevalence figures over the next 20 years.  METHODS:  Summary prevalence estimates of blindness (both according to the US definition of < or =6/60 [< or =20/200] best-corrected visual acuity in the better-seeing eye and the World Health Organization standard of < 6/120 [< 20/400]) and low vision (< 6/12 [< 20/40] best-corrected vision in the better-seeing eye) were prepared separately for black, Hispanic, and white persons in 5-year age intervals starting at 40 years.  The estimated prevalences were based on recent population-based studies in the United States, Australia, and Europe.  These estimates were applied to 2000 US Census data, and to projected US population figures for 2020, to estimate the number of Americans with visual impairment.  Cause-specific prevalences of blindness and low vision were also estimated for the different racial/ethnic groups.  RESULTS:  Based on demographics from the 2000 US Census, an estimated 937 000 (0.78%) Americans older than 40 years were blind (US definition).  An additional 2.4 million Americans (1.98%) had low vision.  The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness.  Cataract was the leading cause of low vision, responsible for approximately 50% of bilateral vision worse than 6/12 (20/40) among white, black, and Hispanic persons.  The number of blind persons in the US is projected to increase by 70% to 1.6 million by 2020, with a similar rise projected for low vision.  CONCLUSIONS:  Blindness or low vision affects approximately 1 in 28 Americans older than 40 years.  The specific causes of visual impairment, and especially blindness, vary greatly by race/ethnicity.  The prevalence of visual disabilities will increase markedly during the next 20 years, owing largely to the aging of the US population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhXjB6io5E4SCEBeYuoi7AfW6udTcc2eZzpkhgMuMURLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7pvVyhuw%253D%253D&md5=b6cf1e965ebb1d210f07439d0e4da2da</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1001%2Farchopht.122.4.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.122.4.477%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Colmain%26aufirst%3DB.%26aulast%3DKlaver%26aufirst%3DC.%2BC.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DD.%2BS.%26aulast%3DKempen%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DH.%2BR.%26aulast%3DMitchell%26aufirst%3DP.%26atitle%3DCauses%2520and%2520prevalence%2520of%2520visual%2520impairment%2520among%2520adults%2520in%2520the%2520United%2520States%26jtitle%3DArch.%2520Ophthalmol.%26date%3D2004%26volume%3D122%26spage%3D477%26epage%3D485%26doi%3D10.1001%2Farchopht.122.4.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Weinreb, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F. A.</span><span> </span><span class="NLM_article-title">The pathophysiology and treatment of glaucoma: a review</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">1901</span><span class="NLM_x">â</span> <span class="NLM_lpage">11</span><span class="refDoi">Â DOI: 10.1001/jama.2014.3192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1001%2Fjama.2014.3192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGkt7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2014&pages=1901-11&author=R.+N.+Weinrebauthor=T.+Aungauthor=F.+A.+Medeiros&title=The+pathophysiology+and+treatment+of+glaucoma%3A+a+review&doi=10.1001%2Fjama.2014.3192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The pathophysiology and treatment of glaucoma: a review</span></div><div class="casAuthors">Weinreb, Robert N.; Aung, Tin; Medeiros, Felipe A.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1901-1911, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">A review.  Importance: Glaucoma is a worldwide leading cause of irreversible vision loss.  Because it may be asymptomatic until a relatively late stage, diagnosis is frequently delayed.  A general understanding of the disease pathophysiol., diagnosis, and treatment may assist primary care physicians in referring high-risk patients for comprehensive ophthalmol. examn. and in more actively participating in the care of patients affected by this condition.  Objective: To describe current evidence regarding the pathophysiol. and treatment of open-angle glaucoma and angle-closure glaucoma.  Evidence Review: A literature search was conducted using MEDLINE, the Cochrane Library, and manuscript refs. for studies published in English between Jan. 2000 and Sept. 2013 on the topics open-angle glaucoma and angle-closure glaucoma.  From the 4334 abstrs. screened, 210 articles were selected that contained information on pathophysiol. and treatment with relevance to primary care physicians.  Findings: The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head.  Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role.  Redn. of intraocular pressure is the only proven method to treat the disease.  Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression.  Conclusions and Relevance: Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with pos. family history or with suspicious optic nerve head findings for complete ophthalmol. examn.  They can improve treatment outcomes by reinforcing the importance of medication adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgeries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6gdyXxGMVDrVg90H21EOLACvtfcHk0lhgEyupBROUaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGkt7zE&md5=114e7c3bacec0c76aa835f7a3a94f287</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.3192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.3192%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DAung%26aufirst%3DT.%26aulast%3DMedeiros%26aufirst%3DF.%2BA.%26atitle%3DThe%2520pathophysiology%2520and%2520treatment%2520of%2520glaucoma%253A%2520a%2520review%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D311%26spage%3D1901%26epage%3D11%26doi%3D10.1001%2Fjama.2014.3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Boland, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jampel, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollenweider, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chelladurai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez-Cuervo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, K. A.</span><span> </span><span class="NLM_article-title">Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">279</span><span class="refDoi">Â DOI: 10.7326/0003-4819-158-4-201302190-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.7326%2F0003-4819-158-4-201302190-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=23420235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BC3szpt12ntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2013&pages=271-279&author=M.+V.+Bolandauthor=A.+M.+Ervinauthor=D.+S.+Friedmanauthor=H.+D.+Jampelauthor=B.+S.+Hawkinsauthor=D.+Vollenweiderauthor=Y.+Chelladuraiauthor=D.+Wardauthor=C.+Suarez-Cuervoauthor=K.+A.+Robinson&title=Comparative+effectiveness+of+treatments+for+open-angle+glaucoma%3A+a+systematic+review+for+the+US+Preventive+Services+Task+Force&doi=10.7326%2F0003-4819-158-4-201302190-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force</span></div><div class="casAuthors">Boland Michael V; Ervin Ann-Margret; Friedman David S; Jampel Henry D; Hawkins Barbara S; Vollenweider Daniela; Chelladurai Yohalakshmi; Ward Darcy; Suarez-Cuervo Catalina; Robinson Karen A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glaucoma is an acquired degeneration of the optic nerve and a leading cause of blindness worldwide.  Medical and surgical treatments that decrease intraocular pressure may prevent visual impairment and blindness.  PURPOSE:  To compare the effectiveness of medical, laser, and surgical treatments in adults with open-angle glaucoma with regard to decreasing intraocular pressure and preventing optic nerve damage, vision loss, and visual impairment.  DATA SOURCES:  MEDLINE, CENTRAL, and an existing database for systematic reviews (through 2 March 2011); MEDLINE, EMBASE, LILACS, and CENTRAL for primary studies (through 30 July 2012).  STUDY SELECTION:  English-language systematic reviews; randomized, controlled trials; and quasi-randomized, controlled trials for most outcomes and observational studies for quality of life and harms.  DATA EXTRACTION:  Two investigators abstracted or checked information about study design, participants, and outcomes and assessed risk of bias and strength of evidence.  DATA SYNTHESIS:  High-level evidence suggests that medical, laser, and surgical treatments decrease intraocular pressure and that medical treatment and trabeculectomy reduce the risk for optic nerve damage and visual field loss compared with no treatment.  The direct effect of treatments on visual impairment and the comparative efficacy of different treatments are not clear.  Harms of medical treatment are primarily local (ocular redness, irritation); surgical treatment carries a small risk for more serious complications.  LIMITATION:  Heterogeneous outcome definitions and measurements among the included studies; exclusion of many treatment studies that did not stratify results by glaucoma type.  CONCLUSION:  Medical and surgical treatments for open-angle glaucoma lower intraocular pressure and reduce the risk for optic nerve damage over the short to medium term.  Which treatments best prevent visual disability and improve patient-reported outcomes is unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9U_u_lrxQNdj_Vg2vObihfW6udTcc2eZGypRSAKmr47ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szpt12ntw%253D%253D&md5=a6b2c197aa7a879e14fb40bdc74839d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-158-4-201302190-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-158-4-201302190-00008%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DM.%2BV.%26aulast%3DErvin%26aufirst%3DA.%2BM.%26aulast%3DFriedman%26aufirst%3DD.%2BS.%26aulast%3DJampel%26aufirst%3DH.%2BD.%26aulast%3DHawkins%26aufirst%3DB.%2BS.%26aulast%3DVollenweider%26aufirst%3DD.%26aulast%3DChelladurai%26aufirst%3DY.%26aulast%3DWard%26aufirst%3DD.%26aulast%3DSuarez-Cuervo%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DK.%2BA.%26atitle%3DComparative%2520effectiveness%2520of%2520treatments%2520for%2520open-angle%2520glaucoma%253A%2520a%2520systematic%2520review%2520for%2520the%2520US%2520Preventive%2520Services%2520Task%2520Force%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2013%26volume%3D158%26spage%3D271%26epage%3D279%26doi%3D10.7326%2F0003-4819-158-4-201302190-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Sharif, N.</span><span> </span><span class="NLM_article-title">Ocular Hypotension: Involvement of Serotonergic 5-HT<sub>2</sub> Receptors</span>. In  <span class="citation_source-journal">5-HT<sub>2C</sub> Receptors in the Pathophysiology of CNS Disease (The Receptors)</span>; <span class="NLM_contrib-group">Di Giovanni, G.; Esposito, E.; Di Matteo, V.</span> Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">; </span>Chapter 26, Vol.  <span class="NLM_volume">22</span>, pp  <span class="NLM_fpage">523</span><span class="NLM_x">â</span> <span class="NLM_lpage">43</span>.<span class="refDoi">Â DOI: 10.1007/978-1-60761-941-3_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1007%2F978-1-60761-941-3_26" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=523-43&author=N.+Sharifauthor=G.+Di+Giovanni&author=E.+Esposito&author=V.+Di+Matteo&title=Ocular+Hypotension%3A+Involvement+of+Serotonergic+5-HT2+Receptors&doi=10.1007%2F978-1-60761-941-3_26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-941-3_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-941-3_26%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%26atitle%3DOcular%2520Hypotension%253A%2520Involvement%2520of%2520Serotonergic%25205-HT2%2520Receptors%26jtitle%3D5-HT2C%2520Receptors%2520in%2520the%2520Pathophysiology%2520of%2520CNS%2520Disease%2520%2528The%2520Receptors%2529%26aulast%3DDi%2BGiovanni%26aufirst%3DG.%26pub%3DHumana%2520Press%26date%3D2011%26volume%3D22%26spage%3D523%26epage%3D43%26doi%3D10.1007%2F978-1-60761-941-3_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drace, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senchyna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of a serotonin receptor (5HT<sub>7</sub>) stimulating cAMP production in human corneal epithelial cells</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4837</span><span class="NLM_x">â</span> <span class="NLM_lpage">4844</span><span class="refDoi">Â DOI: 10.1167/iovs.02-1292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.02-1292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=14578406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD3srgtFaktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=4837-4844&author=J.+Y.+Criderauthor=G.+W.+Williamsauthor=C.+D.+Draceauthor=P.+Katoliauthor=M.+Senchynaauthor=N.+A.+Sharif&title=Pharmacological+characterization+of+a+serotonin+receptor+%285HT7%29+stimulating+cAMP+production+in+human+corneal+epithelial+cells&doi=10.1167%2Fiovs.02-1292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells</span></div><div class="casAuthors">Crider Julie Y; Williams Gary W; Drace Colene D; Katoli Parvaneh; Senchyna Michelle; Sharif Najam A</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4837-44</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  To study the mRNA and pharmacology of a serotonin (5-HT) receptor positively coupled to adenylyl cyclase in normal, primary (P-CEPI), and immortalized human corneal epithelial cells (CEPI-17-CL4), by using numerous 5-HT agonists and antagonists.  To determine and compare cloned human 5-HT7 receptor binding affinities of compounds with their functional potency data.  METHODS:  RT-PCR was used to detect the presence of an mRNA for the human 5-HT7 receptor in CEPI-17-CL4 cells.  Receptor-mediated production of cAMP in cultured cells was measured using an enzyme immunoassay.  Compound binding affinities were determined using [3H]-lysergic acid diethylamide ([3H]-LSD) binding to cell membranes of human embryonic kidney (HEK-293) cells expressing the cloned human 5-HT7 receptor.  RESULTS:  RT-PCR revealed the presence of a 5-HT7 receptor mRNA in CEPI-17-CL4 cells.  Normal P-CEPI cells generated cAMP in response to 5-HT (-log EC50; pEC50=7.6), 5-carboxamidotryptamine (5-CT; pEC50=7.8), 5-methoxy-tryptamine (pEC50=7.0) and 5-methoxy-dimethyl-tryptamine (pEC50=5.7).  In CEPI-17-CL4 cells, serotonergic agonists also stimulated cAMP production with different potencies (pEC50): 5-CT (7.4)>5-HT (6.5)> or =5-methoxy-tryptamine (6.1)>5-methoxy-dimethyl-tryptamine (5.4)> or =8-OH-DPAT (<5.0)=alpha-methyl-5-HT (<5.0).  Various 5-HT receptor antagonists inhibited cAMP production induced by 5-CT in CEPI-17-CL4 cells with different potencies (pKi): methiothepin (8.5)>mesulergine (8.1)=metergoline (8.0)>spiperone (7.4)> or =clozapine (7.2)=SB-258719 (7.2)>mianserin (6.9)>ketanserin (6.3).  Antagonist pKi values in P-CEPI cells were methiothepin (8.7), spiperone (7.4) and SB-258719 (6.6).  The rank order of affinity for displacement of [3H]-LSD from the cloned human 5-HT7 receptor was: methiothepin>ritanserin>mesulergine=clozapine> or =metergoline=5-HT>SB-258719> or =spiperone>mianserin> or =ketanserin.  The functional agonist and antagonist potency data obtained from CEPI-17-CL4 cells correlated well with cloned human 5-HT7 receptor binding affinity data (r=0.69), with P-CEPI cell functional data (r=0.85), and with functional potency data in the literature for the cloned human 5-HT7 receptor (r=0.88).  CONCLUSIONS:  These collective data support the presence of a pharmacologically defined, adenylyl cyclase-coupled 5-HT7 receptor in the CEPI-17-CL4 cells that may have relevance to physiological and/or pathologic functions of 5-HT7 receptors in the human cornea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEd-24j4VqV3RxY89Cm6SyfW6udTcc2eb7O2T0jm5ptLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srgtFaktg%253D%253D&md5=554eda853f3f78f89f522c9e33db5389</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1167%2Fiovs.02-1292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.02-1292%26sid%3Dliteratum%253Aachs%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DWilliams%26aufirst%3DG.%2BW.%26aulast%3DDrace%26aufirst%3DC.%2BD.%26aulast%3DKatoli%26aufirst%3DP.%26aulast%3DSenchyna%26aufirst%3DM.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520serotonin%2520receptor%2520%25285HT7%2529%2520stimulating%2520cAMP%2520production%2520in%2520human%2520corneal%2520epithelial%2520cells%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2003%26volume%3D44%26spage%3D4837%26epage%3D4844%26doi%3D10.1167%2Fiovs.02-1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span> </span><span class="NLM_article-title">Human trabecular meshwork cells express functional serotonin-2 (5HT<sub>2</sub>) receptors: role in IOP reduction</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4001</span><span class="NLM_x">â</span> <span class="NLM_lpage">4010</span><span class="refDoi">Â DOI: 10.1167/iovs.06-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.06-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=16936116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtFejuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=4001-4010&author=N.+A.+Sharifauthor=C.+R.+Kellyauthor=M.+A.+McLaughlin&title=Human+trabecular+meshwork+cells+express+functional+serotonin-2+%285HT2%29+receptors%3A+role+in+IOP+reduction&doi=10.1167%2Fiovs.06-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction</span></div><div class="casAuthors">Sharif Najam A; Kelly Curtis R; McLaughlin Marsha</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4001-10</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  To apply a multidisciplinary approach to the identification and pharmacological characterization of the serotonin (5HT) receptors that mediate functional responses in human trabecular meshwork (h-TM) cells.  To correlate in vitro findings with intraocular pressure (IOP) changes in conscious ocular hypertensive cynomolgus monkeys.  METHODS:  Documented methods were used, including reverse transcription-polymerase chain reaction (RT-PCR), phosphoinositide (PI) turnover, and intracellular Ca2+ ([Ca2+]i) mobilization.  IOP was measured using standard applanation pneumatonometry.  RESULTS:  h-TM cells expressed robust mRNA signals for 5HT2A and 5HT2B receptors. 5HT and its analogues stimulated PI turnover and [Ca2+]i mobilization in h-TM cells from multiple donors (20/24 donors' TM cells responded).  The agonist potencies (EC50) of compounds in mobilizing [Ca2+]i were (nM): 5-methoxy tryptamine, 8 +/- 4; (R)-DOI, 18 +/- 6; alpha-methyl-5HT, 22 +/- 3; 5HT, 40 +/- 7; 5-methoxy-dimethyl tryptamine, 64 +/- 27; and BW-723C86, 1213 +/- 210.  These effects were potently blocked by the 5HT2A-receptor-selective antagonist, M-100907 (Ki = 1 +/- 0.3 nM), but weakly by antagonists of 5HT2B and 5HT2C receptors.  Only 5HT2 receptor agonists such as (R)-DOI (300 microg lowered IOP 34.4% from baseline of 38.2 mm Hg; P < 0.001) and alpha-methyl-5HT (250 microg lowered IOP 30.8% from baseline of 41.8 mm Hg; P < 0.001) lowered IOP in ocular hypertensive cynomolgus monkeys.  CONCLUSIONS:  Strong signals for 5HT2A and 5HT2B receptor mRNAs were detected in h-TM cells.  The receptors that coupled to PI hydrolysis and [Ca2+]i mobilization in h-TM cells were the 5HT2A receptor subtype, which also significantly lowered IOP in a primate model.  These receptors may mediate the ocular hypotensive actions of 5HT2A agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwwU9N7XqJnhJ5E29YNGvQfW6udTcc2eb7O2T0jm5ptLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtFejuw%253D%253D&md5=cff1170b25a9f7339125d4206f345b8e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1167%2Fiovs.06-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.06-0062%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26atitle%3DHuman%2520trabecular%2520meshwork%2520cells%2520express%2520functional%2520serotonin-2%2520%25285HT2%2529%2520receptors%253A%2520role%2520in%2520IOP%2520reduction%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2006%26volume%3D47%26spage%3D4001%26epage%3D4010%26doi%3D10.1167%2Fiovs.06-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, T. L.</span><span> </span><span class="NLM_article-title">Serotonin-2 (5HT<sub>2</sub>) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension</span> <span class="citation_source-journal">J. Ocul. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">â</span> <span class="NLM_lpage">401</span><span class="refDoi">Â DOI: 10.1089/jop.2006.22.389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1089%2Fjop.2006.22.389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=17238805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FjvFOnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=389-401&author=N.+A.+Sharifauthor=J.+Y.+Criderauthor=C.+R.+Kellyauthor=T.+L.+Davis&title=Serotonin-2+%285HT2%29+receptor-mediated+signal+transduction+in+human+ciliary+muscle+cells%3A+role+in+ocular+hypotension&doi=10.1089%2Fjop.2006.22.389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension</span></div><div class="casAuthors">Sharif Najam A; Kelly Curtis R; Crider Julie Y; Davis Terry L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-401</span>
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    </div><div class="casAbstract">PURPOSE AND METHODS:  The aim of this study was to characterize the serotonin (5-hydroxytryptamine; 5-HT) receptors that mediate phosphoinositide (PI) hydrolysis and intracellular Ca2+ ([Ca2+]i) mobilization in isolated cells of human ciliary muscle (h-CM) from multiple donors using a variety of agonists and antagonists.  An additional aim was to visualize the mRNAs and receptor binding sites for 5-HT2 receptors in human ciliary body (h-CB), CM, and other tissues by reverse transcriptase polymerase chain reaction and quantitative autoradiography techniques, respectively, and to correlate with ocular hypotensive activity of such compounds.  RESULTS:  CBs isolated from several donor eyes revealed the presence of 5-HT(2A2C) receptor mRNAs. [3H]-5-HT and [3H]-ketanserin autoradiography on sections of human eyes revealed a high density of 5-HT2 receptor binding sites in the iris, ciliary epithelium, and longitudinal CM.  In isolated h-CM cells, the agonists alpha-methyl-5-HT (EC50=63+/-17 nM), 5-HT (EC50=85+/-16 nM), (R)-DOI (EC50=165+/-47 nM), and 5-methoxy alpha-methyl tryptamine (EC50=1200+/-270 nM) differentially stimulated PI turnover.  These agonists also mobilized [Ca2+]i in h-CM cells with the following potencies (EC50s): 5-methoxy-tryptamine=42+/-11 nM; alpha-methyl-5-HT=36+/-11 nM; (R)-DOI=120 nM; 5-HT=130+/-36 nM; MK-212=470 nM; mCPP>1 microM; BW723C86=1766 nM.  The agonist-induced [Ca2+]i mobilization in h-CM cells was potently blocked by the 5-HT2A-selective antagonist M-100907 (IC50=1.2+/-0.4 nM) but less potently by the antagonists for 5-HT2B (RS-127445, IC50>10 microM) and 5-HT2C (RS-102221, IC50=5.8+/-2.3 microM) receptors.  CONCLUSIONS:  In conclusion, h-CB, h-CM, and CM cells express mRNAs and proteins for 5-HT2 receptor subtypes, of which the predominant functionally active subtype is the 5-HT2A receptor, as defined by agonist and antagonist activities.  These receptors may be responsible for mediating the intraocular pressure reduction observed in recent literature with a number of 5-HT2 agonists, such as (R)-DOI, alpha-methyl-5HT, and AL-34662.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDoQRj6iRMcj0SWnHPWbmmfW6udTcc2eazeIIGiKz34rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FjvFOnsw%253D%253D&md5=787b39232ff9cf05f399ba36829c22de</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1089%2Fjop.2006.22.389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2006.22.389%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DDavis%26aufirst%3DT.%2BL.%26atitle%3DSerotonin-2%2520%25285HT2%2529%2520receptor-mediated%2520signal%2520transduction%2520in%2520human%2520ciliary%2520muscle%2520cells%253A%2520role%2520in%2520ocular%2520hypotension%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D22%26spage%3D389%26epage%3D401%26doi%3D10.1089%2Fjop.2006.22.389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senchyna, M.</span><span> </span><span class="NLM_article-title">Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR</span> <span class="citation_source-journal">Molecular Vision</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">â</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1040-1047&author=N.+A.+Sharifauthor=M.+Senchyna&title=Serotonin+receptor+subtype+mRNA+expression+in+human+ocular+tissues+determined+by+RT-PCR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DSenchyna%26aufirst%3DM.%26atitle%3DSerotonin%2520receptor%2520subtype%2520mRNA%2520expression%2520in%2520human%2520ocular%2520tissues%2520determined%2520by%2520RT-PCR%26jtitle%3DMolecular%2520Vision%26date%3D2006%26volume%3D12%26spage%3D1040%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span> </span><span class="NLM_article-title">Evaluation of the ocular hypotensive response of serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptor ligands in conscious ocular hypertensive cynomolgus monkeys</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">â</span> <span class="NLM_lpage">309</span><span class="refDoi">Â DOI: 10.1124/jpet.103.049528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.103.049528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12676887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=301-309&author=J.+A.+Mayauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=M.+R.+Hellbergauthor=T.+R.+Dean&title=Evaluation+of+the+ocular+hypotensive+response+of+serotonin+5-HT1A+and+5-HT2+receptor+ligands+in+conscious+ocular+hypertensive+cynomolgus+monkeys&doi=10.1124%2Fjpet.103.049528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys</span></div><div class="casAuthors">May, Jesse A.; McLaughlin, Marsha A.; Sharif, Najam A.; Hellberg, Mark R.; Dean, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Published investigations of serotonin-1A (5-hydroxytryptamine1A; 5-HT1A) receptor agonists and serotonin-2A (5-hydroxytryptamine2A; 5-HT2A) receptor antagonists in nonprimate species provide conflicting results with regard to their intraocular pressure-lowering efficacy.  Thus, their therapeutic utility in the treatment of human glaucoma has been confusing.  We evaluated the effect of selected 5-HT1A agonists and 5-HT2A receptor antagonists on intraocular pressure in a nonhuman primate model, the conscious cynomolgus monkey with laser-induced ocular hypertension.  Neither selective 5-HT1A agonists [e.g., R-8-hydroxy-2-(di-n-propylamino)tetralin and flesinoxan] nor selective 5-HT2 receptor antagonists [e.g., R-(+)-Î±-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (M-100907) and 6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxamide (SB-242084)] lowered intraocular pressure in the primate model following topical ocular administration.  However, compds. that function as agonists at both the 5-HT1A and 5-HT2 receptors were found to effectively lower intraocular pressure in the model: 5-hydroxy-Î±-methyltryptamine, 5-methoxy-Î±-methyltryptamine, 5-hydroxy-N,N-dimethyltryptamine (bufotenine), and 5-methoxy-N,N-dimethyltryptamine.  Furthermore, the selective 5-HT2 receptor agonist R-(-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane lowered intraocular pressure in the primate model, demonstrating a pharmacol. response assocd. with activation of the 5-HT2 receptor.  These observations suggest that compds. that function as efficient agonists at 5-HT2 receptors should be considered as potential agents for the control of intraocular pressure in the treatment of ocular hypertension and glaucoma in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6cTSJU_WCOrVg90H21EOLACvtfcHk0liv8j7N0WbnzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksrw%253D&md5=32d960587e00aa0746336d8b5db6881a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.049528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.049528%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DDean%26aufirst%3DT.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520ocular%2520hypotensive%2520response%2520of%2520serotonin%25205-HT1A%2520and%25205-HT2%2520receptor%2520ligands%2520in%2520conscious%2520ocular%2520hypertensive%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D301%26epage%3D309%26doi%3D10.1124%2Fjpet.103.049528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantanarayana, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinke, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">1-((<i>S</i>)-2-Aminopropyl)-1<i>H</i>-indazol-6-ol: A potent peripherally acting 5-HT<sub>2</sub> receptor agonist with ocular hypertensive activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">â</span> <span class="NLM_lpage">328</span><span class="refDoi">Â DOI: 10.1021/jm050663x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050663x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=318-328&author=J.+A.+Mayauthor=A.+P.+Dantanarayanaauthor=P.+W.+Zinkeauthor=M.+A.+McLaughlinauthor=N.+A.+Sharif&title=1-%28%28S%29-2-Aminopropyl%29-1H-indazol-6-ol%3A+A+potent+peripherally+acting+5-HT2+receptor+agonist+with+ocular+hypertensive+activity&doi=10.1021%2Fjm050663x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm050663x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050663x%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DDantanarayana%26aufirst%3DA.%2BP.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3D1-%2528%2528S%2529-2-Aminopropyl%2529-1H-indazol-6-ol%253A%2520A%2520potent%2520peripherally%2520acting%25205-HT2%2520receptor%2520agonist%2520with%2520ocular%2520hypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D318%26epage%3D328%26doi%3D10.1021%2Fjm050663x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusinko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span> </span><span class="NLM_article-title">A novel and selective 5-HT<sub>2</sub> receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-<i>e</i>]indole. 2003</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4188</span><span class="NLM_x">â</span> <span class="NLM_lpage">4195</span><span class="refDoi">Â DOI: 10.1021/jm030205t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030205t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4188-4195&author=J.+A.+Mayauthor=H.+H.+Chenauthor=A.+Rusinkoauthor=V.+M.+Lynchauthor=N.+A.+Sharifauthor=M.+A.+McLaughlin&title=A+novel+and+selective+5-HT2+receptor+agonist+with+ocular+hypotensive+activity%3A+%28S%29-%28%2B%29-1-%282-aminopropyl%29-8%2C9-dihydropyrano%5B3%2C2-e%5Dindole.+2003&doi=10.1021%2Fjm030205t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm030205t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030205t%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DRusinko%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DV.%2BM.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26atitle%3DA%2520novel%2520and%2520selective%25205-HT2%2520receptor%2520agonist%2520with%2520ocular%2520hypotensive%2520activity%253A%2520%2528S%2529-%2528%252B%2529-1-%25282-aminopropyl%2529-8%252C9-dihydropyrano%255B3%252C2-e%255Dindole.%25202003%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4188%26epage%3D4195%26doi%3D10.1021%2Fjm030205t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">May, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, C. P.</span><span> </span><span class="NLM_article-title">Pharmacological Properties and Discriminative Stimulus Effects of a Novel and Selective Serotonin-2 (5-HT<sub>2</sub>) Receptor Agonist AL-38022A [(<i>S</i>)-2-(8,9-dihydro-7<i>H</i>-pyrano[2,3-<i>g</i>]indazol-1-yl)-1-methylethylamine]</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span><span class="refDoi">Â DOI: 10.1016/j.pbb.2008.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.pbb.2008.07.015" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2009&pages=307-314&author=J.+A.+Mayauthor=N.+A.+Sharifauthor=H.-H.+Chenauthor=J.+C.+Liaoauthor=C.+R.+Kellyauthor=R.+A.+Glennonauthor=R.+Youngauthor=J.-X.+Liauthor=+Riceauthor=C.+P.+France&title=Pharmacological+Properties+and+Discriminative+Stimulus+Effects+of+a+Novel+and+Selective+Serotonin-2+%285-HT2%29+Receptor+Agonist+AL-38022A+%5B%28S%29-2-%288%2C9-dihydro-7H-pyrano%5B2%2C3-g%5Dindazol-1-yl%29-1-methylethylamine%5D&doi=10.1016%2Fj.pbb.2008.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2008.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2008.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DJ.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DChen%26aufirst%3DH.-H.%26aulast%3DLiao%26aufirst%3DJ.%2BC.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.-X.%26aulast%3DRice%26aulast%3DFrance%26aufirst%3DC.%2BP.%26atitle%3DPharmacological%2520Properties%2520and%2520Discriminative%2520Stimulus%2520Effects%2520of%2520a%2520Novel%2520and%2520Selective%2520Serotonin-2%2520%25285-HT2%2529%2520Receptor%2520Agonist%2520AL-38022A%2520%255B%2528S%2529-2-%25288%252C9-dihydro-7H-pyrano%255B2%252C3-g%255Dindazol-1-yl%2529-1-methylethylamine%255D%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2009%26volume%3D91%26spage%3D307%26epage%3D314%26doi%3D10.1016%2Fj.pbb.2008.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Doan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">â</span> <span class="NLM_lpage">37</span><span class="refDoi">Â DOI: 10.1124/jpet.102.039255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-37&author=K.+M.+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs&doi=10.1124%2Fjpet.102.039255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Doan, Kelly M. Mahar; Humphreys, Joan E.; Webster, Lindsey O.; Wring, Stephen A.; Shampine, Larry J.; Serabjit-Singh, Cosette J.; Adkison, Kimberly K.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-1037</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to det. whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochem. properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compds. for drug development.  Apparent permeability (Papp) and Pgp substrate profiles for 93 CNS and non-CNS drugs were detd. by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were pos. in the calcein-AM assay when tested at 100 Î¼M.  The CNS drug set (of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (of 45, 42.2%).  Anal. of 18 physicochem. properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer pos. charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group, properties that enhance membrane permeability.  This study on a large, diverse set of marketed compds. clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochem. properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B â A/A â B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qUc-kS0MC7Vg90H21EOLACvtfcHk0ljYpP-VoBRtnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D&md5=bcac11a02278360d6d6ad48718f0d5be</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DK.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D37%26doi%3D10.1124%2Fjpet.102.039255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rager, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, J. I. J.</span><span> </span><span class="NLM_article-title">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1016/j.ijpharm.2004.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.ijpharm.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=15620875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2005&pages=349-59&author=Q.+Wangauthor=J.+D.+Ragerauthor=K.+Weinsteinauthor=P.+S.+Kardosauthor=G.+L.+Dobsonauthor=+Liauthor=J.+I.+J.+Hidalgo&title=Evaluation+of+the+MDR-MDCK+cell+line+as+a+permeability+screen+for+the+blood-brain+barrier&doi=10.1016%2Fj.ijpharm.2004.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span></div><div class="casAuthors">Wang, Qing; Rager, Joseph D.; Weinstein, Kathryn; Kardos, Paula S.; Dobson, Glenn L.; Li, Jibin; Hidalgo, Ismael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-359</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The objectives of this study were to (1) characterize MDR-MDCK monolayers as an in vitro model to predict brain uptake potential; (2) examine the ability of MDR-MDCK monolayers to identify the brain uptake potential of compds. that interact with P-glycoprotein (P-gp).  The study measured the bi-directional transport of 28 compds. across MDR-MDCK monolayers.  The brain uptake of a subset of the compds. was detd. in the rat brain perfusion model.  Drug concns. were analyzed by LC-MS-MS.  CNS-pos. drugs exhibited absorptive permeability coeffs. (Papp, A-B) values ranging from 3.4 Ã 10-6 to 20.2 Ã 10-6 cm/s; whereas CNS-neg. drugs showed Papp (A-B) ranging from 0.03 Ã 10-6 to 0.83 Ã 10-6 cm/s.  Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compds. known to be P-pg substrates, but only enhanced the absorptive flux of compds. with high efflux ratio (>100).  In vitro results were confirmed by brain perfusion studies on selected compds.  MDR-MDCK monolayers can be used to classify compds. into CNS-pos. or CNS-neg. based on the permeability coeffs. (Papp, A-B).  Under the authors' exptl. conditions, compds. with Papp (A-B) >3 Ã 10-6 cm/s have high brain uptake potential; compds. with Papp (A-B) < 1 Ã 10-6 cm/s are unable to penetrate the blood-brain barrier (BBB); the brain uptake of compds. with Papp (A-B) < 1 Ã 10-6 cm/s and a P-gp-mediated efflux ratio of >100 may be enhanced by inhibiting P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvF-zoLte8trVg90H21EOLACvtfcHk0lgjRVe6btJ7tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE&md5=7d2cb9e13b2767b337bf808e73141ae1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DRager%26aufirst%3DJ.%2BD.%26aulast%3DWeinstein%26aufirst%3DK.%26aulast%3DKardos%26aufirst%3DP.%2BS.%26aulast%3DDobson%26aufirst%3DG.%2BL.%26aulast%3DLi%26aulast%3DHidalgo%26aufirst%3DJ.%2BI.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520MDR-MDCK%2520cell%2520line%2520as%2520a%2520permeability%2520screen%2520for%2520the%2520blood-brain%2520barrier%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2005%26volume%3D288%26spage%3D349%26epage%3D59%26doi%3D10.1016%2Fj.ijpharm.2004.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gornemann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centurion, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertz, H. H.</span><span> </span><span class="NLM_article-title">Phenylephrine contracts porcine pulmonary veins via alpha (1B)-, alpha (1D)-, and alpha (2)-adrenoceptors</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">613</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">â</span> <span class="NLM_lpage">92</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2009.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.ejphar.2009.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19376108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A280%3ADC%252BD1MzosFGguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=613&publication_year=2009&pages=86-92&author=T.+Gornemannauthor=C.+M.+Villalonauthor=D.+Centurionauthor=H.+H.+Pertz&title=Phenylephrine+contracts+porcine+pulmonary+veins+via+alpha+%281B%29-%2C+alpha+%281D%29-%2C+and+alpha+%282%29-adrenoceptors&doi=10.1016%2Fj.ejphar.2009.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylephrine contracts porcine pulmonary veins via alpha(1B)-, alpha(1D)-, and alpha(2)-adrenoceptors</span></div><div class="casAuthors">Gornemann Tilo; Villalon Carlos M; Centurion David; Pertz Heinz H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">613</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">86-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have recently shown that the postjunctional alpha(2)-adrenoceptor mediating contraction of porcine pulmonary veins is of the alpha(2C)-subtype.  We could also demonstrate that alpha(1)-adrenoceptors might contribute to the contraction in that blood vessel.  In the present study, we aimed at characterising the alpha(1)-adrenoceptor subtype(s) involved using pharmacological and molecular biological methods.  In isolated rings of porcine pulmonary veins the typical alpha(1)-adrenoceptor agonist phenylephrine caused a concentration-dependent contraction that was inhibited by the alpha(1B)-adrenoceptor selective antagonists 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one (Rec15/2615; pA(2) 8.96+/-0.13) and 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314; pA(2) 7.22+/-0.05), as well as the alpha(1D)-adrenoceptor selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY7378; pA(2) 8.29+/-0.15, slope of the Schild plot 0.75+/-0.09, significantly different from unity, P<0.05), but not by the alpha(1A)-adrenoceptor selective antagonists (+/-)-1,3,5-trimethyl-6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-pyrimidinedione (B8805-033) and N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine (RS-17053).  These findings suggest that phenylephrine activates both alpha(1B)- and alpha(1D)-adrenoceptors.  The observation was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) in porcine pulmonary veins, where mRNA signals for alpha(1B)- and alpha(1D)-adrenoceptors could be detected.  However, the antagonist properties of rauwolscine and yohimbine (non-subtype selective alpha(2)-adrenoceptor antagonists) against phenylephrine showed that this agonist also activates alpha(2)-adrenoceptors in pulmonary veins.  This was strengthened in experiments using tissues that were stimulated with forskolin (cell permeable activator of adenylyl cyclase).  Phenylephrine mimicked the effect of the selective alpha(2)-adrenoceptor agonist UK14304 by causing an inhibition of forskolin-stimulated cAMP accumulation that was blocked by rauwolscine.  It is concluded that, in addition to alpha(1B)- and alpha(1D)-adrenoceptors, phenylephrine can stimulate alpha(2)-adrenoceptors in porcine pulmonary veins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOKKAObCJDdKe0F5ixvZgXfW6udTcc2eZpQguKxk93HLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzosFGguw%253D%253D&md5=ceeee000bca4f54dceefc2f61b2b1d2e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGornemann%26aufirst%3DT.%26aulast%3DVillalon%26aufirst%3DC.%2BM.%26aulast%3DCenturion%26aufirst%3DD.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26atitle%3DPhenylephrine%2520contracts%2520porcine%2520pulmonary%2520veins%2520via%2520alpha%2520%25281B%2529-%252C%2520alpha%2520%25281D%2529-%252C%2520and%2520alpha%2520%25282%2529-adrenoceptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D613%26spage%3D86%26epage%3D92%26doi%3D10.1016%2Fj.ejphar.2009.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Jensen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigart, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laden, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMarco, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoopes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, P. C.</span><span> </span><span class="NLM_article-title">The alpha-1D is the predominant alpha-1-adrenergic receptor subtype in human apicardial coronary arteries</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">â</span> <span class="NLM_lpage">1145</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2009.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.jacc.2009.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19761933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GntbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=1137-1145&author=B.+C.+Jensenauthor=P.+M.+Swigartauthor=M.+E.+Ladenauthor=T.+DeMarcoauthor=C.+Hoopesauthor=P.+C.+Simpson&title=The+alpha-1D+is+the+predominant+alpha-1-adrenergic+receptor+subtype+in+human+apicardial+coronary+arteries&doi=10.1016%2Fj.jacc.2009.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The alpha-1D is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries</span></div><div class="casAuthors">Jensen, Brian C.; Swigart, Philip M.; Laden, Marie-Eve; DeMarco, Teresa; Hoopes, Charles; Simpson, Paul C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1137-1145</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The goal was to identify alpha-1-adrenergic receptor (AR) subtypes in human coronary arteries.  The Î±1-ARs regulate human coronary blood flow.  The Î±1-ARs exist as 3 mol. subtypes, Î±1A, Î±1B, and Î±1D, and the Î±1D subtype mediates coronary vasoconstriction in the mouse.  However, the Î±1A is thought to be the only subtype in human coronary arteries.  We obtained human epicardial coronary arteries and left ventricular (LV) myocardium from 19 transplant recipients and 6 unused donors (age 19 to 70 years; 68% male; 32% with coronary artery disease).  We cultured coronary rings and human coronary smooth muscle cells.  We assayed Î±1- and Î²-AR subtype mRNA by quant. real-time reverse transcription polymerase chain reaction and subtype proteins by radioligand binding and extracellular signal-regulated kinase (ERK) activation.  The Î±1D subtype was 85% of total coronary Î±1-AR mRNA and 75% of total Î±1-AR protein, and Î±1D stimulation activated ERK.  In contrast, the Î±1D was low in LV myocardium.  Total coronary Î±1-AR levels were one-third of Î²-ARs, which were 99% the Î²2 subtype.  The Î±1D subtype is predominant and functional in human epicardial coronary arteries, whereas the Î±1A and Î±1B are present at very low levels.  This distribution is similar to the mouse, where myocardial Î±1A- and Î±1B-ARs mediate beneficial functional responses and coronary Î±1Ds mediate vasoconstriction.  Thus, Î±1D-selective antagonists might mediate coronary vasodilation, without the neg. cardiac effects of nonselective Î±1-AR antagonists in current use.  Furthermore, it could be possible to selectively activate beneficial myocardial Î±1A- and/or Î±1B-AR signaling without causing coronary vasoconstriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyD122nJfVO7Vg90H21EOLACvtfcHk0liw7SA3AJ1lYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GntbbJ&md5=89636f1cd9a7a905b968f9093dbe3b8d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DB.%2BC.%26aulast%3DSwigart%26aufirst%3DP.%2BM.%26aulast%3DLaden%26aufirst%3DM.%2BE.%26aulast%3DDeMarco%26aufirst%3DT.%26aulast%3DHoopes%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DP.%2BC.%26atitle%3DThe%2520alpha-1D%2520is%2520the%2520predominant%2520alpha-1-adrenergic%2520receptor%2520subtype%2520in%2520human%2520apicardial%2520coronary%2520arteries%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3D1137%26epage%3D1145%26doi%3D10.1016%2Fj.jacc.2009.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hellberg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyba, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimko, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinke, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selliah, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeFaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrew, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamini, M. V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallee, V. L.</span><span> </span><span class="NLM_article-title">Identification and Characterization of the Ocular Hypotensive Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist</span> <span class="citation_source-journal">Surv. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S13</span><span class="NLM_x">â</span> <span class="NLM_lpage">S33</span><span class="refDoi">Â DOI: 10.1016/S0039-6257(02)00293-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2FS0039-6257%2802%2900293-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2002&pages=S13-S33&issue=Suppl.+1&author=M.+R.+Hellbergauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=L.+DeSantisauthor=T.+R.+Deanauthor=E.+P.+Kybaauthor=J.+E.+Bishopauthor=P.+G.+Klimkoauthor=P.+W.+Zinkeauthor=R.+D.+Selliahauthor=G.+Barnesauthor=J.+DeFallerauthor=A.+Kotheauthor=T.+Landryauthor=E.+K.+Sullivanauthor=R.+Andrewauthor=A.+A.+Davisauthor=L.+Silverauthor=M.+V.+W.+Bergaminiauthor=S.+Robertsonauthor=A.+L.+Weinerauthor=V.+L.+Sallee&title=Identification+and+Characterization+of+the+Ocular+Hypotensive+Efficacy+of+Travoprost%2C+a+Potent+and+Selective+FP+Prostaglandin+Receptor+Agonist%2C+and+AL-6598%2C+a+DP+Prostaglandin+Receptor+Agonist&doi=10.1016%2FS0039-6257%2802%2900293-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0039-6257%2802%2900293-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0039-6257%252802%252900293-X%26sid%3Dliteratum%253Aachs%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DDeSantis%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DKyba%26aufirst%3DE.%2BP.%26aulast%3DBishop%26aufirst%3DJ.%2BE.%26aulast%3DKlimko%26aufirst%3DP.%2BG.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26aulast%3DSelliah%26aufirst%3DR.%2BD.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DDeFaller%26aufirst%3DJ.%26aulast%3DKothe%26aufirst%3DA.%26aulast%3DLandry%26aufirst%3DT.%26aulast%3DSullivan%26aufirst%3DE.%2BK.%26aulast%3DAndrew%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DA.%2BA.%26aulast%3DSilver%26aufirst%3DL.%26aulast%3DBergamini%26aufirst%3DM.%2BV.%2BW.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DWeiner%26aufirst%3DA.%2BL.%26aulast%3DSallee%26aufirst%3DV.%2BL.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520the%2520Ocular%2520Hypotensive%2520Efficacy%2520of%2520Travoprost%252C%2520a%2520Potent%2520and%2520Selective%2520FP%2520Prostaglandin%2520Receptor%2520Agonist%252C%2520and%2520AL-6598%252C%2520a%2520DP%2520Prostaglandin%2520Receptor%2520Agonist%26jtitle%3DSurv.%2520Ophthalmol.%26date%3D2002%26volume%3D47%26issue%3DSuppl.%25201%26spage%3DS13%26epage%3DS33%26doi%3D10.1016%2FS0039-6257%2802%2900293-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sharif, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drace, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, G.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camras, C.</span><span> </span><span class="NLM_article-title">Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes</span> <span class="citation_source-journal">Exp. Eye Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">â</span> <span class="NLM_lpage">397</span><span class="refDoi">Â DOI: 10.1016/j.exer.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.exer.2008.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=18992242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1SksL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2009&pages=386-397&author=N.+A.+Sharifauthor=M.+A.+McLaughlinauthor=C.+R.+Kellyauthor=P.+Katoliauthor=C.+Draceauthor=S.+Husainauthor=C.+Crossonauthor=C.+Torisauthor=G.-L.+Zhanauthor=C.+Camras&title=Cabergoline%3A+pharmacology%2C+ocular+hypotensive+studies+in+multiple+species%2C+and+aqueous+humor+dynamic+modulation+in+cynomolgus+monkey+eyes&doi=10.1016%2Fj.exer.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes</span></div><div class="casAuthors">Sharif, Najam A.; McLaughlin, Marsha A.; Kelly, Curtis R.; Katoli, Parvaneh; Drace, Colene; Husain, Shahid; Crosson, Craig; Toris, Carol; Zhan, Gui-Lin; Camras, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-397</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aims of the current studies were to det. the in vitro and in vivo ocular and non-ocular pharmacol. properties of cabergoline using well documented receptor binding, cell-based functional assays, and in vivo models.  Cabergoline bound to native and/or human cloned serotonin-2A/B/C (5HT2A/B/C), 5HT1A, 5HT7, Î±2B, and dopamine-2/3 (D2/3) receptor subtypes with nanomolar affinity.  Cabergoline was an agonist at human recombinant 5HT2, 5HT1A, and D2/3 receptors but an antagonist at 5HT7 and Î±2 receptors.  In primary human ciliary muscle (h-CM) and trabecular meshwork (h-TM) cells, cabergoline stimulated phosphoinositide (PI) hydrolysis (EC50 = 19 nM in TM; 76 nM in h-CM) and intracellular Ca2+ ([Ca2+]i) mobilization (EC50 = 570 nM in h-TM; EC50 = 900 nM in h-CM).  Cabergoline-induced [Ca2+]i mobilization in h-TM and h-CM cells was potently antagonized by a 5HT2A-selective antagonist (M-100907, Ki = 0.29-0.53 nM).  Cabergoline also stimulated [Ca2+]i mobilization more potently via human cloned 5HT2A (EC50 = 63.4 nM) than via 5HT2B and 5HT2C receptors.  In h-CM cells, cabergoline (1 Î¼M) stimulated prodn. of pro-matrix metalloproteinases-1 and -3 and synergized with forskolin to enhance cAMP prodn.  Cabergoline (1 Î¼M) perfused through anterior segments of porcine eyes caused a significant (27%) increase in outflow facility.  Topically administered cabergoline (300-500 Î¼g) in Dutch-belted rabbit eyes yielded 4.5 and 1.97 Î¼M levels in the aq. humor 30 and 90 min post-dose but failed to modulate intraocular pressure (IOP).  However, cabergoline was an efficacious IOP-lowering agent in normotensive Brown Norway rats (25% IOP decrease with 6 Î¼g at 4 h post-dose) and in conscious ocular hypertensive cynomolgus monkeys (peak redn. of 30.6% with 50 Î¼g at 3 h post-dose; 30.4% with 500 Î¼g at 7 h post-dose).  In ketamine-sedated monkeys, IOP was significantly lowered at 2.5 h after the second topical ocular dose (300 Î¼g) of cabergoline by 23 and 35% in normotensive and ocular hypertensive eyes, resp.  In normotensive eyes, cabergoline increased uveoscleral outflow (0.69 Î¼L/min-1.61 Î¼L/min, n = 13).  However, only 7 of the 11 ocular hypertensive monkeys showed significantly increased uveoscleral outflow.  These data indicate that cabergoline's most prominent agonist activity involves activation of 5HT2, 5HT1A, and D2/3 receptors.  Since 5HT1A agonists, 5HT7 antagonists, and Î±2 antagonists do not lower IOP in conscious ocular hypertensive monkeys, the 5HT2 and dopaminergic agonist activities of cabergoline probably mediated the IOP redn. obsd. with this compd. in this species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSfP_V_1ptuLVg90H21EOLACvtfcHk0liw7SA3AJ1lYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1SksL8%253D&md5=b0947f7e74baec400e406643fc4d0868</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DKatoli%26aufirst%3DP.%26aulast%3DDrace%26aufirst%3DC.%26aulast%3DHusain%26aufirst%3DS.%26aulast%3DCrosson%26aufirst%3DC.%26aulast%3DToris%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DG.-L.%26aulast%3DCamras%26aufirst%3DC.%26atitle%3DCabergoline%253A%2520pharmacology%252C%2520ocular%2520hypotensive%2520studies%2520in%2520multiple%2520species%252C%2520and%2520aqueous%2520humor%2520dynamic%2520modulation%2520in%2520cynomolgus%2520monkey%2520eyes%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2009%26volume%3D88%26spage%3D386%26epage%3D397%26doi%3D10.1016%2Fj.exer.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Berg, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maayani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaramellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span> </span><span class="NLM_article-title">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">â</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fmol.54.1.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=9658194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=94-104&author=K.+A.+Bergauthor=S.+Maayaniauthor=J.+Goldfarbauthor=C.+Scaramelliniauthor=P.+Leffauthor=W.+P.+Clarke&title=Effector+pathway-dependent+relative+efficacy+at+serotonin+type+2A+and+2C+receptors%3A+evidence+for+agonist-directed+trafficking+of+receptor+stimulus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span></div><div class="casAuthors">Berg, Kelly A.; Maayani, Saul; Goldfarb, Joseph; Scaramellini, Clare; Leff, Paul; Clarke, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">There are many examples of a single receptor coupling directly to more than one cellular signal transduction pathway.  Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same.  In the current expts., we demonstrate that agonists at the human serotonin2A (5-HT2A) and 5-HT2C receptors activate differentially two signal transduction pathways independently coupled to the receptors [phospholipase C (PLC)-mediated inositol phosphate (IP) accumulation and phospholipase A2 (PLA2)-mediated arachidonic acid (AA) release].  The relative efficacies of agonists differed depending on which signal transduction pathway was measured.  Moreover, relative to 5-HT, some 5-HT2C agonists (e.g., 3-trifluoromethylphenyl-piperazine) preferentially activated the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway.  In contrast, when two dependent responses were measured (IP accumulation and calcium mobilization), agonist relative efficacies were not different.  These data strongly support the hypothesis termed "agonist-directed trafficking of receptor stimulus" recently proposed by Kenakin [Trends Pharmacol Sci 16:232-238 (1995)].  Concn.-response curves to 5-HT2C agonists were fit well by a three-state model of receptor activation, suggesting that two active receptor states may be sufficient to explain pathway-dependent agonist efficacy.  Rational drug design that optimizes preferential effector activity within a group of receptor-selective drugs holds the promise of increased selectivity in clin. useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidEqbbZNg07Vg90H21EOLACvtfcHk0lhc4Jv1vfworw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D&md5=99239b54cc498d1254aad42298ea5684</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.54.1.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.54.1.94%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DK.%2BA.%26aulast%3DMaayani%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DJ.%26aulast%3DScaramellini%26aufirst%3DC.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26atitle%3DEffector%2520pathway-dependent%2520relative%2520efficacy%2520at%2520serotonin%2520type%25202A%2520and%25202C%2520receptors%253A%2520evidence%2520for%2520agonist-directed%2520trafficking%2520of%2520receptor%2520stimulus%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D94%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kurrasch-Orbaugh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">â</span> <span class="NLM_lpage">37</span><span class="refDoi">Â DOI: 10.1124/jpet.102.042184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fjpet.102.042184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12490596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Shtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=229-37&author=D.+M.+Kurrasch-Orbaughauthor=V.+J.+Wattsauthor=E.+L.+Barkerauthor=D.+E.+Nichols&title=Serotonin+5-hydroxytryptamine+2A+receptor-coupled+phospholipase+C+and+phospholipase+A2+signaling+pathways+have+different+receptor+reserves&doi=10.1124%2Fjpet.102.042184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves</span></div><div class="casAuthors">Kurrasch-Orbaugh, Deborah M.; Watts, Val J.; Barker, Eric L.; Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">NIH3T3 cells stably expressing the rat 5-hydroxytryptamine2A (5-HT2A) receptor (5500 fmol/mg) were used to explore further the capacity of structurally distinct ligands to elicit differential signaling through the phospholipase C (PLC) or phospholipase A2 (PLA2) signal transduction pathways.  Initial expts. were designed to verify that 5-HT2A receptor-mediated PLA2 activation in NIH3T3 cells is independent from, and not a subsequent result of, 5-HT2A receptor-mediated PLC activation.  In addn., we also explored the extent of receptor reserve for the endogenous ligand, 5-HT, for both PLC and PLA2 activation.  Finally, we employed structurally diverse ligands from the tryptamine, phenethylamine, and ergoline families of 5-HT2A receptor agonists to test the hypothesis of agonist-directed trafficking of 5-HT2A receptor-mediated PLC and PLA2 activation.  To measure agonist-induced pathway activation, we detd. the potency and intrinsic activity of each compd. to activate either the PLA2 pathway or the PLC pathway.  The results showed that a larger receptor reserve exists for 5-HT-induced PLA2 activation than for 5-HT-induced PLC activation.  Furthermore, the data support the hypothesis of agonist-directed trafficking in NIH3T3-5HT2A cells because structurally distinct ligands were able to induce preferential activation of the PLC or PLA2 signaling pathway.  From these data we conclude that structurally distinct ligands can differentially regulate 5-HT2A receptor signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYulzethbNN7Vg90H21EOLACvtfcHk0lhc4Jv1vfworw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Shtw%253D%253D&md5=634d43d309804e16dbec96c9c99ed770</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.042184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.042184%26sid%3Dliteratum%253Aachs%26aulast%3DKurrasch-Orbaugh%26aufirst%3DD.%2BM.%26aulast%3DWatts%26aufirst%3DV.%2BJ.%26aulast%3DBarker%26aufirst%3DE.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DSerotonin%25205-hydroxytryptamine%25202A%2520receptor-coupled%2520phospholipase%2520C%2520and%2520phospholipase%2520A2%2520signaling%2520pathways%2520have%2520different%2520receptor%2520reserves%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D229%26epage%3D37%26doi%3D10.1124%2Fjpet.102.042184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bucci, F. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterbury, L. D.</span><span> </span><span class="NLM_article-title">A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">â</span> <span class="NLM_lpage">2239</span><span class="refDoi">Â DOI: 10.1185/03007995.2011.626018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1185%2F03007995.2011.626018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=21992076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeisr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=2235-2239&author=F.+A.+Bucciauthor=L.+D.+Waterbury&title=A+randomized+comparison+of+to-aqueous+penetration+of+ketorolac+0.45%25%2C+bromfenac+0.09%25+and+nepafenac+0.1%25+in+cataract+patients+undergoing+phacoemulsification&doi=10.1185%2F03007995.2011.626018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized comparison of to-aqueous penetration of ketorolac 0.45%%, bromfenac 0.09%% and nepafenac 0.1%% in cataract patients undergoing phacoemulsification</span></div><div class="casAuthors">Bucci, Frank A., Jr.; Waterbury, L. David</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2235-2239</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Objective: To compare the peak to-aq. penetration of three nonsteroidal anti-inflammatory drugs: ketorolac tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%, and amfenac (the active metabolite of nepafenac) in patients undergoing phacoemulsification.  Methods: A single center, double-masked study randomized 122 patients to receive one of three treatment arms.  On-label dosing of ketorolac (BID), bromfenac (BID), and nepafenac (TID) was instructed for 1 day prior to surgery.  Patients were instructed to instill one drop the morning of surgery.  The patients received four addnl. doses 1 h prior to phacoemulsification.  After completion of the paracentesis site with a superblade, aq. humor (0.15 cc) was collected through the peripheral clear cornea with a 30-gauge needle attached to a TB syringe.  Following collection, aq. samples were stored at -40Â°C prior to anal.  Drug concns. were analyzed by liq. chromatog. tandem mass spectrometry using pos. turbo-ion spray ionization and multiple reaction monitoring mode for quantification.  An independent sample Student's t-test was used to detect between-group differences.  Results: The peak aq. concn. of ketorolac 0.45% was 10 times the concn. of bromfenac 0.09%, and five times the concn. of and 54% greater than the metabolically inactive nepafenac 0.1%.  The mean peak aq. concn. of ketorolac 0.45% was 688.87 Â± 749.6 ng/mL.  Bromfenac achieved a mean peak aq. concn. of 67.64 Â± 62.4 ng/mL. The mean peak aq. concns. of nepafenac and amfenac were 447.10 Â± 225.7 ng/mL and 140.37 Â± 56.6 ng/mL, resp.  The peak concn. of ketorolac was statistically significantly greater than bromfenac (P = 0.0005), nepafenac (P = 0.05), and amfenac (P = 0.005).  A limitation of this study is that aq. samples were collected just prior to surgery and not during the postoperative period due to ethical considerations.  Conclusions: Ketorolac 0.45% achieved significantly greater aq. concns. when compared to bromfenac 0.09% and the active metabolite of nepafenac 0.1% (amfenac) in patients undergoing phacoemulsification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjPAOQeg8Ep7Vg90H21EOLACvtfcHk0lhc4Jv1vfworw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeisr3I&md5=3f2af92abdd25adabb36b3138a1fbb8b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1185%2F03007995.2011.626018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2011.626018%26sid%3Dliteratum%253Aachs%26aulast%3DBucci%26aufirst%3DF.%2BA.%26aulast%3DWaterbury%26aufirst%3DL.%2BD.%26atitle%3DA%2520randomized%2520comparison%2520of%2520to-aqueous%2520penetration%2520of%2520ketorolac%25200.45%2525%252C%2520bromfenac%25200.09%2525%2520and%2520nepafenac%25200.1%2525%2520in%2520cataract%2520patients%2520undergoing%2520phacoemulsification%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2011%26volume%3D27%26spage%3D2235%26epage%3D2239%26doi%3D10.1185%2F03007995.2011.626018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span> </span><span class="NLM_article-title">Serotonergic drugs and valvular heart disease</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">â</span> <span class="NLM_lpage">329</span><span class="refDoi">Â DOI: 10.1517/14740330902931524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1517%2F14740330902931524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19505264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslaiu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=317-329&author=R.+B.+Rothmanauthor=M.+H.+Baumann&title=Serotonergic+drugs+and+valvular+heart+disease&doi=10.1517%2F14740330902931524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonergic drugs and valvular heart disease</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-329</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT) releasers (Â±)-fenfluramine and (+)-fenfluramine were withdrawn from clin. use owing to increased risk of valvular heart disease.  One prevailing hypothesis (i.e., the 5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease.  Here, we critically evaluate the possible mechanisms responsible for fenfluramine-assocd. valve disease.  Findings from in vitro and in vivo expts. performed in our lab. are reviewed.  The data are integrated with existing literature to address the validity of the 5-HT hypothesis and suggest alternative explanations.  The overwhelming majority of evidence refutes the 5-HT hypothesis.  A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT2B receptors on heart valves by the metabolite norfenfluramine.  Future serotonergic medications should be designed to lack 5-HT2B agonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-LBvT-OQ77Vg90H21EOLACvtfcHk0ljqzM3oG0x7eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslaiu74%253D&md5=1ecc83ce1f8e149d64e4d61dd9fd4418</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14740330902931524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740330902931524%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26atitle%3DSerotonergic%2520drugs%2520and%2520valvular%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2009%26volume%3D8%26spage%3D317%26epage%3D329%26doi%3D10.1517%2F14740330902931524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Elangbam, C. S.</span><span> </span><span class="NLM_article-title">Drug-induced valvulopathy: an update</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">48</span><span class="refDoi">Â DOI: 10.1177/0192623310378027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1177%2F0192623310378027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=20716786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCrtLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=837-48&author=C.+S.+Elangbam&title=Drug-induced+valvulopathy%3A+an+update&doi=10.1177%2F0192623310378027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced valvulopathy: an update</span></div><div class="casAuthors">Elangbam, Chandikumar S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">837-848</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Drug-induced valvulopathy is a serious liability for certain compd. classes in development and for some marketed drugs intended for human use.  Reports of valvulopathy led to the withdrawal of fenfluramines (anorexigens) and pergolide (antiparkinson drug) from the United States market in 1997 and 2007, resp.  The mechanism responsible for the pathogenesis of valvulopathy by these drugs is likely a result of an "off-target" effect via activation of 5-hydroxytryptamine (5-HT) 2B receptor (5-HT2BR) expressed on heart valve leaflets.  Microscopically, the affected valve leaflets showed plaques of proliferative myofibroblasts in an abundant extracellular matrix, composed primarily of glycosaminoglycans.  However, the valvular effects caused by fenfluramines and pergolide were not initially predicted from routine preclin. toxicity studies, and to date there are no specific validated animal models or preclin./toxicol. screens to accurately predict drug-induced valvulopathy.  This review covers the structure and function of heart valves and highlights major advances toward understanding the 5-HT2BR-mediated pathogenesis of the lesion and subsequently, development of appropriate animal models using novel techniques/expts., use of functional screens against 5-HT2BR, and more consistent sampling and pathol. evaluation of valves in preclin. studies that will aid in avoidance of future drug-induced valvulopathy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtdCK4EVKYXrVg90H21EOLACvtfcHk0ljqzM3oG0x7eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCrtLvO&md5=b78c74a5c98673322df0d8393996df71</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1177%2F0192623310378027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310378027%26sid%3Dliteratum%253Aachs%26aulast%3DElangbam%26aufirst%3DC.%2BS.%26atitle%3DDrug-induced%2520valvulopathy%253A%2520an%2520update%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D837%26epage%3D48%26doi%3D10.1177%2F0192623310378027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hutcheson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merryman, W. D.</span><span> </span><span class="NLM_article-title">Serotonin receptors and heart valve diseaseâIt was meant 2B</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2011.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.pharmthera.2011.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=21440001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=146-157&author=J.+D.+Hutchesonauthor=V.+Setolaauthor=B.+L.+Rothauthor=W.+D.+Merryman&title=Serotonin+receptors+and+heart+valve+disease%E2%80%94It+was+meant+2B&doi=10.1016%2Fj.pharmthera.2011.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin receptors and heart valve disease-It was meant 2B</span></div><div class="casAuthors">Hutcheson, Joshua D.; Setola, Vincent; Roth, Bryan L.; Merryman, W. David</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-157</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Carcinoid heart disease was one of the first valvular pathologies studied in mol. detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue.  Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those obsd. in carcinoid patients.  The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s.  The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT2B receptor as the likely mol. target leading to heart valve tissue fibrosis.  Subsequent studies have identified numerous other activators of the 5-HT2B receptor, and consequently, the use of many of these mols. has been linked to heart valve disease.  Herein, we: review the mol. properties of the 5-HT2B receptor including factors that differentiate the 5-HT2B receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT2B receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT2B receptor activity, and speculate on potential therapeutic benefits of 5-HT2B receptor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4R8A9Ia-r3LVg90H21EOLACvtfcHk0ljqzM3oG0x7eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO&md5=b97c1992208a501b1959c2f48f3ca9cd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%2BD.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMerryman%26aufirst%3DW.%2BD.%26atitle%3DSerotonin%2520receptors%2520and%2520heart%2520valve%2520disease%25E2%2580%2594It%2520was%2520meant%25202B%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D146%26epage%3D157%26doi%3D10.1016%2Fj.pharmthera.2011.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Andrejak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tribouilloy, C.</span><span> </span><span class="NLM_article-title">Drug-induced valvular heart disease: An update</span> <span class="citation_source-journal">Arch. Cardiovas. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1016/j.acvd.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1016%2Fj.acvd.2013.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=23769407" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2013&pages=333-339&author=M.+Andrejakauthor=C.+Tribouilloy&title=Drug-induced+valvular+heart+disease%3A+An+update&doi=10.1016%2Fj.acvd.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.acvd.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acvd.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAndrejak%26aufirst%3DM.%26aulast%3DTribouilloy%26aufirst%3DC.%26atitle%3DDrug-induced%2520valvular%2520heart%2520disease%253A%2520An%2520update%26jtitle%3DArch.%2520Cardiovas.%2520Dis.%26date%3D2013%26volume%3D106%26spage%3D333%26epage%3D339%26doi%3D10.1016%2Fj.acvd.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revankar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">710</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><span class="refDoi">Â DOI: 10.1124/mol.109.058057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1124%2Fmol.109.058057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=19570945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1eitrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=710-22&author=X.-P.+Huangauthor=V.+Setolaauthor=P.+N.+Yadavauthor=J.+A.+Allenauthor=S.+C.+Roganauthor=B.+J.+Hansonauthor=C.+Revankarauthor=M.+Robersauthor=C.+Doucetteauthor=B.+L.+Roth&title=Parallel+functional+activity+profiling+reveals+valvulopathogens+are+potent+5-hydroxytryptamine%282B%29+receptor+agonists%3A+implications+for+drug+safety+assessment&doi=10.1124%2Fmol.109.058057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment</span></div><div class="casAuthors">Huang, Xi-Ping; Setola, Vincent; Yadav, Prem N.; Allen, John A.; Rogan, Sarah C.; Hanson, Bonnie J.; Revankar, Chetana; Robers, Matt; Doucette, Chris; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">710-722</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market.  Pharmacol. studies of VHD-assocd. medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists.  We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD.  To identify current or future drugs that might induce VHD, we screened approx. 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening.  Of these 2200 compds., 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens.  Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications.  Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity).  In these assays, the known valvulopathogens were efficacious at concns. as low as 30 nM, whereas the other compds. were less so.  Hierarchical clustering anal. of the pEC50 data revealed that ropinirole (which is not assocd. with valvulopathy) was clearly segregated from known valvulopathogens.  Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compds. likely to induce valvular heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6tCEte6PXtLVg90H21EOLACvtfcHk0lgXIZFMZ0mtXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1eitrvF&md5=48f3f3a220c542bc42b7378cc79d73d0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.058057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.058057%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRogan%26aufirst%3DS.%2BC.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DRevankar%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%26aulast%3DDoucette%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DParallel%2520functional%2520activity%2520profiling%2520reveals%2520valvulopathogens%2520are%2520potent%25205-hydroxytryptamine%25282B%2529%2520receptor%2520agonists%253A%2520implications%2520for%2520drug%2520safety%2520assessment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D710%26epage%3D22%26doi%3D10.1124%2Fmol.109.058057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gabelt, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, P. L.</span><span> </span><span class="NLM_article-title">Aqueous humor dynamics in monkeys after topical R-DOI</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4691</span><span class="NLM_x">â</span> <span class="NLM_lpage">6</span><span class="refDoi">Â DOI: 10.1167/iovs.05-0647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1167%2Fiovs.05-0647" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4691-6&author=B.+T.+Gabeltauthor=M.+Okkaauthor=T.+R.+Deanauthor=P.+L.+Kaufman&title=Aqueous+humor+dynamics+in+monkeys+after+topical+R-DOI&doi=10.1167%2Fiovs.05-0647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0647%26sid%3Dliteratum%253Aachs%26aulast%3DGabelt%26aufirst%3DB.%2BT.%26aulast%3DOkka%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26atitle%3DAqueous%2520humor%2520dynamics%2520in%2520monkeys%2520after%2520topical%2520R-DOI%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4691%26epage%3D6%26doi%3D10.1167%2Fiovs.05-0647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosecrans, J. A.</span><span> </span><span class="NLM_article-title">Discriminative stimulus properties of the hallucinogenic agent DOM</span> <span class="citation_source-journal">Commun. Psychopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=7297054" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1980&pages=501-506&author=R.+Youngauthor=R.+A.+Glennonauthor=J.+A.+Rosecrans&title=Discriminative+stimulus+properties+of+the+hallucinogenic+agent+DOM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DRosecrans%26aufirst%3DJ.%2BA.%26atitle%3DDiscriminative%2520stimulus%2520properties%2520of%2520the%2520hallucinogenic%2520agent%2520DOM%26jtitle%3DCommun.%2520Psychopharm.%26date%3D1980%26volume%3D4%26spage%3D501%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benington, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, R. D.</span><span> </span><span class="NLM_article-title">Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1168</span><span class="refDoi">Â DOI: 10.1021/jm00352a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00352a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=1163-1168&author=R.+A.+Glennonauthor=R.+Youngauthor=F.+Beningtonauthor=R.+D.+Morin&title=Behavioral+and+serotonin+receptor+properties+of+4-substituted+derivatives+of+the+hallucinogen+1-%282%2C5-dimethoxyphenyl%29-2-aminopropane&doi=10.1021%2Fjm00352a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00352a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00352a013%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DYoung%26aufirst%3DR.%26aulast%3DBenington%26aufirst%3DF.%26aulast%3DMorin%26aufirst%3DR.%2BD.%26atitle%3DBehavioral%2520and%2520serotonin%2520receptor%2520properties%2520of%25204-substituted%2520derivatives%2520of%2520the%2520hallucinogen%25201-%25282%252C5-dimethoxyphenyl%2529-2-aminopropane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D1163%26epage%3D1168%26doi%3D10.1021%2Fjm00352a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Otwinowski, Z.; Minor, W.</span><span> </span><span class="NLM_article-title">DENZO-SMN</span>, in  <span class="citation_source-book">Methods in Enzymology</span>; <span class="NLM_contrib-group">Carter, C. W.,  Jr.; Sweets, R. M.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: New York,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>Macromolecular Crystallography, part A, Vol.  <span class="NLM_volume">276</span>, pp  <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=307-326&author=Z.+Otwinowski&author=W.+Minorauthor=C.+W.+Carter&author=R.+M.+Sweets&title=Methods+in+Enzymology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26atitle%3DDENZO-SMN%26btitle%3DMethods%2520in%2520Enzymology%26aulast%3DCarter%26aufirst%3DC.%2BW.%26pub%3DAcademic%2520Press%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Altomare, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascarano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacovazzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagliardi, A.</span><span> </span><span class="NLM_article-title">SIR92. A program for crystal structure solution</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">â</span> <span class="NLM_lpage">350</span><span class="refDoi">Â DOI: 10.1107/S0021889892010331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1107%2FS0021889892010331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK3sXlsV2rs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=343-350&author=A.+Altomareauthor=G.+Cascaranoauthor=C.+Giacovazzoauthor=A.+Guagliardi&title=SIR92.+A+program+for+crystal+structure+solution&doi=10.1107%2FS0021889892010331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Completion and refinement of crystal structures with SIR92</span></div><div class="casAuthors">Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-50</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">An automatic procedure for recovering a complete crystal structure after a direct phasing process is described.  The procedure consists mainly of a Fourier recycling method that can be implemented in any direct-methods package.  The residual R value attained at the end of the process provides an est. of the degree of success of the structure detn.  The procedure can also be applied using a small mol. fragment as prior information.  The procedure was implemented into SIR92, the successor to SIR88.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2koCpbMjTTbVg90H21EOLACvtfcHk0liUL_B6SJ13Xg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsV2rs7Y%253D&md5=09257ca3c0f0932f25e52b0f13e40ff6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889892010331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889892010331%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DA.%26aulast%3DCascarano%26aufirst%3DG.%26aulast%3DGiacovazzo%26aufirst%3DC.%26aulast%3DGuagliardi%26aufirst%3DA.%26atitle%3DSIR92.%2520A%2520program%2520for%2520crystal%2520structure%2520solution%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1993%26volume%3D26%26spage%3D343%26epage%3D350%26doi%3D10.1107%2FS0021889892010331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span>SHELXL97. Program for the Refinement of Crystal Structures; <span class="NLM_publisher-name">University of Gottingen</span>: <span class="NLM_publisher-loc">Gottingen, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+M.+Sheldrick&title=SHELXL97.+Program+for+the+Refinement+of+Crystal+Structures"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26jtitle%3DSHELXL97.%2520Program%2520for%2520the%2520Refinement%2520of%2520Crystal%2520Structures%26pub%3DUniversity%2520of%2520Gottingen%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Wilson, A. J. C.</span>, Ed.  <span class="citation_source-book">International Tables for X-ray Crystallography</span>; <span class="NLM_publisher-name">Kluwer Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">C</span>, Tables 4.2.6.8 and 6.1.1.4.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=A.+J.+C.+Wilson&title=International+Tables+for+X-ray+Crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BJ.%2BC.%26btitle%3DInternational%2520Tables%2520for%2520X-ray%2520Crystallography%26pub%3DKluwer%2520Academic%2520Press%26date%3D1992%26volume%3DC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span>SHELXTL/PC, version 5.03; <span class="NLM_publisher-name">Siemens Analytical X-ray Instruments, Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+M.+Sheldrick&title=SHELXTL%2FPC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26jtitle%3DSHELXTL%252FPC%26pub%3DSiemens%2520Analytical%2520X-ray%2520Instruments%252C%2520Inc%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Cohen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fludzinski, L. A.</span><span> </span><span class="NLM_article-title">Contractile serotonergic receptor in rat stomach fundus</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=3668856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaL2sXmt12qsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1987&pages=264-269&author=M.+L.+Cohenauthor=L.+A.+Fludzinski&title=Contractile+serotonergic+receptor+in+rat+stomach+fundus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Contractile serotoninergic receptor in rat stomach fundus</span></div><div class="casAuthors">Cohen, Marlene L.; Fludzinski, Laura A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">264-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The possibility was examd. that 5HT-induced contractions in the rat stomach fundus were mediated by interaction with receptors identical with either 5HT1A, 5HT1B, or 5HT1C binding sites or 5HT3 receptors.  Contractile concn.-response curves for several 5HT agonists [5-carboxamidotryptamine, TR3369, MK212, quipazine, RU 24969, 8-hydroxy-2-(di-propylamino)tetralin, TVXQ7821, and BEA 1654Cl] were obtained in the rat stomach fundus.  However, neither the potency nor max. response of these agonists in contracting the rat stomach fundus correlated with the affinity of agonists at 5HT1A, 5Ht1B, or 5HT1C binding sites.  These agonists were interacting with 5HT receptors in the fundus based on the ability of 1-(1-naphthyl)piperazine (10-7M) to antagonize the contractile response of the relatively potent agonists.  TVXQ7821 and BEA1654Cl did not produce a marked contractile response in the fundus and also did not antagonize the contractile response to 5HT, suggesting that these agents have little, if any, affinity for the serotoninergic receptor-mediating contraction in the fundus.  The putative 5HT1A-selective receptor antagonists, WB410-1 and spiroxatrine, did not block 5HT-induced contractions in the rat stomach fundus in concns. consistent with their affinity at 5HT1A binding sites.  The nonselective 5HT1A and 5HT1B receptor antagonist, cyanopindolol, also did not block 5HT-induced contractions in the rat stomach fundus.  Mianserin, a selective ligand at 5HT1C binding sites, and the 5HT3 selective receptor antagonist, ICS 205-930, did not competitively or potently antagonize 5HT-induced contractions in the rat stomach fundus.  Apparently, the contractile response to 5HT in the rat stomach fundus is not mediated by interaction with receptors identical with the 5HT1A, 5HT1B, or 5HT1C binding sites in brain membranes or with 5HT3 receptors.  These data support the idea that the 5HT receptor in the rat stomach fundus is unique and distinct from known 5HT binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofOVSGK6DYk7Vg90H21EOLACvtfcHk0liHFm91nURDbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmt12qsL0%253D&md5=5c391cfd561bb2d850db59f7fba25353</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BL.%26aulast%3DFludzinski%26aufirst%3DL.%2BA.%26atitle%3DContractile%2520serotonergic%2520receptor%2520in%2520rat%2520stomach%2520fundus%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1987%26volume%3D243%26spage%3D264%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Crider, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, N. A.</span><span> </span><span class="NLM_article-title">Adenylyl cyclase activity mediated by adrenoceptors in immortalized human trabecular meshwork and nonpigmented ciliary epithelial cells</span> <span class="citation_source-journal">J. Ocul. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span><span class="refDoi">Â DOI: 10.1089/108076802760116142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1089%2F108076802760116142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=12099543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVyjtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=221-230&author=J.+Y.+Criderauthor=N.+A.+Sharif&title=Adenylyl+cyclase+activity+mediated+by+adrenoceptors+in+immortalized+human+trabecular+meshwork+and+nonpigmented+ciliary+epithelial+cells&doi=10.1089%2F108076802760116142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Adenylyl cyclase activity mediated by Î²-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells</span></div><div class="casAuthors">Crider, Julie Y.; Sharif, Najam A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Non-pigmented ciliary epithelial (NPE) and trabecular meshwork (TM) cells are important in maintaining normal aq. humor dynamics through the inflow and outflow routes, resp.  The current studies were undertaken to evaluate the ability of several Î²-adrenergic receptor agonists to stimulate various antagonists to inhibit cAMP prodn. in cultured immortalized human TM and NPE cells using an automated enzyme immunoassay.  Isoproterenol was the most potent agonist in both the NPE and TM cells.  The rank order of potency of agonists in NPE and TM cells, resp., was: isoproterenol [EC50 = 37 and 66 nM] > epinephrine [EC50 = 112 and 526 nM] > albuterol [EC50 = 426 and 785 nM] > norepinephrine [EC50 = 3 and > 10 Î¼M] > phenylephrine [EC50 > 10 Î¼M for both] = dopamine [EC50 > 10 Î¼M for both].  The isoproterenol-induced cAMP prodn. was inhibited by various antagonists with the following rank order of potency in NPE and TM cells, resp.: propranolol [Ki = 0.2 and 0.3 nM] = ICI-118551 [Ki = 0.5 and 0.4 nM] > levobunolol [Ki = 1.1 and 2.1 nM] > levobetaxolol [Ki = 13 and 14 nM] = racemic betaxolol [Ki = 43 and 19 nM] > dextrobetaxolol [Ki = 2705 and 1980 nM] > atenolol [Ki > 4000 nM for both].  These detailed pharmacol. studies using a variety of agonists and antagonists further supported the presence of Î²2-adrenergic receptors in immortalized human NPE and TM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu9hlkQhMXdbVg90H21EOLACvtfcHk0liHFm91nURDbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVyjtrs%253D&md5=04e82e05e2a17ba0e92ea53c0e4a3818</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2F108076802760116142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076802760116142%26sid%3Dliteratum%253Aachs%26aulast%3DCrider%26aufirst%3DJ.%2BY.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DAdenylyl%2520cyclase%2520activity%2520mediated%2520by%2520adrenoceptors%2520in%2520immortalized%2520human%2520trabecular%2520meshwork%2520and%2520nonpigmented%2520ciliary%2520epithelial%2520cells%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D18%26spage%3D221%26epage%3D230%26doi%3D10.1089%2F108076802760116142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kenny, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpot, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span> </span><span class="NLM_article-title">Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">â</span> <span class="NLM_lpage">986</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.1995.tb15907.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=10.1111%2Fj.1476-5381.1995.tb15907.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=7582530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Glu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1995&pages=981-986&author=B.+A.+Kennyauthor=D.+H.+Chalmersauthor=P.+C.+Philpotauthor=A.+M.+Naylor&title=Characterization+of+an+alpha+1D-adrenoceptor+mediating+the+contractile+response+of+rat+aorta&doi=10.1111%2Fj.1476-5381.1995.tb15907.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an Î±1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline</span></div><div class="casAuthors">Kenny, B. A.; Chalmers, D. H.; Philpott, P. C.; Naylor, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">981-6</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">The affinities of a no. of Î±1-adrenoceptor antagonists were detd. by displacement of [3H]-prazosin binding from cloned human Î±1A-adrenoceptors (previously designated cloned Î±1c subtype), Î±1B, Î±1D and rat Î±1D-adrenoceptors, stably expressed in rat-1 fibroblasts.  Functional affinity ests. for these compds. were also detd. from noradrenaline-mediated contractions of rat aorta.  BMY 7378 displayed high affinity for cloned human Î±1D-adrenoceptors (pKi = 8.2) and was selective over Î±1A (pK1 = 6.2) and Î±1B subtypes (6.7).  WB 4101, benoxathian and phentolamine displayed high affinity for Î±1A and Î±1D adrenoceptors compared to the Î±1B subtype.  Spiperone displayed high affinity and selectivity for Î±1B adrenoceptors (pK1 8.8).  5-Methyl-urapidil was selective for cloned Î±1A adrenoceptors.  Comparative binding affinities (pKi) for compds. at cloned human and rat1D adrenoceptors were almost identical (r = 0.99, slope = 1.08).  Prazosin, doxazosin and 5-methyl-urapidil were potent, competitive antagonists of noradrenaline-mediated contractions of rat aorta (pA2 values of 9.8, 8.8 and 7.8 resp.).  The selective Î±1D antagonist BMY 7378 was also a potent antagonist on rat aorta (PKB = 8.3) but the interaction of this compd. was not consistent with competitive antagonism at a single population of receptors.  Functional affinities for compds. detd. against noradrenaline-mediated contractions of rat aorta correlated well with binding affinities at cloned Î±1D-adrenoceptors (r = 0.96), but not with Î±1A (r = 0.61) or Î±1B (r = 0.46) subtypes.  Noradrenaline-mediated contractions of rat aorta were sensitive to the alkylating effects of chloroethylclonidine (CEC).  CEC (10 Î¼M) caused a small rightward shift in the noradrenaline concn.-response curve.  CEC at 100 Î¼M caused a further shift and suppression of the max. response to noradrenaline.  The results of this study suggest that noradrenaline predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an Î±1D-adrenoceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ783cY-ZQdrVg90H21EOLACvtfcHk0liHFm91nURDbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Glu78%253D&md5=655e4e2b98a7fd7c586b434fd4383af5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb15907.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb15907.x%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DB.%2BA.%26aulast%3DChalmers%26aufirst%3DD.%2BH.%26aulast%3DPhilpot%26aufirst%3DP.%2BC.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26atitle%3DCharacterization%2520of%2520an%2520alpha%25201D-adrenoceptor%2520mediating%2520the%2520contractile%2520response%2520of%2520rat%2520aorta%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D115%26spage%3D981%26epage%3D986%26doi%3D10.1111%2Fj.1476-5381.1995.tb15907.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Shulgin, A. T.</span><span> </span><span class="NLM_article-title">Characterization of Three New Psychotomimetics</span>. In  <span class="citation_source-book">The Psychopharmacology of Hallucinogens</span>; <span class="NLM_contrib-group">Stillman, R. C.; Willette, R. E.</span>, Eds.; <span class="NLM_publisher-name">Pergamon Press</span>: <span class="NLM_publisher-loc">Elmsford, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">1978</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&pages=74-83&author=A.+T.+Shulginauthor=R.+C.+Stillman&author=R.+E.+Willette&title=The+Psychopharmacology+of+Hallucinogens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShulgin%26aufirst%3DA.%2BT.%26atitle%3DCharacterization%2520of%2520Three%2520New%2520Psychotomimetics%26btitle%3DThe%2520Psychopharmacology%2520of%2520Hallucinogens%26aulast%3DStillman%26aufirst%3DR.%2BC.%26pub%3DPergamon%2520Press%26date%3D1978%26spage%3D74%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Shulgin, A. T.; Shulgin, A.</span> <span class="citation_source-book">PIHKAL: A Chemical Love Story</span>; <span class="NLM_publisher-name">Transform Press</span>: <span class="NLM_publisher-loc">Berkeley, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">633</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=633-637&author=A.+T.+Shulgin&author=A.+Shulgin&title=PIHKAL%3A+A+Chemical+Love+Story"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShulgin%26aufirst%3DA.%2BT.%26btitle%3DPIHKAL%253A%2520A%2520Chemical%2520Love%2520Story%26pub%3DTransform%2520Press%26date%3D1991%26spage%3D633%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00857">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21441"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00857">10.1021/acs.jmedchem.5b00857</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional ligand binding data for <b>13</b>; elemental analysis data; thermal ellipsoids for <b>13</b>; unit cell packing diagram; crystal data and structure refinement for <b>13</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00857/suppl_file/jm5b00857_si_001.pdf">jm5b00857_si_001.pdf (266.95 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00857&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-22%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00857%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00857" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                718KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b3743a4ad1d3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
